ClinicalTrials.gg
CompletedNCT04955626Updated Nov 10, 2025Results posted

To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.

A Phase 3 interventional study of BNT162b2 and Placebo in SARS-CoV-2 Infection and COVID-19, sponsored by BioNTech SE. Completed at 154 sites in 5 countries. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-10.

Sponsored by BioNTech SE · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
16,372
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.

Enrollment
2nd of 54
16,372 · median 575
Started
2021
with 29 others
Phase 3
18 of 54
1 open now
Registered
18th of 54
by date
Lead sponsor
20 of 54
BioNTech SE

Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 2nd largest by enrollment, is one of 30 that started in 2021, is one of 18 in phase 3, and was the 18th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About BNT162 Vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 12 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing BNT162 Vaccine in COVID-19, or all of them as a file.
02

Study summary

Substudy A: The study will evaluate the safety, tolerability, and efficacy of a booster dose of BNT162b2 when administered to participants having previously received 2 doses of BNT162b2 at least 6 months prior to randomization.

The study is designed to describe vaccine efficacy of a booster dose of BNT162b2 over time against COVID-19

  • At a dose of 30µg (as studied in the Phase 2/3 study C4591001)
  • In healthy adults 16 years of age and older
  • The duration of the study for each participant will be up to approximately 12 months.
  • The study will be conducted in the United States, Brazil and South Africa

Substudy B: The study will assess the safety and tolerability of a single dose of BNT162b2 as compared to placebo control, through the potential analysis of serum troponin levels, in participants ≥12 and ≤30 years of age who have received 2 or 3 prior doses of BNT162b2 (30-µg doses) with their last dose at least 4 months (120 days) prior to randomization.

  • Blood samples will be collected for troponin testing
  • The duration of the study for each participant will be up to approximately 2 months.
  • The study will be conducted in the United States, Germany, Poland and South Africa

Substudy C: The study will assess the safety, tolerability, and immunogenicity of a booster (third) dose of BNT162b2 at doses of 10 µg or 30 µg in participants who have completed a 2-dose primary series of BNT162b2 (30 µg doses) at least 5 months (150 days) prior to randomization.

  • In healthy adults 12 years of age and older
  • The duration of the study for each participant will be up to approximately 12 months.
  • The study will be conducted in the United States, Germany and South Africa

Substudy D: The study will assess the safety, tolerability, and immunogenicity of a 2-dose primary series of BNT162b2 OMI, and as a booster (third, fourth or fifth) dose

  • Participants in Cohort 1 will have completed a 2-dose primary series of BNT162b2 (30-µg doses), with their last dose 90 to 240 days prior to enrolment
  • Participants in Cohort 2 will be enrolled from Study C4591001 and C4591031 Substudy A and will have completed a 2-dose primary series and received a single booster (third) dose of BNT162b2, with their last dose 90 to 180 days prior to randomization
  • Participants in Cohort 3 who are COVID-19 vaccine-naïve and have not experienced COVID-19 will be enrolled to receive 2 doses (primary series) of BNT162b2 OMI, 3 weeks apart, with a dose of BNT162b2 approximately 5 months (150 days) later. If participants do not consent to receive BNT162b2 as a third dose, they will not receive a third dose. No participants should receive BNT162b2 OMI as a third dose.

    • In healthy adults 18 to 55 years of age
    • The duration of the study for each participant will be up to approximately 12 months.
    • The study will be conducted in the United States and South Africa

Substudy E: This study will assess the safety, tolerability, and immunogenicity of high-dose BNT162b2 (60 µg), high-dose BNT162b2 OMI (60 µg), and a high-dose combination of BNT162b2 and BNT162b2 OMI at 60 µg (30 µg each), given as a single dose

  • In healthy adults 18 years of age and older who have received 3 prior doses of BNT162b2 (30 µg) with the most recent dose being 5 to 12 months (150 to 360 days) prior to randomization
  • The duration of the study for each participant will be approximately 6 months.
  • The study will be conducted in the United States

Substudy F: This study will assess the safety, tolerability, and immunogenicity of high-dose BNT162b2 (60 µg), high-dose BNT162b2 OMI (60 µg), and a high-dose combination of BNT162b2 and BNT162b2 OMI at 60 µg (30 µg each), given as a single dose.

  • In healthy adults 60 years of age and older who have received 3 prior doses of BNT162b2 (30 µg) with the most recent dose being ≥4 months prior to randomization
  • The duration of the study for each participant will be approximately 6 months.
  • The study will be conducted in Israel
03

Conditions studied

  • SARS-CoV-2 Infection
  • COVID-19

Keywords

  • COVID-19
  • Coronavirus
  • Vaccine
  • SARS-CoV-2
  • RNA Vaccine
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Substudy A

Inclusion Criteria:

  • Male or female participants ≥16 years of age at Visit 1 (Day 1) who participated in C4591001.
  • Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.
  • Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
  • Capable of giving signed .
  • Participants who have received 2 prior doses of 30 µg BNT162b2 19-42 days apart, with the second dose being at least 175 days before Visit 1 (Day 1).

Exclusion Criteria:

  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention.
  • Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19.
  • individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  • Women who are pregnant or breastfeeding.
  • Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic , eg, for cancer or an disease, or planned receipt throughout the study.
  • Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19, from 90 days before study intervention administration, or planned receipt throughout the study.
  • Prior receipt of any COVID-19 vaccine other than BNT162b2.
  • Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
  • Receipt of medications intended to prevent COVID-19.
  • Prior receipt of more than 2 doses of BNT162b2 30 µg.
  • Participation in other studies involving study intervention within 28 days prior to study entry, other than C4591001, and/or within 28 days of confirmed receipt of BNT162b2 within the study.

Substudy B

Inclusion Criteria:

  • Male or female participants 12 to 30 years of age, inclusive, who have received 2 prior doses of 30 µg BNT162b2 19 to 60 days apart, with the second dose being at least at least 4 months (120 days) before Visit 1 (Day 1)
  • Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.
  • Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
  • Capable of giving signed informed consent.

Exclusion Criteria:

  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention.
  • Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19.
  • Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  • Women who are pregnant or breastfeeding.
  • Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study.
  • Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19, from 90 days before study intervention administration, or planned receipt throughout the study.
  • Prior receipt of any COVID-19 vaccine other than BNT162b2.
  • Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
  • Receipt of medications intended to prevent COVID-19.
  • Prior receipt of more than 3 doses of BNT162b2 30 µg.
  • Participation in other studies involving study intervention within 28 days prior to study entry through and including 28 days after the last dose of study intervention, with the exception of non-Pfizer interventional studies for prevention of COVID-19, which are prohibited throughout study participation.

Substudy C

Inclusion Criteria:

  • Male or female participants ≥12 years of age, inclusive, who have received 2 prior doses of 30 µg BNT162b2 19 to 60 days apart, with the second dose being at least 150 days before Visit 301 (Day 1)
  • Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.
  • Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
  • Capable of giving signed informed consent.

Exclusion Criteria:

  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention.
  • Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19.
  • Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  • Women who are pregnant or breastfeeding.
  • Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study.
  • Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19, from 90 days before study intervention administration, or planned receipt throughout the study.
  • Prior receipt of any COVID-19 vaccine other than BNT162b2.
  • Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
  • Receipt of medications intended to prevent COVID-19.
  • Prior receipt of more than 2 doses of BNT162b2 30 µg.
  • Participation in other studies involving study intervention within 28 days prior to study entry through and including 28 days after the last dose of study intervention, with the exception of non-Pfizer interventional studies for prevention of COVID-19, which are prohibited throughout study participation.

Substudy D

Inclusion Criteria:

  • Male or female participants 18 to 55 years of age inclusive
  • Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.
  • Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
  • Cohort 2: Participants who provided a serum sample at Visit 3 in Study C4591001, with Visit 3 occurring within the protocol-specified window.
  • Capable of giving signed informed consent
  • Cohort 1: Participants who have received 2 prior doses of 30 µg BNT162b2, with the second dose being 90 to 240 days before Visit 401 (Day 1) or Cohort 2: Participants who have received 3 prior doses of 30 µg BNT162b2, with the third dose being 90 to 180 days before Visit 401 (Day 1).

Exclusion Criteria:

  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention.
  • Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19.
  • Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  • Women who are pregnant or breastfeeding.
  • Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study.
  • Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19, from 90 days before study intervention administration, or planned receipt throughout the study.
  • Cohorts 1 and 2: prior receipt of any COVID-19 vaccine other than BNT162b2.
  • Cohort 3 only: prior receipt of any COVID-19 vaccine.
  • Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
  • Receipt of medications intended to prevent COVID 19.
  • Participation in other studies involving study intervention within 28 days prior to study entry through and including 28 days after the last dose of study intervention, with the exception of non-Pfizer interventional studies for prevention of COVID-19, which are prohibited throughout study participation.

Substudy E

Inclusion Criteria:

  • Groups 1-6: Male or female participants >55 years of age
  • Groups 7-9: Male or female participants 18 to 55 years of age
  • Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.
  • Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
  • Capable of giving signed informed consent.
  • Participants who have received 3 prior doses of 30 µg BNT162b2, with the third dose being 5 to 12 months (150 to 360 days) before Visit 601 (Day 1).
  • Groups 7 to 9 (sentinel participants): Screening troponin levels must be within normal range prior to randomization.

Exclusion Criteria:

  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention.
  • Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19.
  • Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  • Women who are pregnant or breastfeeding.
  • Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study.
  • Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19, from 90 days before study intervention administration, or planned receipt throughout the study.
  • Prior receipt of any COVID-19 vaccine other than BNT162b2.
  • Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
  • Receipt of medications intended to prevent COVID-19.
  • Participation in other studies involving study intervention within 28 days prior to study entry through and including 28 days after the last dose of study intervention, with the exception of non-Pfizer interventional studies for prevention of COVID-19, which are prohibited throughout study participation.

Substudy F

Inclusion Criteria:

  • Male or female participants ≥60 years of age
  • Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.
  • Healthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
  • Capable of giving signed informed consent.
  • Participants who have received 3 prior doses of 30 µg BNT162b2, with the third dose being ≥4 months before Visit 701 (Day 1).

Exclusion Criteria:

  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention.
  • Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID-19.
  • Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  • Women who are pregnant or breastfeeding.
  • Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study.
  • Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19, from 90 days before study intervention administration, or planned receipt throughout the study.
  • Prior receipt of any COVID-19 vaccine other than BNT162b2.
  • Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
  • Receipt of medications intended to prevent COVID-19.
  • Participation in other studies involving study intervention within 28 days prior to study entry through and including 28 days after the last dose of study intervention, with the exception of non-Pfizer interventional studies for prevention of COVID-19, which are prohibited throughout study participation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
16,372 participants (actual)

Study arms

  • Experimental
    10 µg dose

    1 dose

    Biological: BNT162b2

  • Placebo comparator
    Placebo

    1 dose

    Other: Placebo

  • Experimental
    30 µg dose

    1 dose

    Biological: BNT162b2 · Biological: BNT162b2 OMI · Biological: Combination BNT162b2 and BNT162b2 OMI · Biological: Combination (Bivalent) BNT162b2 and BNT162b2 OMI

  • Experimental
    60 µg dose

    1 dose

    Biological: BNT162b2 · Biological: BNT162b2 OMI · Biological: Combination BNT162b2 and BNT162b2 OMI · Biological: Combination (Bivalent) BNT162b2 and BNT162b2 OMI

Interventions

  • BiologicalBNT162b2

    Intramuscular Injection

  • OtherPlacebo

    Intramuscular Injection

  • BiologicalBNT162b2 OMI

    Intramuscular Injection

  • BiologicalCombination BNT162b2 and BNT162b2 OMI

    30-µg (15-µg each) or 60-µg (30-µg each) Site prepared dosing suspension from 1 vial each of diluted BNT162b2 and BNT162b2 OMI Intramuscular Injection

  • BiologicalCombination (Bivalent) BNT162b2 and BNT162b2 OMI

    30-µg (15-µg each) or 60-µg (30-µg each) Preformulated bivalent mixture (no dilution required) presented in a single vial Intramuscular Injection

06

What researchers measure

Primary outcomes

  1. SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection at Interim Analysis: Evaluable Efficacy Population

    Occurrences (number of cases) of first COVID-19 infection in participants after booster dose per 1000 person-year, without past SARS-CoV-2 infection at interim analysis were reported in this outcome measure.

    Time frame: From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year [PY]) for BNT162b2 was 0.823 and for Placebo was 0.792

  2. SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection at Interim Analysis: Evaluable Efficacy Population

    Occurrences (number of cases) of first COVID-19 infection in participants after booster dose with and without past SARS-CoV-2 infection at interim analysis were reported in this outcome measure.

    Time frame: From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 0.871 and for Placebo was 0.835

  3. SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection at Final Analysis: Evaluable Efficacy Population

    Occurrences (number of cases) of first COVID-19 infection in participants after booster dose without past SARS-CoV-2 infection at final analysis were reported in this outcome measure.

    Time frame: From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 1.098 and for Placebo was 0.932

  4. SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection at Final Analysis: Evaluable Efficacy Population

    Occurrences (number of cases) of first COVID-19 infection in participants after booster dose with and without past SARS-CoV-2 infection at final analysis were reported in this outcome measure.

    Time frame: From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 1.173 and for Placebo was 0.989

  5. SSA: Percentage of Participants Reporting Adverse Events

    An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: From booster dose (Day 1) to 1 month after booster dose

  6. SSA: Percentage of Participants Reporting Serious Adverse Events (SAE)

    An SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); congenital anomaly/birth defect; or that was considered as an important medical event.

    Time frame: BNT162b2 30 mcg, Placebo then BNT162b2 30 mcg: From BNT162b2 dose to 6 months after BNT162b2 dose; Placebo: From placebo dose to unblinding for original placebo participants. Median blinded follow-up period for Placebo group=2.8 months

  7. SSB: Percentage of Participants With Elevated Troponin I Level Pre-Dose; Vaccination 1

    Percentage of participants with elevated troponin I levels before administration of Vaccination 1 were reported in this outcome measure.

    Time frame: Pre-dose on Day 1 (Vaccination 1)

  8. SSB: Percentage of Participants With Elevated Troponin I Level Within 5 Days After Vaccination 1

    Percentage of participants with elevated troponin I levels within 5 days after administration of Vaccination 1 were reported in this outcome measure.

    Time frame: Within 5 days after Vaccination 1

  9. SSB: Percentage of Participants With Elevated Troponin I Level Pre-Vaccination 2 (1 Month After Vaccination 1)

    Percentage of participants with elevated troponin I levels pre vaccination 2 were reported in this outcome measure.

    Time frame: Pre-Vaccination 2 (1 month after Vaccination 1)

  10. SSB: Percentage of Participants With Elevated Troponin I Level Within 5 Days After Vaccination 2

    Percentage of participants with elevated troponin I levels within 5 days after administration of Vaccination 2 were reported in this outcome measure.

    Time frame: Within 5 days after vaccination 2

  11. SSB: Percentage of Participants With Elevated Troponin I Level 1 Month After Vaccination 2

    Percentage of participants with elevated troponin I levels within 1 month after administration of Vaccination 2 were reported in this outcome measure.

    Time frame: 1 month after Vaccination 2

  12. SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1

    Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 1 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.

    Time frame: Day 1 up to Day 7 after Vaccination 1

  13. SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2

    Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 2 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.

    Time frame: Day 1 up to Day 7 after Vaccination 2

  14. SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1

    Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to (\>=) 38.0 degree Celsius (deg C) and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 up to Day 7 after Vaccination 1

  15. SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2

    Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to (\>=) 38.0 degree Celsius (deg C) and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 up to Day 7 after Vaccination 2

  16. SSB: Percentage of Participants Reporting Adverse Events (AEs) 1 Month After Vaccination 1

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after Vaccination 1 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Vaccination 1 up to 1 Month After Vaccination 1

  17. SSB: Percentage of Participants Reporting Adverse Events (AEs) 1 Month After Vaccination 2

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after Vaccination 2 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: Vaccination 2 up to 1 month after Vaccination 2

  18. SSB: Percentage of Participants Reporting Serious Adverse Events (SAEs) 1 Month After Vaccination 1

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: Vaccination 1 up to 1 month after Vaccination 1

  19. SSB: Percentage of Participants Reporting Serious Adverse Events (SAEs) 1 Month After Vaccination 2

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: Vaccination 2 up to 1 month after Vaccination 2

  20. SSC: Percentage of Participants With Local Reactions Within 7 Days After Booster Dose

    Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 cm and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after the booster (third) dose and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.

    Time frame: Day 1 up to Day 7 after the booster dose

  21. SSC: Percentage of Participants With Systemic Events Within 7 Days After Booster Dose

    Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to (\>=) 38.0 degree Celsius (deg C) and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24 h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 up to Day 7 after the booster dose

  22. SSC: Percentage of Participants Reporting Adverse Events From Booster Dose Through 1 Month After Booster Dose

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from booster (third) dose up to 1 month after booster (third) dose were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From booster dose (Day 1) up to 1 month after booster dose

  23. SSC: Percentage of Participants Reporting Serious Adverse Events From Booster Dose Through 6 Months After Booster Dose

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: From booster dose (Day 1) up to 6 months after booster dose

  24. SSC: Geometric Mean Titers (GMT) of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Baseline

    GMT of SARS-CoV-2 reference-strain-neutralizing titers at baseline (before the booster dose) was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).

    Time frame: At baseline (pre-dose)

  25. SSC: GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at 1 Month After the Booster Dose

    GMT of SARS-CoV-2 reference-strain-neutralizing titers at 1 month after the booster dose was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).

    Time frame: 1 month after the booster dose

  26. SSC: Geometric Mean Fold-Rise (GMFR) of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Baseline to 1 Month After the Booster Dose

    GMFR of SARS-CoV-2 reference-strain-neutralizing titers from baseline to 1 month after the booster dose received in this sub-study was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

    Time frame: From baseline to 1 month after the booster dose

  27. SSC: Percentage of Participants With Seroresponse to Reference-Strain at 1 Month After the Booster Dose

    Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month after the booster dose was reported in this outcome measure.

    Time frame: 1 month after the booster dose

  28. SSD: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1

    Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu=0.5 centimeter (cm) and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection (inj) site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit/hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 1 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.

    Time frame: Day 1 up to Day 7 after Vaccination 1

  29. SSD: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2

    Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 2 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.

    Time frame: Day 1 up to Day 7 after Vaccination 2

  30. SSD: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 3

    Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 3 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.

    Time frame: Day 1 up to Day 7 after Vaccination 3

  31. SSD: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1

    Systemic events were recorded in e-diary. Fever: oral temperature \>= 38.0 deg C, categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 up to Day 7 after Vaccination 1

  32. SSD: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2

    Systemic events were recorded in e-diary. Fever: oral temperature \>= 38.0 deg C, categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 up to Day 7 after Vaccination 2

  33. SSD: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 3

    Systemic events were recorded in e-diary. Fever: oral temperature \>= 38.0 deg C and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 up to Day 7 after Vaccination 3

  34. SSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Last Study Vaccination: Cohort 1

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from first study vaccination (Day 1) up to 1 month after last study vaccination were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From Day 1 up to 1 month after last study vaccination

  35. SSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Vaccination 1: Cohort 2

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from first study vaccination (Day 1) up to 1 month after Vaccination 1 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From first study vaccination (Day 1) up to 1 month after Vaccination 1

  36. SSD: Percentage of Participants Reporting Adverse Events (AEs) From Second Study Vaccination Through 1 Month After Second Study Vaccination: Cohort 2

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from Vaccination 2 up to 1 month after Vaccination 2 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From Vaccination 2 up to 1 month after Vaccination 2

  37. SSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Second Study Vaccination: Cohort 3

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from first study vaccination (Day 1) up to 1 month after Vaccination 2 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From first study vaccination (Day 1) up to 1 month after Vaccination 2

  38. SSD: Percentage of Participants Reporting Adverse Events (AEs) From Third Study Vaccination Through 1 Month After Third Study Vaccination: Cohort 3

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from Vaccination 3 up to 1 month after Vaccination 3 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From Vaccination 3 up to 1 month after Vaccination 3

  39. SSD: Percentage of Participants Reporting Serious Adverse Events (SAEs) From First Study Vaccination (Day 1) Through 6 Months After Last Study Vaccination: Cohort 1 and Cohort 3

    A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: From first study vaccination (Day 1) up to 6 months after last study vaccination

  40. SSD: Percentage of Participants Reporting SAEs From First Study Vaccination (Day 1) Through 6 Months After Vaccination 1 (For Participants Who Received 1 Dose Only) and up to Vaccination 2 (For Participants Who Received 2 Doses): Cohort 2

    A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: From vaccination 1 (Day 1) up to 6 months after vaccination 1 (participants received 1 dose only); From vaccination 1 up to before vaccination 2 (participants received 2 doses)

  41. SSD: Percentage of Participants Reporting Serious Adverse Events (SAEs) From First Study Vaccination Through 6 Months After Vaccination 2: Cohort 2

    A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: From first study vaccination (Day 1) up to 6 months after vaccination 2

  42. SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After First Study Vaccination: Comparison Between Cohort 2 Group 3 and Group 4

    GMR was calculated based on GMT levels of SSD: Cohort 2: Group 3 and SSD: Cohort 2: Group 4 and reported in statistical analysis section below. GMT of SARS-CoV-2 Omicron strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after first study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).

    Time frame: 1 month after Vaccination 1

  43. SSD: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After First Study Vaccination: Comparison Between Cohort 2 Group 3 and Group 4

    Seroresponse: achieving \>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse 1 month after first study vaccination was reported in this outcome measure.

    Time frame: 1 month after Vaccination 1

  44. SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After First Study Vaccination: Comparison Between Cohort 1 Group 1 and Group 2b

    GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after first study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).

    Time frame: 1 month after Vaccination 1

  45. SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers: Comparison Between 1 Month After Second Study Vaccination for Cohort 1 Group 2 and 1 Month After First Study Vaccination for Cohort 1 Group 2b

    GMR was calculated based on GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after Vaccination 2 for Group 2 and 1 month after Vaccination 1 for Group 2b was reported. GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution).

    Time frame: For Cohort 1 Group 2b:1 month after Vaccination 1; for Cohort 1 Group 2: 1 month after Vaccination 2

  46. Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After First Study Vaccination: Comparison Between Cohort 1 Group 1 and Group 2b

    Seroresponse: achieving \>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse 1 month after first study vaccination was reported in this outcome measure.

    Time frame: 1 month after Vaccination 1

  47. SSD: Percentage of Participants With Seroresponse to SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Vaccination 2: Comparison Between 1 Month After Vaccination 2 for Cohort 1 Group 2 and 1 Month After Vaccination 1 for Cohort 1 Group 2b

    Seroresponse: achieving \>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below LLOQ, postvaccination measure of \>= 4 × LLOQ is considered seroresponse. Exact 2-sided CI, based on Clopper and Pearson method was used. Percentage of participants achieving seroresponse 1 month after second study vaccination for Group 2 and 1 month after study vaccination for Group 2b was reported in this outcome measure.

    Time frame: For Cohort 1 Group 2b:1 month after Vaccination 1; for Cohort 1 Group 2: 1 month after Vaccination 2

  48. SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After Second Study Vaccination: Cohort 3

    GMR calculated based on GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMR comparison between GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers of participants of SSD Cohort 3: Group 5 to GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers of participants of study C4591001 (NCT04368728) Phase 3 BNT162b2 single arm 18-55 years of age, at 1 month after vaccination 2 was reported. GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (student's t distribution).

    Time frame: 1 month after Vaccination 2

  49. SSD: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Second Study Vaccination: Cohort 3

    EIP:eligible participants received 2 doses of study drug as randomized with Dose2 received within 19-42 days after Dose1 (SSD Cohort 3:Group 5), had valid determinate immunogenicity result from blood sample collected within 28-42 days after 2nd study vaccination, had no other important protocol deviations as determined by clinician. Data of eligible participants from Study C4591001 Phase 3 BNT162b2 single arm 18-55 years was included for comparison.'N'=participants evaluable for outcome measure.

    Time frame: 1 month after Vaccination 2

  50. SSE: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination

    Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu=0.5 centimeter (cm) and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm),severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis/exfoliative dermatitis \[redness\]).Pain at injection site was graded as mild (did not interfere with activity),moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit/hospitalization for severe pain). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions within 7 days after study vaccination and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.

    Time frame: Day 1 up to Day 7 after study vaccination

  51. SSE: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination

    Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to 38.0 deg C and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C \& \>40.0 deg C. Fatigue, headache, chills, muscle pain and joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit or hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \> 2 times in 24h, severe: required intravenous hydration and Grade 4: ER or hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit or hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 up to Day 7 after study vaccination

  52. SSE: Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Study Vaccination

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after study vaccination were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From study vaccination up to 1 Month after study vaccination

  53. SSE: Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 6 Month After Study Vaccination

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: From study vaccination up to 6 Months after study vaccination

  54. SSE: Percentage of Participants With Elevated Troponin I Levels Before the Study Vaccination- 18 to 55 Years of Age

    Percentage of participants with elevated troponin I levels before study vaccination were reported in this outcome measure.

    Time frame: Before study vaccination (pre-dose)

  55. SSE: Percentage of Participants With Elevated Troponin I Levels 3 Days After Study Vaccination- 18 to 55 Years of Age

    Percentage of participants with elevated troponin I levels before study vaccination were reported in this outcome measure.

    Time frame: 3 days after study vaccination

  56. SSE: Geometric Mean Ratio (GMR) Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After Study Vaccination

    GMR calculated based on GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).

    Time frame: 1 month after study vaccination

  57. SSE: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Study Vaccination

    Seroresponse was defined as achieving \>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below lower limit of quantification (LLOQ), postvaccination measure of \>= 4 × LLOQ is considered seroresponse. Exact 2-sided CI, based on Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.

    Time frame: 1 month after study vaccination

  58. SSF: Geometric Mean Titer (GMTs) of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers Before Vaccination

    GMT of SARS-CoV-2 Omicron BA.1 strain neutralizing titers before vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).

    Time frame: Before vaccination (pre-dose)

  59. SSF: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination

    Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (necrosis \[swelling\] or necrosis/exfoliative dermatitis \[redness\]). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after study vaccination and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.

    Time frame: Day 1 up to Day 7 after the study vaccination

  60. SSF: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination

    Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to 38.0 deg C and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C \& \>40.0 deg C. Fatigue, headache, chills, muscle pain and joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit or hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \> 2 times in 24h, severe: required intravenous hydration and Grade 4: ER or hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit or hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.

    Time frame: Day 1 up to Day 7 after the study vaccination

  61. SSF: Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Study Vaccination

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after study vaccination were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From study vaccination up to 1 Month after study vaccination

  62. SSF: Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 6 Months After Study Vaccination

    An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: From study vaccination up to 6 Months after study vaccination

  63. SSF: GMTs of SARS-CoV-2 Reference-Strain-Neutralizing Titers Before Vaccination

    GMT of SARS-CoV-2 reference-strain-neutralizing titers before vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).

    Time frame: Before vaccination (pre-dose)

  64. SSF: GMTs of SARS-CoV-2 Omicron BA.4/BA.5 Strain Neutralizing Titers Before Vaccination

    GMT of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers before vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).

    Time frame: Before vaccination (pre-dose)

  65. SSF: Geometric Mean Ratio (GMR) Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Day 7

    GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at Day 7 were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Day 7 (7 days after vaccination)

  66. SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Day 7

    GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at Day 7 were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Day 7 (7 days after vaccination)

  67. SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain Neutralizing Titers at Day 7

    GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at Day 7 were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Day 7 (7 days after vaccination)

  68. SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 1

    GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at 1 month were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Month 1 (1 month after vaccination)

  69. SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 1

    GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at 1 month were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Month 1 (1 month after vaccination)

  70. SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 1

    GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at 1 month were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Month 1 (1 month after vaccination)

  71. SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 3

    GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at 3 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Month 3 (3 month after vaccination)

  72. SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 3

    GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at 3 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Month 3 (3 month after vaccination)

  73. SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 3

    GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at 3 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Month 3 (3 month after vaccination)

  74. SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 6

    GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at 6 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Month 6 (6 month after vaccination)

  75. SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 6

    GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at 6 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Month 6 (6 months after vaccination)

  76. SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 6

    GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at 6 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: Month 6 (6 months after vaccination)

  77. SSF: Geometric Mean Fold-Rise (GMFR) of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination

    GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to Day 7 was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

    Time frame: From before the study vaccination to Day 7 (7 days after vaccination)

  78. SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination

    GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to Day 7 was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

    Time frame: From before the study vaccination to Day 7 (7 days after vaccination)

  79. SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination

    GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to Day 7 was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

    Time frame: From before the study vaccination to Day 7 (7 days after vaccination)

  80. SSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination

    GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to 1 month was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

    Time frame: From before the study vaccination to 1 month after vaccination

  81. SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination

    GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 1 month was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

    Time frame: From before the study vaccination to 1 month after vaccination

  82. SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination

    GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to 1 month was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

    Time frame: From before the study vaccination to 1 month after vaccination

  83. SSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination

    GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to 3 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

    Time frame: From before the study vaccination to 3 months after vaccination

  84. SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination

    GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 3 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

    Time frame: From before the study vaccination to 3 months after vaccination

  85. SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination

    GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to 3 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

    Time frame: From before the study vaccination to 3 months after vaccination

  86. SSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination

    GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to 6 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

    Time frame: From before the study vaccination to 6 months after vaccination

  87. SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination

    GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 6 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

    Time frame: From before the study vaccination to 6 months after vaccination

  88. SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination

    GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to 6 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

    Time frame: From before the study vaccination to 6 months after vaccination

  89. SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Day 7

    Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse on Day 7 was reported in this outcome measure.

    Time frame: Day 7 (7 days after vaccination)

  90. SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Day 7

    Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse on Day 7 was reported in this outcome measure.

    Time frame: Day 7 (7 days after vaccination)

  91. SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Day 7

    Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse on Day 7 was reported in this outcome measure.

    Time frame: Day 7 (7 days after vaccination)

  92. SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 1

    Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.

    Time frame: Month 1 (1 month after vaccination)

  93. SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 1

    Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.

    Time frame: Month 1 (1 month after vaccination)

  94. SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 1

    Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.

    Time frame: Month 1 (1 month after vaccination)

  95. SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 3

    Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 3 months was reported in this outcome measure.

    Time frame: Month 3 (3 months after vaccination)

  96. SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 3

    Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 3 months was reported in this outcome measure.

    Time frame: Month 3 (3 months after vaccination)

  97. SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 3

    Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 3 months was reported in this outcome measure.

    Time frame: Month 3 (3 months after vaccination)

  98. SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 6

    Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 6 months was reported in this outcome measure.

    Time frame: Month 6 (6 months after vaccination)

  99. SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 6

    Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 6 months was reported in this outcome measure.

    Time frame: Month 6 (6 months after vaccination)

  100. SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 6

    Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 6 months was reported in this outcome measure.

    Time frame: Month 6 (6 months after vaccination)

Secondary outcomes

  1. SSA: Occurrence of First Severe COVID-19 Infection (FDA Definition) Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection: Evaluable Efficacy Population

    Occurrence (number of cases) of first severe COVID-19 infection based on FDA definition after booster dose without past SARS-CoV-2 infection is reported. FDA definition: confirmed COVID-19 and presence of at least 1 of the following: 1) clinical signs at rest indicative of severe systemic illness (respiratory rate greater than or equal to \[\>=\]30 breaths per minute, heart rate \>= 125 beats per minute, oxygen saturation less than or equal to \[\<=\]93% on room air at sea level, or Horovitz quotient \<300 mmHg); 2) respiratory failure (needing high-flow oxygen, noninvasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation); 3) evidence of shock (systolic blood pressure \[BP\] \<90 mmHg, diastolic BP \<60 mmHg, or requiring vasopressors); 4) significant acute renal, hepatic, or neurologic dysfunction; 5) admission to an intensive care unit; 6) death.

    Time frame: From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 1.105 and for Placebo was 0.951

  2. SSA: Occurrence of First Severe COVID-19 Infection (FDA Definition) Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection: Evaluable Efficacy Population

    Occurrence (number of cases) of first severe COVID-19 infection based on FDA definition after booster dose with and without past SARS-CoV-2 infection is reported. FDA definition: confirmed COVID-19 and presence of at least 1 of the following: 1) clinical signs at rest indicative of severe systemic illness (respiratory rate \>= 30 breaths per minute, heart rate \>= 125 beats per minute, oxygen saturation \<= 93% on room air at sea level, or Horovitz quotient \<300 mm Hg); 2) respiratory failure (defined as needing high-flow oxygen, noninvasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation); 3) evidence of shock (systolic BP \<90 mm Hg, diastolic BP \<60 mm Hg, or requiring vasopressors); 4) significant acute renal, hepatic, or neurologic dysfunction; 5) admission to an intensive care unit; 6) death.

    Time frame: From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 1.182 and for Placebo was 1.011

  3. SSA: Occurrence of First Severe COVID-19 Infection (CDC Definition) Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection

    Occurrence (number of cases) of first severe COVID-19 infection based on CDC definition after booster dose without past SARS-CoV-2 infection is reported. CDC definition: confirmed COVID-19 and presence of at least 1 of the following: 1) hospitalization; 2) admission to an intensive care unit; 3) intubation or mechanical ventilation; 4) death.

    Time frame: From 7 Days after booster vaccination

  4. SSA: Occurrence of First Severe COVID-19 Infection (CDC Definition) Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection

    Occurrence (number of cases) of first severe COVID-19 infection based on CDC definition after booster dose with and without past SARS-CoV-2 infection is reported. CDC definition: confirmed COVID-19 AND presence of at least 1 of the following: 1) hospitalization; 2) admission to an intensive care unit; 3) intubation or mechanical ventilation; 4) death.

    Time frame: From 7 Days after booster vaccination

  5. SSC: GMTs of SARS-CoV-2 Reference-Strain Neutralizing Titers at Baseline and 7 Days After the Booster Dose

    GMT of SARS-CoV-2 reference-strain neutralizing titers at baseline and 7 days after the booster dose was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).

    Time frame: At baseline and 7 days after the booster dose

  6. SSC: GMTs of SARS-CoV-2 Omicron BA.1- Neutralizing Titers at Baseline and 7 Days After the Booster Dose

    GMT of SARS-CoV-2 Omicron BA.1- neutralizing titers at baseline and 7 days after the booster dose was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).

    Time frame: At baseline and 7 days after booster dose

  7. SSC: GMFRs of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Baseline to 7 Days After the Booster Dose

    GMFR of SARS-CoV-2 reference-strain-neutralizing titers from baseline (before the booster dose) to 7 days after the booster dose was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

    Time frame: From baseline (before booster dose) to 7 days after the booster dose

  8. SSC: GMFRs of SARS-CoV-2 Omicron BA.1-Neutralizing Titers From Baseline to 7 Days After the Booster Dose

    GMFR of SARS-CoV-2 Omicron BA.1-strain-neutralizing titers from baseline (before the booster dose) to 7 days after the booster dose was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

    Time frame: From baseline (before booster dose) to 7 days after the booster dose

  9. SSC: Percentages of Participants With Seroresponse to Reference Strain at 7 Days After the Booster Dose

    Seroresponse was defined as achieving \>= 4-fold rise from before booster dose. If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse to reference strain at 7 days after the booster dose was reported in this outcome measure.

    Time frame: 7 days after the booster dose

  10. SSC: Percentages of Participants With Seroresponse to Omicron BA.1 at 7 Days After the Booster Dose

    Seroresponse was defined as achieving \>= 4-fold rise from before booster dose. If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse to Omicron BA.1 strain at 7 days after the booster dose was reported in this outcome measure.

    Time frame: 7 days after the booster dose

  11. SSE: GMR Based on Geometric Mean Titers of SARS-CoV-2 Reference Strain Neutralizing Titers at 1 Month After the Study Vaccination- >55 Years of Age

    GMR based on GMT of SARS-CoV-2 reference strain neutralizing titers was calculated and reported in statistical analysis section. GMT of SARS-CoV-2 Reference strain-neutralizing titers at 1 month after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).

    Time frame: 1 month after study vaccination

07

Results

Posted Nov 10, 2025

Participant flow

This study was conducted in 6 parts: sub-study A (SSA), sub-study B (SSB), sub-study C (SSC), sub-study D (SSD), sub-study E (SSE) and sub-study F (SSF).

Blinded Period
Participant flow — Blinded Period
MilestoneSSA: BNT162b2 30 mcg: Blinded and Open Label PeriodSSA: Placebo: Blinded Period, Then BNT162b2 30 mcg Open-Label PeriodSSB: BNT162b2 30 mcg Then PlaceboSSB: Placebo Then BNT162b2 30 mcgSSC: BNT162b2 10 mcgSSC: BNT162b2 30 mcgSSD: Cohort 1: Group 1SSD: Cohort 1: Group 2SSD: Cohort 1: Group 2bSSD: Cohort 2: Group 3SSD: Cohort 2: Group 4SSD: Cohort 3: Group 5SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcgSSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcgSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
Started508050417537327565216197204315325210303030482159321202020202020305302307307308313211921202021
Safety analysis set508050417537327565216197204315323210303030482159321202020202020305302307307308313211921202021
Completed421227266936958197183193286293159283027450151302191919192019292294291299294307211921202021
Not completed4659501927396719141129325120332819111101138168146000000
Withdrew: Lost to follow-up282871432645810320001225000000312220000000
Withdrew: Protocol violation5140122000461002646010100465343000000
Withdrew: Death020000021102000000000001001101000000
Withdrew: Adverse event011100000110000000100000001000000000
Withdrew: No longer meets eligibility criteria120100001011000302000000100100000000
Withdrew: Other5434200221011000001000000002000000000
Withdrew: Physician decision110300110005000000000000000000000000
Withdrew: Withdrawal by subject2662141612953151172011125001000515142000000
Withdrew: Refused further study procedures000000100002000000000000000000000000
Withdrew: Participants entered open label period454449060000000000000000000000000000000000
Withdrew: Withdrawal by parent/guardian001101000000000000000000000000000000
Withdrew: Medication error000000000020000000000000000040000000
Open-Label Period
Participant flow — Open-Label Period
MilestoneSSA: BNT162b2 30 mcg: Blinded and Open Label PeriodSSA: Placebo: Blinded Period, Then BNT162b2 30 mcg Open-Label PeriodSSB: BNT162b2 30 mcg Then PlaceboSSB: Placebo Then BNT162b2 30 mcgSSC: BNT162b2 10 mcgSSC: BNT162b2 30 mcgSSD: Cohort 1: Group 1SSD: Cohort 1: Group 2SSD: Cohort 1: Group 2bSSD: Cohort 2: Group 3SSD: Cohort 2: Group 4SSD: Cohort 3: Group 5SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcgSSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcgSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
Started454449060000000000000000000000000000000000
Received open-label bnt162b2 30 mcg454444300000000000000000000000000000000000
Completed327238780000000000000000000000000000000000
Not completed127210280000000000000000000000000000000000
Withdrew: Lost to follow-up109410000000000000000000000000000000000
Withdrew: Protocol violation377480000000000000000000000000000000000
Withdrew: Death550000000000000000000000000000000000
Withdrew: No longer meets eligibility criteria2040000000000000000000000000000000000
Withdrew: Other6214290000000000000000000000000000000000
Withdrew: Physician decision200000000000000000000000000000000000
Withdrew: Withdrawal by subject135250000000000000000000000000000000000
Withdrew: Refused further study procedures100000000000000000000000000000000000
Withdrew: Adverse event100000000000000000000000000000000000
Withdrew: Withdrawal by parent/guardian100000000000000000000000000000000000
Withdrew: Did not receive open-label bnt162b2 30 mcg04760000000000000000000000000000000000

Outcome measures

PrimarySSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection at Interim Analysis: Evaluable Efficacy Population

Occurrences (number of cases) of first COVID-19 infection in participants after booster dose per 1000 person-year, without past SARS-CoV-2 infection at interim analysis were reported in this outcome measure.

Time frame:
From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year [PY]) for BNT162b2 was 0.823 and for Placebo was 0.792
Reported as:
Number · Number of first Covid-19 cases/1000 PY
SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection at Interim Analysis: Evaluable Efficacy Population
Number of first Covid-19 cases/1000 PYSSA: BNT162b2 30 mcg: Blinded and Open Label PeriodSSA: Placebo: Blinded Period
SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection at Interim Analysis: Evaluable Efficacy Population7.290155.303
Statistical analysis
  • SSA: BNT162b2 30 mcg: Blinded and Open Label Period vs SSA: Placebo: Blinded Period · Adjusted surveillance time: 95.3 · 95% CI 89.5 to 98.3
PrimarySSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection at Interim Analysis: Evaluable Efficacy Population

Occurrences (number of cases) of first COVID-19 infection in participants after booster dose with and without past SARS-CoV-2 infection at interim analysis were reported in this outcome measure.

Time frame:
From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 0.871 and for Placebo was 0.835
Reported as:
Number · Number of first Covid-19 cases/1000 PY
SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection at Interim Analysis: Evaluable Efficacy Population
Number of first Covid-19 cases/1000 PYSSA: BNT162b2 30 mcg: Blinded and Open Label PeriodSSA: Placebo: Blinded Period
SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection at Interim Analysis: Evaluable Efficacy Population8.037148.503
Statistical analysis
  • SSA: BNT162b2 30 mcg: Blinded and Open Label Period vs SSA: Placebo: Blinded Period · Adjusted surveillance time: 94.6 · 95% CI 88.5 to 97.9
PrimarySSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection at Final Analysis: Evaluable Efficacy Population

Occurrences (number of cases) of first COVID-19 infection in participants after booster dose without past SARS-CoV-2 infection at final analysis were reported in this outcome measure.

Time frame:
From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 1.098 and for Placebo was 0.932
Reported as:
Number · Number of first Covid-19 cases/1000 PY
SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection at Final Analysis: Evaluable Efficacy Population
Number of first Covid-19 cases/1000 PYSSA: BNT162b2 30 mcg: Blinded and Open Label PeriodSSA: Placebo: Blinded Period
SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection at Final Analysis: Evaluable Efficacy Population57.377158.798
Statistical analysis
  • SSA: BNT162b2 30 mcg: Blinded and Open Label Period vs SSA: Placebo: Blinded Period · Adjusted surveillance time: 63.9 · 95% CI 51.1 to 73.5
PrimarySSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection at Final Analysis: Evaluable Efficacy Population

Occurrences (number of cases) of first COVID-19 infection in participants after booster dose with and without past SARS-CoV-2 infection at final analysis were reported in this outcome measure.

Time frame:
From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 1.173 and for Placebo was 0.989
Reported as:
Number · Number of first Covid-19 cases/1000 PY
SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection at Final Analysis: Evaluable Efficacy Population
Number of first Covid-19 cases/1000 PYSSA: BNT162b2 30 mcg: Blinded and Open Label PeriodSSA: Placebo: Blinded Period
SSA: Occurrence of First COVID-19 Infection After Booster Dose Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection at Final Analysis: Evaluable Efficacy Population57.118151.668
Statistical analysis
  • SSA: BNT162b2 30 mcg: Blinded and Open Label Period vs SSA: Placebo: Blinded Period · Adjusted surveillance time: 62.4 · 95% CI 49.5 to 72.2
PrimarySSA: Percentage of Participants Reporting Adverse Events

An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
From booster dose (Day 1) to 1 month after booster dose
Reported as:
Number · Percentage of participants
SSA: Percentage of Participants Reporting Adverse Events
Percentage of participantsSSA: BNT162b2 30 mcg: Blinded and Open Label PeriodSSA: Placebo: Blinded Period
SSA: Percentage of Participants Reporting Adverse Events26.3 (25.0 to 27.5)7.1 (6.4 to 7.8)
PrimarySSA: Percentage of Participants Reporting Serious Adverse Events (SAE)

An SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); congenital anomaly/birth defect; or that was considered as an important medical event.

Time frame:
BNT162b2 30 mcg, Placebo then BNT162b2 30 mcg: From BNT162b2 dose to 6 months after BNT162b2 dose; Placebo: From placebo dose to unblinding for original placebo participants. Median blinded follow-up period for Placebo group=2.8 months
Reported as:
Number · Percentage of participants
SSA: Percentage of Participants Reporting Serious Adverse Events (SAE)
Percentage of participantsSSA: BNT162b2 30 mcg: Blinded and Open Label PeriodSSA: Placebo: Blinded PeriodSSA: Original Placebo/BNT162b2 30 mcg: Open Label Period
SSA: Percentage of Participants Reporting Serious Adverse Events (SAE)1.4 (1.1 to 1.8)0.8 (0.6 to 1.1)1.0 (0.7 to 1.3)
PrimarySSB: Percentage of Participants With Elevated Troponin I Level Pre-Dose; Vaccination 1

Percentage of participants with elevated troponin I levels before administration of Vaccination 1 were reported in this outcome measure.

Time frame:
Pre-dose on Day 1 (Vaccination 1)
Reported as:
Number · Percentage of participants
SSB: Percentage of Participants With Elevated Troponin I Level Pre-Dose; Vaccination 1
Percentage of participantsSSB: BNT162b2 30 mcg Then PlaceboSSB: Placebo Then BNT162b2 30 mcg
SSB: Percentage of Participants With Elevated Troponin I Level Pre-Dose; Vaccination 10.7 (0.2 to 1.5)0.5 (0.1 to 1.4)
PrimarySSB: Percentage of Participants With Elevated Troponin I Level Within 5 Days After Vaccination 1

Percentage of participants with elevated troponin I levels within 5 days after administration of Vaccination 1 were reported in this outcome measure.

Time frame:
Within 5 days after Vaccination 1
Reported as:
Number · Percentage of participants
SSB: Percentage of Participants With Elevated Troponin I Level Within 5 Days After Vaccination 1
Percentage of participantsSSB: BNT162b2 30 mcg Then PlaceboSSB: Placebo Then BNT162b2 30 mcg
SSB: Percentage of Participants With Elevated Troponin I Level Within 5 Days After Vaccination 11.0 (0.4 to 2.0)0.6 (0.2 to 1.5)
PrimarySSB: Percentage of Participants With Elevated Troponin I Level Pre-Vaccination 2 (1 Month After Vaccination 1)

Percentage of participants with elevated troponin I levels pre vaccination 2 were reported in this outcome measure.

Time frame:
Pre-Vaccination 2 (1 month after Vaccination 1)
Reported as:
Number · Percentage of participants
SSB: Percentage of Participants With Elevated Troponin I Level Pre-Vaccination 2 (1 Month After Vaccination 1)
Percentage of participantsSSB: BNT162b2 30 mcg Then PlaceboSSB: Placebo Then BNT162b2 30 mcg
SSB: Percentage of Participants With Elevated Troponin I Level Pre-Vaccination 2 (1 Month After Vaccination 1)1.1 (0.4 to 2.3)0.3 (0.0 to 1.2)
PrimarySSB: Percentage of Participants With Elevated Troponin I Level Within 5 Days After Vaccination 2

Percentage of participants with elevated troponin I levels within 5 days after administration of Vaccination 2 were reported in this outcome measure.

Time frame:
Within 5 days after vaccination 2
Reported as:
Number · Percentage of participants
SSB: Percentage of Participants With Elevated Troponin I Level Within 5 Days After Vaccination 2
Percentage of participantsSSB: BNT162b2 30 mcg Then PlaceboSSB: Placebo Then BNT162b2 30 mcg
SSB: Percentage of Participants With Elevated Troponin I Level Within 5 Days After Vaccination 21.5 (0.7 to 2.7)0.3 (0.0 to 1.1)
PrimarySSB: Percentage of Participants With Elevated Troponin I Level 1 Month After Vaccination 2

Percentage of participants with elevated troponin I levels within 1 month after administration of Vaccination 2 were reported in this outcome measure.

Time frame:
1 month after Vaccination 2
Reported as:
Number · Percentage of participants
SSB: Percentage of Participants With Elevated Troponin I Level 1 Month After Vaccination 2
Percentage of participantsSSB: BNT162b2 30 mcg Then PlaceboSSB: Placebo Then BNT162b2 30 mcg
SSB: Percentage of Participants With Elevated Troponin I Level 1 Month After Vaccination 20.7 (0.2 to 1.7)0.3 (0.0 to 1.1)
PrimarySSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1

Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 1 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.

Time frame:
Day 1 up to Day 7 after Vaccination 1
Reported as:
Number · Percentage of participants
SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1
Percentage of participantsSSB: BNT162b2 30 mcg Then PlaceboSSB: Placebo Then BNT162b2 30 mcg
Redness: Any5.8 (4.2 to 7.7)0.5 (0.1 to 1.4)
Redness: Mild4.4 (3.1 to 6.1)0.4 (0.1 to 1.2)
Redness: Moderate1.1 (0.5 to 2.1)0.1 (0.0 to 0.8)
Redness: Severe0.3 (0.0 to 1.0)0 (0.0 to 0.5)
Redness: Grade 40 (0.0 to 0.5)0 (0.0 to 0.5)
Swelling: Any6.6 (4.9 to 8.6)0.5 (0.1 to 1.4)
Swelling: Mild5.0 (3.5 to 6.8)0.4 (0.1 to 1.2)
Swelling: Moderate1.5 (0.7 to 2.6)0 (0.0 to 0.5)
Swelling: Severe0.1 (0.0 to 0.7)0.1 (0.0 to 0.8)
Swelling: Grade 40 (0.0 to 0.5)0 (0.0 to 0.5)
Pain at injection site: Any74.4 (71.1 to 77.5)13.9 (11.4 to 16.6)
Pain at injection site: Mild48.7 (45.1 to 52.4)12.2 (9.9 to 14.8)
Pain at injection site: Moderate25.4 (22.3 to 28.7)1.6 (0.9 to 2.9)
Pain at injection site: Severe0.3 (0.0 to 1.0)0 (0.0 to 0.5)
Pain at injection site: Grade 40 (0.0 to 0.5)0 (0.0 to 0.5)
PrimarySSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2

Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 2 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.

Time frame:
Day 1 up to Day 7 after Vaccination 2
Reported as:
Number · Percentage of participants
SSB: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2
Percentage of participantsSSB: BNT162b2 30 mcg Then PlaceboSSB: Placebo Then BNT162b2 30 mcg
Redness: Any0.7 (0.2 to 1.6)4.6 (3.2 to 6.5)
Redness: Mild0.3 (0.0 to 1.0)2.8 (1.7 to 4.4)
Redness: Moderate0.4 (0.1 to 1.2)1.5 (0.7 to 2.7)
Redness: Severe0 (0.0 to 0.5)0.3 (0.0 to 1.1)
Redness: Grade 40 (0.0 to 0.5)0 (0.0 to 0.5)
Swelling: Any0.4 (0.1 to 1.2)5.5 (3.9 to 7.5)
Swelling: Mild0.4 (0.1 to 1.2)3.4 (2.2 to 5.1)
Swelling: Moderate0 (0.0 to 0.5)1.9 (1.0 to 3.3)
Swelling: Severe0 (0.0 to 0.5)0.1 (0.0 to 0.8)
Swelling: Grade 40 (0.0 to 0.5)0 (0.0 to 0.5)
Pain at injection site: Any8.8 (6.8 to 11.1)71.7 (68.2 to 75.1)
Pain at injection site: Mild6.7 (4.9 to 8.8)40.3 (36.6 to 44.1)
Pain at injection site: Moderate2.1 (1.2 to 3.5)30.5 (27.0 to 34.1)
Pain at injection site: Severe0 (0.0 to 0.5)0.9 (0.3 to 1.9)
Pain at injection site: Grade 40 (0.0 to 0.5)0 (0.0 to 0.5)
PrimarySSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1

Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to (\>=) 38.0 degree Celsius (deg C) and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 up to Day 7 after Vaccination 1
Reported as:
Number · Percentage of participants
SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1
Percentage of participantsSSB: BNT162b2 30 mcg Then PlaceboSSB: Placebo Then BNT162b2 30 mcg
Fever: >=38 deg C6.0 (4.4 to 8.0)1.9 (1.1 to 3.2)
Fever: 38.0 to 38.4 deg C4.1 (2.8 to 5.8)1.4 (0.7 to 2.5)
Fever: >38.4 to 38.9 deg C1.7 (0.9 to 3.0)0.3 (0.0 to 1.0)
Fever: >38.9 to 40.0 deg C0.1 (0.0 to 0.7)0.3 (0.0 to 1.0)
Fever: >40.0 deg C0 (0.0 to 0.5)0 (0.0 to 0.5)
Fatigue: Any54.2 (50.6 to 57.8)31.9 (28.5 to 35.4)
Fatigue: Mild27.4 (24.3 to 30.8)19.5 (16.7 to 22.6)
Fatigue: Moderate25.3 (22.2 to 28.6)12.2 (9.9 to 14.8)
Fatigue: Severe1.5 (0.7 to 2.6)0.1 (0.0 to 0.8)
Fatigue: Grade 40 (0.0 to 0.5)0 (0.0 to 0.5)
Headache: Any42.6 (39.0 to 46.2)28.3 (25.0 to 31.7)
Headache: Mild24.2 (21.2 to 27.5)18.0 (15.3 to 21.0)
Headache: Moderate17.3 (14.6 to 20.2)10.0 (7.9 to 12.4)
Headache: Severe1.1 (0.5 to 2.1)0.3 (0.0 to 1.0)
Headache: Grade 40 (0.0 to 0.5)0 (0.0 to 0.5)
Chills: Any17.1 (14.5 to 20.0)5.9 (4.3 to 7.9)
Chills: Mild10.6 (8.5 to 13.0)4.4 (3.0 to 6.1)
Chills: Moderate6.3 (4.7 to 8.3)1.5 (0.8 to 2.7)
Chills: Severe0.3 (0.0 to 1.0)0 (0.0 to 0.5)
Chills: Grade 40 (0.0 to 0.5)0 (0.0 to 0.5)
Vomiting: Any3.2 (2.1 to 4.7)0.8 (0.3 to 1.8)
Vomiting: Mild2.8 (1.7 to 4.3)0.7 (0.2 to 1.6)
Vomiting: Moderate0.4 (0.1 to 1.2)0.1 (0.0 to 0.8)
Vomiting: Severe0 (0.0 to 0.5)0 (0.0 to 0.5)
Vomiting: Grade 40 (0.0 to 0.5)0 (0.0 to 0.5)
Diarrhea: Any7.4 (5.6 to 9.5)7.4 (5.6 to 9.6)
Diarrhea: Mild6.4 (4.8 to 8.4)6.0 (4.4 to 8.0)
Diarrhea: Moderate0.9 (0.4 to 1.9)1.4 (0.7 to 2.5)
Diarrhea: Severe0 (0.0 to 0.5)0 (0.0 to 0.5)
Diarrhea: Grade 40 (0.0 to 0.5)0 (0.0 to 0.5)
New or worsened muscle pain: Any27.6 (24.4 to 30.9)7.7 (5.9 to 9.9)
New or worsened muscle pain: Mild14.1 (11.6 to 16.8)5.1 (3.6 to 6.9)
New or worsened muscle pain: Moderate13.3 (10.9 to 15.9)2.5 (1.5 to 3.9)
New or worsened muscle pain: Severe0.3 (0.0 to 1.0)0.1 (0.0 to 0.8)
New or worsened muscle pain: Grade 40 (0.0 to 0.5)0 (0.0 to 0.5)
New or worsened joint pain: Any12.9 (10.5 to 15.5)4.5 (3.1 to 6.3)
New or worsened joint pain: Mild8.3 (6.4 to 10.5)3.0 (1.9 to 4.5)
New or worsened joint pain: Moderate4.3 (2.9 to 6.0)1.5 (0.8 to 2.7)
New or worsened joint pain: Severe0.3 (0.0 to 1.0)0 (0.0 to 0.5)
New or worsened joint pain: Grade 40 (0.0 to 0.5)0 (0.0 to 0.5)
PrimarySSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2

Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to (\>=) 38.0 degree Celsius (deg C) and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 up to Day 7 after Vaccination 2
Reported as:
Number · Percentage of participants
SSB: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2
Percentage of participantsSSB: BNT162b2 30 mcg Then PlaceboSSB: Placebo Then BNT162b2 30 mcg
Fever: >=38 deg C0.4 (0.1 to 1.2)4.3 (2.9 to 6.1)
Fever: 38.0 to 38.4 deg C0.3 (0.0 to 1.0)2.5 (1.5 to 4.0)
Fever: >38.4 to 38.9 deg C0.1 (0.0 to 0.8)1.3 (0.6 to 2.5)
Fever: >38.9 to 40.0 deg C0 (0.0 to 0.5)0.4 (0.1 to 1.3)
Fever: >40.0 deg C0 (0.0 to 0.5)0 (0.0 to 0.5)
Fatigue: Any17.6 (14.8 to 20.6)47.3 (43.5 to 51.2)
Fatigue: Mild8.6 (6.7 to 11.0)18.8 (15.9 to 21.9)
Fatigue: Moderate8.5 (6.5 to 10.8)27.1 (23.8 to 30.6)
Fatigue: Severe0.4 (0.1 to 1.2)1.5 (0.7 to 2.7)
Fatigue: Grade 40 (0.0 to 0.5)0 (0.0 to 0.5)
Headache: Any17.8 (15.1 to 20.9)39.7 (36.0 to 43.5)
Headache: Mild10.3 (8.2 to 12.8)19.8 (16.8 to 23.0)
Headache: Moderate7.2 (5.4 to 9.4)19.0 (16.1 to 22.2)
Headache: Severe0.3 (0.0 to 1.0)0.9 (0.3 to 1.9)
Headache: Grade 40 (0.0 to 0.5)0 (0.0 to 0.5)
Chills: Any3.7 (2.4 to 5.3)22.3 (19.2 to 25.7)
Chills: Mild2.3 (1.3 to 3.7)13.2 (10.8 to 16.0)
Chills: Moderate1.1 (0.5 to 2.2)8.8 (6.8 to 11.2)
Chills: Severe0.3 (0.0 to 1.0)0.3 (0.0 to 1.1)
Chills: Grade 40 (0.0 to 0.5)0 (0.0 to 0.5)
Vomiting: Any1.0 (0.4 to 2.0)1.9 (1.0 to 3.3)
Vomiting: Mild0.7 (0.2 to 1.6)1.8 (0.9 to 3.1)
Vomiting: Moderate0.3 (0.0 to 1.0)0.1 (0.0 to 0.8)
Vomiting: Severe0 (0.0 to 0.5)0 (0.0 to 0.5)
Vomiting: Grade 40 (0.0 to 0.5)0 (0.0 to 0.5)
Diarrhea: Any3.3 (2.1 to 4.8)8.0 (6.1 to 10.4)
Diarrhea: Mild2.1 (1.2 to 3.5)6.5 (4.8 to 8.7)
Diarrhea: Moderate1.1 (0.5 to 2.2)1.5 (0.7 to 2.7)
Diarrhea: Severe0 (0.0 to 0.5)0 (0.0 to 0.5)
Diarrhea: Grade 40 (0.0 to 0.5)0 (0.0 to 0.5)
New or worsened muscle pain: Any4.5 (3.1 to 6.3)29.2 (25.8 to 32.8)
New or worsened muscle pain: Mild2.3 (1.3 to 3.7)15.9 (13.2 to 18.9)
New or worsened muscle pain: Moderate2.1 (1.2 to 3.5)12.9 (10.5 to 15.7)
New or worsened muscle pain: Severe0.1 (0.0 to 0.8)0.3 (0.0 to 1.1)
New or worsened muscle pain: Grade 40 (0.0 to 0.5)0 (0.0 to 0.5)
New or worsened joint pain: Any3.1 (2.0 to 4.7)12.2 (9.8 to 14.9)
New or worsened joint pain: Mild1.6 (0.8 to 2.8)7.4 (5.6 to 9.7)
New or worsened joint pain: Moderate1.6 (0.8 to 2.8)4.8 (3.3 to 6.7)
New or worsened joint pain: Severe0 (0.0 to 0.5)0 (0.0 to 0.5)
New or worsened joint pain: Grade 40 (0.0 to 0.5)0 (0.0 to 0.5)
PrimarySSB: Percentage of Participants Reporting Adverse Events (AEs) 1 Month After Vaccination 1

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after Vaccination 1 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Vaccination 1 up to 1 Month After Vaccination 1
Reported as:
Number · Percentage of participants
SSB: Percentage of Participants Reporting Adverse Events (AEs) 1 Month After Vaccination 1
Percentage of participantsSSB: BNT162b2 30 mcg Then PlaceboSSB: Placebo Then BNT162b2 30 mcg
SSB: Percentage of Participants Reporting Adverse Events (AEs) 1 Month After Vaccination 19.4 (7.4 to 11.7)10.4 (8.3 to 12.8)
PrimarySSB: Percentage of Participants Reporting Adverse Events (AEs) 1 Month After Vaccination 2

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after Vaccination 2 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
Vaccination 2 up to 1 month after Vaccination 2
Reported as:
Number · Percentage of participants
SSB: Percentage of Participants Reporting Adverse Events (AEs) 1 Month After Vaccination 2
Percentage of participantsSSB: BNT162b2 30 mcg Then PlaceboSSB: Placebo Then BNT162b2 30 mcg
SSB: Percentage of Participants Reporting Adverse Events (AEs) 1 Month After Vaccination 25.6 (4.1 to 7.5)7.4 (5.6 to 9.6)
PrimarySSB: Percentage of Participants Reporting Serious Adverse Events (SAEs) 1 Month After Vaccination 1

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
Vaccination 1 up to 1 month after Vaccination 1
Reported as:
Number · Percentage of participants
SSB: Percentage of Participants Reporting Serious Adverse Events (SAEs) 1 Month After Vaccination 1
Percentage of participantsSSB: BNT162b2 30 mcg Then PlaceboSSB: Placebo Then BNT162b2 30 mcg
SSB: Percentage of Participants Reporting Serious Adverse Events (SAEs) 1 Month After Vaccination 10.1 (0.0 to 0.7)0.3 (0.0 to 1.0)
PrimarySSB: Percentage of Participants Reporting Serious Adverse Events (SAEs) 1 Month After Vaccination 2

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
Vaccination 2 up to 1 month after Vaccination 2
Reported as:
Number · Percentage of participants
SSB: Percentage of Participants Reporting Serious Adverse Events (SAEs) 1 Month After Vaccination 2
Percentage of participantsSSB: BNT162b2 30 mcg Then PlaceboSSB: Placebo Then BNT162b2 30 mcg
SSB: Percentage of Participants Reporting Serious Adverse Events (SAEs) 1 Month After Vaccination 20 (0.0 to 0.5)0.1 (0.0 to 0.8)
PrimarySSC: Percentage of Participants With Local Reactions Within 7 Days After Booster Dose

Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 cm and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after the booster (third) dose and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.

Time frame:
Day 1 up to Day 7 after the booster dose
Reported as:
Number · Percentage of participants
SSC: Percentage of Participants With Local Reactions Within 7 Days After Booster Dose
Percentage of participantsSSC: BNT162b2 10 mcgSSC: BNT162b2 30 mcg
Redness: Any1.3 (0.0 to 7.2)6.3 (1.7 to 15.2)
Redness: Mild1.3 (0.0 to 7.2)4.7 (1.0 to 13.1)
Redness: Moderate0 (0.0 to 4.8)1.6 (0.0 to 8.4)
Redness: Severe0 (0.0 to 4.8)0 (0.0 to 5.6)
Redness: Grade 40 (0.0 to 4.8)0 (0.0 to 5.6)
Swelling: Any2.7 (0.3 to 9.3)9.4 (3.5 to 19.3)
Swelling: Mild2.7 (0.3 to 9.3)6.3 (1.7 to 15.2)
Swelling: Moderate0 (0.0 to 4.8)3.1 (0.4 to 10.8)
Swelling: Severe0 (0.0 to 4.8)0 (0.0 to 5.6)
Swelling: Grade 40 (0.0 to 4.8)0 (0.0 to 5.6)
Pain at the injection site: Any56.0 (44.1 to 67.5)78.1 (66.0 to 87.5)
Pain at the injection site: Mild40.0 (28.9 to 52.0)46.9 (34.3 to 59.8)
Pain at the injection site: Moderate16.0 (8.6 to 26.3)31.3 (20.2 to 44.1)
Pain at the injection site: Severe0 (0.0 to 4.8)0 (0.0 to 5.6)
Pain at the injection site: Grade 40 (0.0 to 4.8)0 (0.0 to 5.6)
PrimarySSC: Percentage of Participants With Systemic Events Within 7 Days After Booster Dose

Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to (\>=) 38.0 degree Celsius (deg C) and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24 h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 up to Day 7 after the booster dose
Reported as:
Number · Percentage of participants
SSC: Percentage of Participants With Systemic Events Within 7 Days After Booster Dose
Percentage of participantsSSC: BNT162b2 10 mcgSSC: BNT162b2 30 mcg
Fever: >=38.0 deg C4.0 (0.8 to 11.2)6.3 (1.7 to 15.2)
Fever: >=38.0°C to 38.4 deg C2.7 (0.3 to 9.3)3.1 (0.4 to 10.8)
Fever: >38.4°C to 38.9 deg C0 (0.0 to 4.8)1.6 (0.0 to 8.4)
Fever: >38.9°C to 40.0 deg C1.3 (0.0 to 7.2)0 (0.0 to 5.6)
Fever: >40.0 deg C0 (0.0 to 4.8)1.6 (0.0 to 8.4)
Fatigue: Any49.3 (37.6 to 61.1)54.7 (41.7 to 67.2)
Fatigue: Mild22.7 (13.8 to 33.8)25.0 (15.0 to 37.4)
Fatigue: Moderate25.3 (16.0 to 36.7)26.6 (16.3 to 39.1)
Fatigue: Severe1.3 (0.0 to 7.2)3.1 (0.4 to 10.8)
Fatigue: Grade 40 (0.0 to 4.8)0 (0.0 to 5.6)
Headache: Any41.3 (30.1 to 53.3)53.1 (40.2 to 65.7)
Headache: Mild21.3 (12.7 to 32.3)31.3 (20.2 to 44.1)
Headache: Moderate20.0 (11.6 to 30.8)20.3 (11.3 to 32.2)
Headache: Severe0 (0.0 to 4.8)1.6 (0.0 to 8.4)
Headache: Grade 40 (0.0 to 4.8)0 (0.0 to 5.6)
Chills: Any13.3 (6.6 to 23.2)23.4 (13.8 to 35.7)
Chills: Mild5.3 (1.5 to 13.1)12.5 (5.6 to 23.2)
Chills: Moderate8.0 (3.0 to 16.6)10.9 (4.5 to 21.2)
Chills: Severe0 (0.0 to 4.8)0 (0.0 to 5.6)
Chills: Grade 40 (0.0 to 4.8)0 (0.0 to 5.6)
Vomiting: Any1.3 (0.0 to 7.2)3.1 (0.4 to 10.8)
Vomiting: Mild0 (0.0 to 4.8)1.6 (0.0 to 8.4)
Vomiting: Moderate1.3 (0.0 to 7.2)1.6 (0.0 to 8.4)
Vomiting: Severe0 (0.0 to 4.8)0 (0.0 to 5.6)
Vomiting: Grade 40 (0.0 to 4.8)0 (0.0 to 5.6)
Diarrhea: Any4.0 (0.8 to 11.2)9.4 (3.5 to 19.3)
Diarrhea: Mild2.7 (0.3 to 9.3)9.4 (3.5 to 19.3)
Diarrhea: Moderate1.3 (0.0 to 7.2)0 (0.0 to 5.6)
Diarrhea: Severe0 (0.0 to 4.8)0 (0.0 to 5.6)
Diarrhea: Grade 40 (0.0 to 4.8)0 (0.0 to 5.6)
New or worsened muscle pain: Any24.0 (14.9 to 35.3)37.5 (25.7 to 50.5)
New or worsened muscle pain: Mild4.0 (0.8 to 11.2)20.3 (11.3 to 32.2)
New or worsened muscle pain: Moderate20.0 (11.6 to 30.8)17.2 (8.9 to 28.7)
New or worsened muscle pain: Severe0 (0.0 to 4.8)0 (0.0 to 5.6)
New or worsened muscle pain: Grade 40 (0.0 to 4.8)0 (0.0 to 5.6)
New or worsened joint pain: Any14.7 (7.6 to 24.7)15.6 (7.8 to 26.9)
New or worsened joint pain: Mild5.3 (1.5 to 13.1)10.9 (4.5 to 21.2)
New or worsened joint pain: Moderate9.3 (3.8 to 18.3)4.7 (1.0 to 13.1)
New or worsened joint pain: Severe0 (0.0 to 4.8)0 (0.0 to 5.6)
New or worsened joint pain: Grade 40 (0.0 to 4.8)0 (0.0 to 5.6)
PrimarySSC: Percentage of Participants Reporting Adverse Events From Booster Dose Through 1 Month After Booster Dose

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from booster (third) dose up to 1 month after booster (third) dose were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From booster dose (Day 1) up to 1 month after booster dose
Reported as:
Number · Percentage of participants
SSC: Percentage of Participants Reporting Adverse Events From Booster Dose Through 1 Month After Booster Dose
Percentage of participantsSSC: BNT162b2 10 mcgSSC: BNT162b2 30 mcg
SSC: Percentage of Participants Reporting Adverse Events From Booster Dose Through 1 Month After Booster Dose4.0 (0.8 to 11.2)7.7 (2.5 to 17.0)
PrimarySSC: Percentage of Participants Reporting Serious Adverse Events From Booster Dose Through 6 Months After Booster Dose

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
From booster dose (Day 1) up to 6 months after booster dose
Reported as:
Number · Percentage of participants
SSC: Percentage of Participants Reporting Serious Adverse Events From Booster Dose Through 6 Months After Booster Dose
Percentage of participantsSSC: BNT162b2 10 mcgSSC: BNT162b2 30 mcg
SSC: Percentage of Participants Reporting Serious Adverse Events From Booster Dose Through 6 Months After Booster Dose0 (0.0 to 4.8)1.5 (0.0 to 8.3)
PrimarySSC: Geometric Mean Titers (GMT) of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Baseline

GMT of SARS-CoV-2 reference-strain-neutralizing titers at baseline (before the booster dose) was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).

Time frame:
At baseline (pre-dose)
Reported as:
Geometric mean · Titer
SSC: Geometric Mean Titers (GMT) of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Baseline
TiterSSC: BNT162b2 10 mcgSSC: BNT162b2 30 mcg
SSC: Geometric Mean Titers (GMT) of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Baseline1337.2 (941.5 to 1899.2)1648.4 (1087.5 to 2498.6)
PrimarySSC: GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at 1 Month After the Booster Dose

GMT of SARS-CoV-2 reference-strain-neutralizing titers at 1 month after the booster dose was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).

Time frame:
1 month after the booster dose
Reported as:
Geometric mean · Titer
SSC: GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at 1 Month After the Booster Dose
TiterSSC: BNT162b2 10 mcgSSC: BNT162b2 30 mcg
SSC: GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at 1 Month After the Booster Dose11672.4 (9754.8 to 13967.0)15680.7 (13308.9 to 18475.2)
PrimarySSC: Geometric Mean Fold-Rise (GMFR) of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Baseline to 1 Month After the Booster Dose

GMFR of SARS-CoV-2 reference-strain-neutralizing titers from baseline to 1 month after the booster dose received in this sub-study was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

Time frame:
From baseline to 1 month after the booster dose
Reported as:
Geometric mean · Fold rise
SSC: Geometric Mean Fold-Rise (GMFR) of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Baseline to 1 Month After the Booster Dose
Fold riseSSC: BNT162b2 10 mcgSSC: BNT162b2 30 mcg
SSC: Geometric Mean Fold-Rise (GMFR) of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Baseline to 1 Month After the Booster Dose8.6 (6.4 to 11.6)9.5 (6.5 to 13.9)
PrimarySSC: Percentage of Participants With Seroresponse to Reference-Strain at 1 Month After the Booster Dose

Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month after the booster dose was reported in this outcome measure.

Time frame:
1 month after the booster dose
Reported as:
Number · Percentage of participants
SSC: Percentage of Participants With Seroresponse to Reference-Strain at 1 Month After the Booster Dose
Percentage of participantsSSC: BNT162b2 10 mcgSSC: BNT162b2 30 mcg
SSC: Percentage of Participants With Seroresponse to Reference-Strain at 1 Month After the Booster Dose67.7 (54.9 to 78.8)66.7 (52.5 to 78.9)
PrimarySSD: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1

Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu=0.5 centimeter (cm) and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection (inj) site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit/hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 1 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.

Time frame:
Day 1 up to Day 7 after Vaccination 1
Reported as:
Number · Percentage of participants
SSD: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1
Percentage of participantsSSD: Cohort 1: Group 1SSD: Cohort 1: Group 2SSD: Cohort 1: Group 2bSSD: Cohort 2: Group 3SSD: Cohort 2: Group 4SSD: Cohort 3: Group 5
Redness: Any3.4 (1.4 to 6.8)5.7 (2.9 to 10.0)2.5 (0.8 to 5.7)7.1 (4.5 to 10.7)4.3 (2.3 to 7.2)5.4 (2.6 to 9.7)
Redness: Mild1.0 (0.1 to 3.4)4.2 (1.8 to 8.0)1.0 (0.1 to 3.5)4.4 (2.4 to 7.4)3.9 (2.1 to 6.8)3.2 (1.2 to 6.9)
Redness: Moderate1.4 (0.3 to 4.2)1.6 (0.3 to 4.5)1.5 (0.3 to 4.3)2.7 (1.2 to 5.3)0.3 (0.0 to 1.8)2.2 (0.6 to 5.4)
Redness: Severe1.0 (0.1 to 3.4)0 (0.0 to 1.9)0 (0.0 to 1.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 2.0)
Redness: Grade 40 (0.0 to 1.8)0 (0.0 to 1.9)0 (0.0 to 1.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 2.0)
Swelling: Any8.2 (4.9 to 12.8)7.3 (4.0 to 11.9)5.5 (2.8 to 9.6)8.5 (5.6 to 12.3)8.9 (5.9 to 12.7)11.3 (7.1 to 16.7)
Swelling: Mild4.3 (2.0 to 8.1)4.2 (1.8 to 8.0)4.5 (2.1 to 8.3)5.4 (3.1 to 8.7)6.9 (4.3 to 10.4)6.5 (3.4 to 11.0)
Swelling: Moderate3.9 (1.7 to 7.5)2.6 (0.9 to 6.0)1.0 (0.1 to 3.5)3.1 (1.4 to 5.7)2.0 (0.7 to 4.2)4.8 (2.2 to 9.0)
Swelling: Severe0 (0.0 to 1.8)0.5 (0.0 to 2.9)0 (0.0 to 1.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 2.0)
Swelling: Grade 40 (0.0 to 1.8)0 (0.0 to 1.9)0 (0.0 to 1.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 2.0)
Injection site pain: Any46.4 (39.4 to 53.4)42.7 (35.6 to 50.0)42.3 (35.4 to 49.4)78.2 (73.1 to 82.8)78.9 (73.9 to 83.4)54.3 (46.8 to 61.5)
Injection site pain: Mild30.9 (24.7 to 37.7)27.1 (20.9 to 34.0)32.3 (25.9 to 39.3)59.2 (53.3 to 64.9)61.5 (55.8 to 67.0)27.7 (21.4 to 34.6)
Injection site pain: Moderate15.0 (10.4 to 20.6)14.1 (9.5 to 19.8)9.5 (5.8 to 14.4)18.4 (14.1 to 23.3)16.4 (12.5 to 21.1)26.1 (19.9 to 33.0)
Injection site pain: Severe0.5 (0.0 to 2.7)1.6 (0.3 to 4.5)0.5 (0.0 to 2.7)0.7 (0.1 to 2.4)1.0 (0.2 to 2.9)0.5 (0.0 to 2.9)
Injection site pain: Grade 40 (0.0 to 1.8)0 (0.0 to 1.9)0 (0.0 to 1.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.9)
PrimarySSD: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2

Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 2 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.

Time frame:
Day 1 up to Day 7 after Vaccination 2
Reported as:
Number · Percentage of participants
SSD: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2
Percentage of participantsSSD: Cohort 1: Group 2SSD: Cohort 2: Group 3SSD: Cohort 2: Group 4SSD: Cohort 3: Group 5
Redness: Any5.7 (2.7 to 10.6)5.1 (2.5 to 9.2)4.1 (1.9 to 7.7)4.3 (1.6 to 9.1)
Redness: Mild4.5 (1.8 to 9.0)3.6 (1.4 to 7.2)4.1 (1.9 to 7.7)2.1 (0.4 to 6.1)
Redness: Moderate1.3 (0.2 to 4.5)1.5 (0.3 to 4.4)0 (0.0 to 1.7)2.1 (0.4 to 6.1)
Redness: Severe0 (0.0 to 2.3)0 (0.0 to 1.9)0 (0.0 to 1.7)0 (0.0 to 2.6)
Redness: Grade 40 (0.0 to 2.3)0 (0.0 to 1.9)0 (0.0 to 1.7)0 (0.0 to 2.6)
Swelling: Any8.9 (5.0 to 14.5)4.1 (1.8 to 7.9)6.5 (3.6 to 10.6)9.2 (5.0 to 15.3)
Swelling: Mild7.0 (3.5 to 12.2)2.0 (0.6 to 5.1)5.5 (2.9 to 9.5)5.7 (2.5 to 10.9)
Swelling: Moderate1.3 (0.2 to 4.5)2.0 (0.6 to 5.1)0.9 (0.1 to 3.3)3.5 (1.2 to 8.1)
Swelling: Severe0.6 (0.0 to 3.5)0 (0.0 to 1.9)0 (0.0 to 1.7)0 (0.0 to 2.6)
Swelling: Grade 40 (0.0 to 2.3)0 (0.0 to 1.9)0 (0.0 to 1.7)0 (0.0 to 2.6)
Injection site pain: Any40.1 (32.4 to 48.2)74.5 (67.8 to 80.4)70.6 (64.1 to 76.6)34.5 (26.7 to 42.9)
Injection site pain: Mild29.9 (22.9 to 37.8)55.6 (48.4 to 62.7)57.8 (50.9 to 64.4)21.1 (14.7 to 28.8)
Injection site pain: Moderate10.2 (5.9 to 16.0)18.9 (13.7 to 25.1)12.4 (8.3 to 17.5)13.4 (8.3 to 20.1)
Injection site pain: Severe0 (0.0 to 2.3)0 (0.0 to 1.9)0.5 (0.0 to 2.5)0 (0.0 to 2.6)
Injection site pain0 (0.0 to 2.3)0 (0.0 to 1.9)0 (0.0 to 1.7)0 (0.0 to 2.6)
PrimarySSD: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 3

Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (\> 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after Vaccination 3 and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.

Time frame:
Day 1 up to Day 7 after Vaccination 3
Reported as:
Number · Percentage of participants
SSD: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 3
Percentage of participantsSSD: Cohort 3: Group 5
Redness: Any4.5 (1.8 to 9.1)
Redness: Mild1.3 (0.2 to 4.6)
Redness: Moderate3.2 (1.1 to 7.4)
Redness: Severe0 (0.0 to 2.4)
Redness: Grade 40 (0.0 to 2.4)
Swelling: Any10.4 (6.1 to 16.3)
Swelling: Mild3.2 (1.1 to 7.4)
Swelling: Moderate7.1 (3.6 to 12.4)
Swelling: Severe0 (0.0 to 2.4)
Swelling: Grade 40 (0.0 to 2.4)
Pain at the injection site: Any39.0 (31.2 to 47.1)
Pain at the injection site: Mild19.5 (13.5 to 26.6)
Pain at the injection site: Moderate18.8 (13.0 to 25.9)
Pain at the injection site: Severe0.6 (0.0 to 3.6)
Pain at the injection site: Grade 40 (0.0 to 2.4)
PrimarySSD: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1

Systemic events were recorded in e-diary. Fever: oral temperature \>= 38.0 deg C, categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 up to Day 7 after Vaccination 1
Reported as:
Number · Percentage of participants
SSD: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1
Percentage of participantsSSD: Cohort 1: Group 1SSD: Cohort 1: Group 2SSD: Cohort 1: Group 2bSSD: Cohort 2: Group 3SSD: Cohort 2: Group 4SSD: Cohort 3: Group 5
Fever: Any5.8 (3.0 to 9.9)2.6 (0.9 to 6.0)5.0 (2.4 to 9.0)8.8 (5.9 to 12.7)7.2 (4.6 to 10.8)4.8 (2.2 to 9.0)
Fever: >=38.0 deg C to 38.4 deg C4.3 (2.0 to 8.1)1.6 (0.3 to 4.5)2.5 (0.8 to 5.7)4.8 (2.6 to 7.9)3.9 (2.1 to 6.8)1.1 (0.1 to 3.8)
Fever: >38.4 deg C to 38.9 deg C0.5 (0.0 to 2.7)0.5 (0.0 to 2.9)1.5 (0.3 to 4.3)3.4 (1.6 to 6.2)3.0 (1.4 to 5.5)2.7 (0.9 to 6.2)
Fever: >38.9 deg C to 40.0 deg C1.0 (0.1 to 3.4)0.5 (0.0 to 2.9)1.0 (0.1 to 3.5)0.3 (0.0 to 1.9)0.3 (0.0 to 1.8)1.1 (0.1 to 3.8)
Fever: >40.0 deg C0 (0.0 to 1.8)0 (0.0 to 1.9)0 (0.0 to 1.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 2.0)
Fever: Unknown0 (0.0 to 1.8)0 (0.0 to 1.9)0 (0.0 to 1.8)0.3 (0.0 to 1.9)0 (0.0 to 1.2)0 (0.0 to 2.0)
Fatigue: Any32.4 (26.0 to 39.2)26.6 (20.5 to 33.4)28.4 (22.2 to 35.1)64.6 (58.9 to 70.1)60.5 (54.8 to 66.1)39.2 (32.2 to 46.7)
Fatigue: Mild18.8 (13.8 to 24.8)14.6 (9.9 to 20.4)16.4 (11.6 to 22.3)26.5 (21.6 to 32.0)29.3 (24.2 to 34.7)16.7 (11.6 to 22.8)
Fatigue: Moderate12.6 (8.4 to 17.9)12.0 (7.7 to 17.4)10.9 (7.0 to 16.1)34.7 (29.3 to 40.4)28.9 (23.9 to 34.4)22.0 (16.3 to 28.7)
Fatigue: Severe1.0 (0.1 to 3.4)0 (0.0 to 1.9)1.0 (0.1 to 3.5)3.4 (1.6 to 6.2)2.3 (0.9 to 4.7)0.5 (0.0 to 3.0)
Fatigue: Grade 40 (0.0 to 1.8)0 (0.0 to 1.9)0 (0.0 to 1.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 2.0)
Headache: Any30.9 (24.7 to 37.7)27.1 (20.9 to 34.0)27.4 (21.3 to 34.1)47.6 (41.8 to 53.5)45.1 (39.4 to 50.8)27.4 (21.1 to 34.4)
Headache: Mild20.3 (15.0 to 26.4)15.6 (10.8 to 21.5)16.4 (11.6 to 22.3)27.2 (22.2 to 32.7)25.7 (20.8 to 31.0)10.2 (6.3 to 15.5)
Headache: Moderate10.1 (6.4 to 15.1)9.4 (5.7 to 14.4)10.4 (6.6 to 15.5)18.4 (14.1 to 23.3)17.4 (13.3 to 22.2)16.7 (11.6 to 22.8)
Headache: Severe0.5 (0.0 to 2.7)2.1 (0.6 to 5.2)0.5 (0.0 to 2.7)2.0 (0.8 to 4.4)2.0 (0.7 to 4.2)0.5 (0.0 to 3.0)
Headache: Grade 40 (0.0 to 1.8)0 (0.0 to 1.9)0 (0.0 to 1.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 2.0)
Chills: Any15.0 (10.4 to 20.6)11.5 (7.3 to 16.8)10.4 (6.6 to 15.5)31.6 (26.4 to 37.3)26.3 (21.5 to 31.6)14.0 (9.3 to 19.8)
Chills: Mild10.1 (6.4 to 15.1)6.8 (3.7 to 11.3)8.0 (4.6 to 12.6)13.3 (9.6 to 17.7)15.1 (11.3 to 19.7)7.0 (3.8 to 11.7)
Chills: Moderate4.3 (2.0 to 8.1)4.7 (2.2 to 8.7)2.5 (0.8 to 5.7)17.0 (12.9 to 21.8)10.2 (7.0 to 14.2)7.0 (3.8 to 11.7)
Chills: Severe0.5 (0.0 to 2.7)0 (0.0 to 1.9)0 (0.0 to 1.8)1.4 (0.4 to 3.4)1.0 (0.2 to 2.9)0 (0.0 to 2.0)
Chills: Grade 40 (0.0 to 1.8)0 (0.0 to 1.9)0 (0.0 to 1.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 2.0)
Vomiting: Any1.0 (0.1 to 3.4)2.1 (0.6 to 5.2)3.5 (1.4 to 7.0)2.7 (1.2 to 5.3)1.6 (0.5 to 3.8)2.2 (0.6 to 5.4)
Vomiting: Mild1.0 (0.1 to 3.4)1.6 (0.3 to 4.5)2.5 (0.8 to 5.7)2.4 (1.0 to 4.8)1.6 (0.5 to 3.8)0.5 (0.0 to 3.0)
Vomiting: Moderate0 (0.0 to 1.8)0.5 (0.0 to 2.9)1.0 (0.1 to 3.5)0.3 (0.0 to 1.9)0 (0.0 to 1.2)1.6 (0.3 to 4.6)
Vomiting: Severe0 (0.0 to 1.8)0 (0.0 to 1.9)0 (0.0 to 1.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 2.0)
Vomiting: Grade 40 (0.0 to 1.8)0 (0.0 to 1.9)0 (0.0 to 1.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 2.0)
Diarrhea: Any9.2 (5.6 to 14.0)8.3 (4.8 to 13.2)6.5 (3.5 to 10.8)8.5 (5.6 to 12.3)11.5 (8.2 to 15.6)8.1 (4.6 to 13.0)
Diarrhea: Mild8.2 (4.9 to 12.8)7.8 (4.4 to 12.6)5.0 (2.4 to 9.0)7.5 (4.7 to 11.1)9.2 (6.2 to 13.0)3.8 (1.5 to 7.6)
Diarrhea: Moderate1.0 (0.1 to 3.4)0.5 (0.0 to 2.9)1.5 (0.3 to 4.3)1.0 (0.2 to 3.0)2.0 (0.7 to 4.2)3.8 (1.5 to 7.6)
Diarrhea: Severe0 (0.0 to 1.8)0 (0.0 to 1.9)0 (0.0 to 1.8)0 (0.0 to 1.2)0.3 (0.0 to 1.8)0.5 (0.0 to 3.0)
Diarrhea: Grade 40 (0.0 to 1.8)0 (0.0 to 1.9)0 (0.0 to 1.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 2.0)
New or worsened muscle pain: Any15.5 (10.8 to 21.1)16.1 (11.2 to 22.1)13.9 (9.5 to 19.5)34.0 (28.6 to 39.7)28.3 (23.3 to 33.7)19.9 (14.4 to 26.4)
New or worsened muscle pain: Mild7.2 (4.1 to 11.7)6.8 (3.7 to 11.3)7.5 (4.2 to 12.0)14.6 (10.8 to 19.2)16.8 (12.8 to 21.5)6.5 (3.4 to 11.0)
New or worsened muscle pain: Moderate8.2 (4.9 to 12.8)9.4 (5.7 to 14.4)6.5 (3.5 to 10.8)18.7 (14.4 to 23.6)10.5 (7.3 to 14.5)12.9 (8.4 to 18.6)
New or worsened muscle pain: Severe0 (0.0 to 1.8)0 (0.0 to 1.9)0 (0.0 to 1.8)0.7 (0.1 to 2.4)1.0 (0.2 to 2.9)0.5 (0.0 to 3.0)
New or worsened muscle pain: Grade 40 (0.0 to 1.8)0 (0.0 to 1.9)0 (0.0 to 1.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 2.0)
New or worsened joint pain: Any11.1 (7.2 to 16.2)13.5 (9.0 to 19.2)10.0 (6.2 to 14.9)23.5 (18.7 to 28.7)15.1 (11.3 to 19.7)12.4 (8.0 to 18.0)
New or worsened joint pain: Mild5.3 (2.7 to 9.3)6.8 (3.7 to 11.3)4.5 (2.1 to 8.3)10.2 (7.0 to 14.2)7.9 (5.1 to 11.5)3.8 (1.5 to 7.6)
New or worsened joint pain: Moderate5.3 (2.7 to 9.3)6.3 (3.3 to 10.7)5.5 (2.8 to 9.6)12.2 (8.7 to 16.5)7.2 (4.6 to 10.8)8.6 (5.0 to 13.6)
New or worsened joint pain: Severe0.5 (0.0 to 2.7)0.5 (0.0 to 2.9)0 (0.0 to 1.8)1.0 (0.2 to 3.0)0 (0.0 to 1.2)0 (0.0 to 2.0)
New or worsened joint pain: Grade 40 (0.0 to 1.8)0 (0.0 to 1.9)0 (0.0 to 1.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 2.0)
PrimarySSD: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2

Systemic events were recorded in e-diary. Fever: oral temperature \>= 38.0 deg C, categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 up to Day 7 after Vaccination 2
Reported as:
Number · Percentage of participants
SSD: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2
Percentage of participantsSSD: Cohort 1: Group 2SSD: Cohort 2: Group 3SSD: Cohort 2: Group 4SSD: Cohort 3: Group 5
Fever: Any1.3 (0.2 to 4.5)5.1 (2.5 to 9.2)6.0 (3.2 to 10.0)2.1 (0.4 to 6.1)
Fever:>=38.0 deg C-38.4 deg C0 (0.0 to 2.3)2.6 (0.8 to 5.9)3.7 (1.6 to 7.1)0.7 (0.0 to 3.9)
Fever:>38.4 deg C-38.9 deg C1.3 (0.2 to 4.5)1.0 (0.1 to 3.6)1.8 (0.5 to 4.7)1.4 (0.2 to 5.1)
Fever:>38.9 deg C-40.0 deg C0 (0.0 to 2.3)1.0 (0.1 to 3.6)0.5 (0.0 to 2.5)0 (0.0 to 2.6)
Fever:>40.0 deg C0 (0.0 to 2.3)0 (0.0 to 1.9)0 (0.0 to 1.7)0 (0.0 to 2.6)
Fever: Unknown0 (0.0 to 2.3)0.5 (0.0 to 2.8)0 (0.0 to 1.7)0 (0.0 to 2.6)
Fatigue: Any17.8 (12.2 to 24.7)60.9 (53.7 to 67.8)54.3 (47.5 to 61.1)27.0 (19.8 to 35.1)
Fatigue: Mild11.5 (6.9 to 17.5)27.9 (21.8 to 34.7)26.9 (21.2 to 33.3)13.5 (8.3 to 20.2)
Fatigue: Moderate5.7 (2.7 to 10.6)32.0 (25.5 to 39.0)25.1 (19.5 to 31.4)12.1 (7.2 to 18.6)
Fatigue: Severe0.6 (0.0 to 3.5)1.0 (0.1 to 3.6)2.3 (0.7 to 5.2)1.4 (0.2 to 5.0)
Fatigue: Grade 40 (0.0 to 2.3)0 (0.0 to 1.9)0 (0.0 to 1.7)0 (0.0 to 2.6)
Headache: Any24.8 (18.3 to 32.4)39.8 (32.9 to 47.0)37.3 (30.9 to 44.1)19.7 (13.5 to 27.2)
Headache: Mild13.4 (8.5 to 19.7)26.5 (20.5 to 33.3)18.0 (13.1 to 23.7)10.6 (6.0 to 16.8)
Headache: Moderate10.8 (6.4 to 16.8)13.3 (8.9 to 18.8)17.1 (12.3 to 22.7)9.2 (5.0 to 15.1)
Headache: Severe0.6 (0.0 to 3.5)0 (0.0 to 1.9)2.3 (0.8 to 5.3)0 (0.0 to 2.6)
Headache: Grade 40 (0.0 to 2.3)0 (0.0 to 1.9)0 (0.0 to 1.7)0 (0.0 to 2.6)
Chills: Any12.1 (7.4 to 18.3)21.8 (16.3 to 28.3)19.4 (14.3 to 25.2)7.1 (3.5 to 12.7)
Chills: Mild7.0 (3.5 to 12.2)10.7 (6.7 to 15.8)12.4 (8.4 to 17.6)2.1 (0.4 to 6.1)
Chills: Moderate5.1 (2.2 to 9.8)10.7 (6.7 to 15.8)6.5 (3.6 to 10.6)5.0 (2.0 to 10.0)
Chills: Severe0 (0.0 to 2.3)0.5 (0.0 to 2.8)0.5 (0.0 to 2.5)0 (0.0 to 2.6)
Chills: Grade 40 (0.0 to 2.3)0 (0.0 to 1.9)0 (0.0 to 1.7)0 (0.0 to 2.6)
Vomiting: Any2.5 (0.7 to 6.4)0.5 (0.0 to 2.8)1.8 (0.5 to 4.7)2.1 (0.4 to 6.1)
Vomiting: Mild1.9 (0.4 to 5.5)0.5 (0.0 to 2.8)1.8 (0.5 to 4.7)2.1 (0.4 to 6.1)
Vomiting: Moderate0.6 (0.0 to 3.5)0 (0.0 to 1.9)0 (0.0 to 1.7)0 (0.0 to 2.6)
Vomiting: Severe0 (0.0 to 2.3)0 (0.0 to 1.9)0 (0.0 to 1.7)0 (0.0 to 2.6)
Vomiting: Grade 40 (0.0 to 2.3)0 (0.0 to 1.9)0 (0.0 to 1.7)0 (0.0 to 2.6)
Diarrhea: Any5.1 (2.2 to 9.8)9.7 (5.9 to 14.7)6.0 (3.2 to 10.0)6.4 (3.0 to 11.9)
Diarrhea: Mild3.8 (1.4 to 8.1)8.2 (4.7 to 12.9)5.1 (2.6 to 8.9)4.3 (1.6 to 9.1)
Diarrhea: Moderate1.3 (0.2 to 4.5)1.5 (0.3 to 4.4)0.9 (0.1 to 3.3)2.1 (0.4 to 6.1)
Diarrhea: Severe0 (0.0 to 2.3)0 (0.0 to 1.9)0 (0.0 to 1.7)0 (0.0 to 2.6)
Diarrhea: Grade 40 (0.0 to 2.3)0 (0.0 to 1.9)0 (0.0 to 1.7)0 (0.0 to 2.6)
New or worsened muscle pain: Any10.8 (6.4 to 16.8)27.6 (21.4 to 34.4)26.7 (21.0 to 33.1)8.6 (4.5 to 14.5)
New or worsened muscle pain: Mild5.7 (2.7 to 10.6)17.9 (12.8 to 23.9)14.7 (10.3 to 20.2)4.3 (1.6 to 9.1)
New or worsened muscle pain: Moderate4.5 (1.8 to 9.0)9.7 (5.9 to 14.7)11.1 (7.2 to 16.0)4.3 (1.6 to 9.1)
New or worsened muscle pain: Severe0.6 (0.0 to 3.5)0 (0.0 to 1.9)0.9 (0.1 to 3.3)0 (0.0 to 2.6)
New or worsened muscle pain: Grade 40 (0.0 to 2.3)0 (0.0 to 1.9)0 (0.0 to 1.7)0 (0.0 to 2.6)
New or worsened joint pain: Any7.6 (4.0 to 13.0)14.3 (9.7 to 20.0)12.0 (8.0 to 17.1)5.7 (2.5 to 10.9)
New or worsened joint pain: Mild3.2 (1.0 to 7.3)7.1 (4.0 to 11.7)6.5 (3.6 to 10.6)2.1 (0.4 to 6.1)
New or worsened joint pain: Moderate4.5 (1.8 to 9.0)6.1 (3.2 to 10.5)5.5 (2.9 to 9.5)3.6 (1.2 to 8.1)
New or worsened joint pain: Severe0 (0.0 to 2.3)1.0 (0.1 to 3.6)0 (0.0 to 1.7)0 (0.0 to 2.6)
New or worsened joint pain: Grade 40 (0.0 to 2.3)0 (0.0 to 1.9)0 (0.0 to 1.7)0 (0.0 to 2.6)
PrimarySSD: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 3

Systemic events were recorded in e-diary. Fever: oral temperature \>= 38.0 deg C and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and new or worsened joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit/hospitalization). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, severe: required intravenous hydration and Grade 4: ER visit/hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit/hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 up to Day 7 after Vaccination 3
Reported as:
Number · Percentage of participants
SSD: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 3
Percentage of participantsSSD: Cohort 3: Group 5
Fever: Any2.6 (0.7 to 6.5)
Fever: >=38.0 deg C to 38.4 deg C0.6 (0.0 to 3.6)
Fever: >38.4 deg C to 38.9 deg C1.3 (0.2 to 4.6)
Fever: >38.9 deg C to 40.0 deg C0.6 (0.0 to 3.6)
Fever: >40.0 deg C0 (0.0 to 2.4)
Fatigue: Any22.7 (16.4 to 30.2)
Fatigue: Mild3.9 (1.4 to 8.3)
Fatigue: Moderate18.2 (12.4 to 25.2)
Fatigue: Severe0.6 (0.0 to 3.6)
Fatigue: Grade 40 (0.0 to 2.4)
Headache: Any25.3 (18.7 to 33.0)
Headache: Mild9.1 (5.1 to 14.8)
Headache: Moderate14.9 (9.7 to 21.6)
Headache: Severe1.3 (0.2 to 4.6)
Headache: Grade 40 (0.0 to 2.4)
Chills: Any9.1 (5.1 to 14.8)
Chills: Mild4.5 (1.8 to 9.1)
Chills: Moderate3.2 (1.1 to 7.4)
Chills: Severe1.3 (0.2 to 4.6)
Chills: Grade 40 (0.0 to 2.4)
Vomiting: Any2.6 (0.7 to 6.5)
Vomiting: Mild1.3 (0.2 to 4.6)
Vomiting: Moderate1.3 (0.2 to 4.6)
Vomiting: Severe0 (0.0 to 2.4)
Vomiting: Grade 40 (0.0 to 2.4)
Diarrhea: Any1.9 (0.4 to 5.6)
Diarrhea: Mild1.3 (0.2 to 4.6)
Diarrhea: Moderate0.6 (0.0 to 3.6)
Diarrhea: Severe0 (0.0 to 2.4)
Diarrhea: Grade 40 (0.0 to 2.4)
New or worsened muscle pain: Any14.9 (9.7 to 21.6)
New or worsened muscle pain: Mild4.5 (1.8 to 9.1)
New or worsened muscle pain: Moderate10.4 (6.1 to 16.3)
New or worsened muscle pain: Severe0 (0.0 to 2.4)
New or worsened muscle pain: Grade 40 (0.0 to 2.4)
New or worsened joint pain: Any9.1 (5.1 to 14.8)
New or worsened joint pain: Mild3.2 (1.1 to 7.4)
New or worsened joint pain: Moderate5.2 (2.3 to 10.0)
New or worsened joint pain: Severe0.6 (0.0 to 3.6)
New or worsened joint pain: Grade 40 (0.0 to 2.4)
PrimarySSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Last Study Vaccination: Cohort 1

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from first study vaccination (Day 1) up to 1 month after last study vaccination were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From Day 1 up to 1 month after last study vaccination
Reported as:
Number · Percentage of participants
SSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Last Study Vaccination: Cohort 1
Percentage of participantsSSD: Cohort 1: Group 1SSD: Cohort 1: Group 2SSD: Cohort 1: Group 2b
SSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Last Study Vaccination: Cohort 13.2 (1.3 to 6.6)6.1 (3.2 to 10.4)2.0 (0.5 to 4.9)
PrimarySSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Vaccination 1: Cohort 2

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from first study vaccination (Day 1) up to 1 month after Vaccination 1 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From first study vaccination (Day 1) up to 1 month after Vaccination 1
Reported as:
Number · Percentage of participants
SSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Vaccination 1: Cohort 2
Percentage of participantsSSD: Cohort 2: Group 3SSD: Cohort 2: Group 4
SSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Vaccination 1: Cohort 24.1 (2.2 to 7.0)3.7 (1.9 to 6.4)
PrimarySSD: Percentage of Participants Reporting Adverse Events (AEs) From Second Study Vaccination Through 1 Month After Second Study Vaccination: Cohort 2

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from Vaccination 2 up to 1 month after Vaccination 2 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From Vaccination 2 up to 1 month after Vaccination 2
Reported as:
Number · Percentage of participants
SSD: Percentage of Participants Reporting Adverse Events (AEs) From Second Study Vaccination Through 1 Month After Second Study Vaccination: Cohort 2
Percentage of participantsSSD: Cohort 2: Group 3SSD: Cohort 2: Group 4
SSD: Percentage of Participants Reporting Adverse Events (AEs) From Second Study Vaccination Through 1 Month After Second Study Vaccination: Cohort 22.3 (0.8 to 5.4)3.8 (1.7 to 7.1)
PrimarySSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Second Study Vaccination: Cohort 3

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from first study vaccination (Day 1) up to 1 month after Vaccination 2 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From first study vaccination (Day 1) up to 1 month after Vaccination 2
Reported as:
Number · Percentage of participants
SSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Second Study Vaccination: Cohort 3
Percentage of participantsSSD: Cohort 3: Group 5
SSD: Percentage of Participants Reporting Adverse Events (AEs) From First Study Vaccination (Day 1) Through 1 Month After Second Study Vaccination: Cohort 36.7 (3.7 to 10.9)
PrimarySSD: Percentage of Participants Reporting Adverse Events (AEs) From Third Study Vaccination Through 1 Month After Third Study Vaccination: Cohort 3

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs from Vaccination 3 up to 1 month after Vaccination 3 were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From Vaccination 3 up to 1 month after Vaccination 3
Reported as:
Number · Percentage of participants
SSD: Percentage of Participants Reporting Adverse Events (AEs) From Third Study Vaccination Through 1 Month After Third Study Vaccination: Cohort 3
Percentage of participantsSSD: Cohort 3: Group 5
SSD: Percentage of Participants Reporting Adverse Events (AEs) From Third Study Vaccination Through 1 Month After Third Study Vaccination: Cohort 30.6 (0.0 to 3.2)
PrimarySSD: Percentage of Participants Reporting Serious Adverse Events (SAEs) From First Study Vaccination (Day 1) Through 6 Months After Last Study Vaccination: Cohort 1 and Cohort 3

A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
From first study vaccination (Day 1) up to 6 months after last study vaccination
Reported as:
Number · Percentage of participants
SSD: Percentage of Participants Reporting Serious Adverse Events (SAEs) From First Study Vaccination (Day 1) Through 6 Months After Last Study Vaccination: Cohort 1 and Cohort 3
Percentage of participantsSSD: Cohort 1: Group 1SSD: Cohort 1: Group 2SSD: Cohort 1: Group 2bSSD: Cohort 3: Group 5
SSD: Percentage of Participants Reporting Serious Adverse Events (SAEs) From First Study Vaccination (Day 1) Through 6 Months After Last Study Vaccination: Cohort 1 and Cohort 30.9 (0.1 to 3.3)1.5 (0.3 to 4.4)1.0 (0.1 to 3.5)3.8 (1.7 to 7.4)
PrimarySSD: Percentage of Participants Reporting SAEs From First Study Vaccination (Day 1) Through 6 Months After Vaccination 1 (For Participants Who Received 1 Dose Only) and up to Vaccination 2 (For Participants Who Received 2 Doses): Cohort 2

A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
From vaccination 1 (Day 1) up to 6 months after vaccination 1 (participants received 1 dose only); From vaccination 1 up to before vaccination 2 (participants received 2 doses)
Reported as:
Number · Percentage of participants
SSD: Percentage of Participants Reporting SAEs From First Study Vaccination (Day 1) Through 6 Months After Vaccination 1 (For Participants Who Received 1 Dose Only) and up to Vaccination 2 (For Participants Who Received 2 Doses): Cohort 2
Percentage of participantsSSD: Cohort 2: Group 3SSD: Cohort 2: Group 4
SSD: Percentage of Participants Reporting SAEs From First Study Vaccination (Day 1) Through 6 Months After Vaccination 1 (For Participants Who Received 1 Dose Only) and up to Vaccination 2 (For Participants Who Received 2 Doses): Cohort 21.6 (0.5 to 3.7)0.6 (0.1 to 2.2)
PrimarySSD: Percentage of Participants Reporting Serious Adverse Events (SAEs) From First Study Vaccination Through 6 Months After Vaccination 2: Cohort 2

A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
From first study vaccination (Day 1) up to 6 months after vaccination 2
Reported as:
Number · Percentage of participants
SSD: Percentage of Participants Reporting Serious Adverse Events (SAEs) From First Study Vaccination Through 6 Months After Vaccination 2: Cohort 2
Percentage of participantsSSD: Cohort 2: Group 3SSD: Cohort 2: Group 4
SSD: Percentage of Participants Reporting Serious Adverse Events (SAEs) From First Study Vaccination Through 6 Months After Vaccination 2: Cohort 20.5 (0.0 to 2.6)1.3 (0.3 to 3.6)
PrimarySSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After First Study Vaccination: Comparison Between Cohort 2 Group 3 and Group 4

GMR was calculated based on GMT levels of SSD: Cohort 2: Group 3 and SSD: Cohort 2: Group 4 and reported in statistical analysis section below. GMT of SARS-CoV-2 Omicron strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after first study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).

Time frame:
1 month after Vaccination 1
Reported as:
Geometric mean · Titer
SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After First Study Vaccination: Comparison Between Cohort 2 Group 3 and Group 4
TiterSSD: Cohort 2: Group 3SSD: Cohort 2: Group 4
SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After First Study Vaccination: Comparison Between Cohort 2 Group 3 and Group 41929.2 (1631.5 to 2281.1)1099.6 (932.0 to 1297.4)
Statistical analysis
  • SSD: Cohort 2: Group 3 vs SSD: Cohort 2: Group 4 · Geometric mean ration (gmr): 1.75 · 95% CI 1.39 to 2.22
PrimarySSD: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After First Study Vaccination: Comparison Between Cohort 2 Group 3 and Group 4

Seroresponse: achieving \>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse 1 month after first study vaccination was reported in this outcome measure.

Time frame:
1 month after Vaccination 1
Reported as:
Number · Percentage of participants
SSD: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After First Study Vaccination: Comparison Between Cohort 2 Group 3 and Group 4
Percentage of participantsSSD: Cohort 2: Group 3SSD: Cohort 2: Group 4
SSD: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After First Study Vaccination: Comparison Between Cohort 2 Group 3 and Group 462.3 (53.4 to 70.7)39.3 (31.1 to 47.9)
Statistical analysis
  • SSD: Cohort 2: Group 3 vs SSD: Cohort 2: Group 4 · Difference in percentages: 23.0 · 95% CI 11.1 to 34.3
PrimarySSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After First Study Vaccination: Comparison Between Cohort 1 Group 1 and Group 2b

GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after first study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).

Time frame:
1 month after Vaccination 1
Reported as:
Geometric mean · Titer
SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After First Study Vaccination: Comparison Between Cohort 1 Group 1 and Group 2b
TiterSSD: Cohort 1: Group 1SSD: Cohort 1: Group 2b
SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After First Study Vaccination: Comparison Between Cohort 1 Group 1 and Group 2b5094.1 (4118.2 to 6301.2)1775.6 (1484.8 to 2123.4)
Statistical analysis
  • SSD: Cohort 1: Group 1 vs SSD: Cohort 1: Group 2b · Geometric mean ration (gmr): 2.87 · 95% CI 2.18 to 3.78
PrimarySSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers: Comparison Between 1 Month After Second Study Vaccination for Cohort 1 Group 2 and 1 Month After First Study Vaccination for Cohort 1 Group 2b

GMR was calculated based on GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after Vaccination 2 for Group 2 and 1 month after Vaccination 1 for Group 2b was reported. GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (based on Student's t distribution).

Time frame:
For Cohort 1 Group 2b:1 month after Vaccination 1; for Cohort 1 Group 2: 1 month after Vaccination 2
Reported as:
Geometric mean · Titer
SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers: Comparison Between 1 Month After Second Study Vaccination for Cohort 1 Group 2 and 1 Month After First Study Vaccination for Cohort 1 Group 2b
TiterSSD: Cohort 1: Group 2SSD: Cohort 1: Group 2b
SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers: Comparison Between 1 Month After Second Study Vaccination for Cohort 1 Group 2 and 1 Month After First Study Vaccination for Cohort 1 Group 2b4684.3 (3937.4 to 5573.0)1775.6 (1484.8 to 2123.4)
Statistical analysis
  • SSD: Cohort 1: Group 2 vs SSD: Cohort 1: Group 2b · Geometric mean ratio (gmr): 2.64 · 95% CI 2.06 to 3.38
PrimaryPercentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After First Study Vaccination: Comparison Between Cohort 1 Group 1 and Group 2b

Seroresponse: achieving \>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse 1 month after first study vaccination was reported in this outcome measure.

Time frame:
1 month after Vaccination 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After First Study Vaccination: Comparison Between Cohort 1 Group 1 and Group 2b
Percentage of participantsSSD: Cohort 1: Group 1SSD: Cohort 1: Group 2b
Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After First Study Vaccination: Comparison Between Cohort 1 Group 1 and Group 2b88.0 (80.0 to 93.6)59.0 (48.7 to 68.7)
Statistical analysis
  • SSD: Cohort 1: Group 1 vs SSD: Cohort 1: Group 2b · Difference in percentages: 29.0 · 95% CI 17.2 to 40.3
PrimarySSD: Percentage of Participants With Seroresponse to SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Vaccination 2: Comparison Between 1 Month After Vaccination 2 for Cohort 1 Group 2 and 1 Month After Vaccination 1 for Cohort 1 Group 2b

Seroresponse: achieving \>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below LLOQ, postvaccination measure of \>= 4 × LLOQ is considered seroresponse. Exact 2-sided CI, based on Clopper and Pearson method was used. Percentage of participants achieving seroresponse 1 month after second study vaccination for Group 2 and 1 month after study vaccination for Group 2b was reported in this outcome measure.

Time frame:
For Cohort 1 Group 2b:1 month after Vaccination 1; for Cohort 1 Group 2: 1 month after Vaccination 2
Reported as:
Number · Percentage of participants
SSD: Percentage of Participants With Seroresponse to SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Vaccination 2: Comparison Between 1 Month After Vaccination 2 for Cohort 1 Group 2 and 1 Month After Vaccination 1 for Cohort 1 Group 2b
Percentage of participantsSSD: Cohort 1: Group 2SSD: Cohort 1: Group 2b
SSD: Percentage of Participants With Seroresponse to SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Vaccination 2: Comparison Between 1 Month After Vaccination 2 for Cohort 1 Group 2 and 1 Month After Vaccination 1 for Cohort 1 Group 2b80.0 (70.8 to 87.3)59.0 (48.7 to 68.7)
Statistical analysis
  • SSD: Cohort 1: Group 2 vs SSD: Cohort 1: Group 2b · Difference in percentages: 21.0 · 95% CI 8.3 to 33.2
PrimarySSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After Second Study Vaccination: Cohort 3

GMR calculated based on GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMR comparison between GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers of participants of SSD Cohort 3: Group 5 to GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers of participants of study C4591001 (NCT04368728) Phase 3 BNT162b2 single arm 18-55 years of age, at 1 month after vaccination 2 was reported. GMTs and corresponding 2-sided CIs were calculated by exponentiating mean logarithm of titers and corresponding CIs (student's t distribution).

Time frame:
1 month after Vaccination 2
Reported as:
Geometric mean · Titer
SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After Second Study Vaccination: Cohort 3
TiterSSD: Cohort 3: Group 5C4591001 Study Cohort
SSD: GMR Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After Second Study Vaccination: Cohort 32892.2 (2522.3 to 3316.3)290.6 (241.2 to 350.1)
Statistical analysis
  • SSD: Cohort 3: Group 5 vs C4591001 Study Cohort · Geometric mean ration (gmr): 9.95 · 95% CI 7.90 to 12.53
PrimarySSD: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Second Study Vaccination: Cohort 3

EIP:eligible participants received 2 doses of study drug as randomized with Dose2 received within 19-42 days after Dose1 (SSD Cohort 3:Group 5), had valid determinate immunogenicity result from blood sample collected within 28-42 days after 2nd study vaccination, had no other important protocol deviations as determined by clinician. Data of eligible participants from Study C4591001 Phase 3 BNT162b2 single arm 18-55 years was included for comparison.'N'=participants evaluable for outcome measure.

Time frame:
1 month after Vaccination 2
Reported as:
Number · Percentage of participants
SSD: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Second Study Vaccination: Cohort 3
Percentage of participantsSSD: Cohort 3: Group 5C4591001 Study Cohort
SSD: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Second Study Vaccination: Cohort 386.2 (79.7 to 91.2)80.8 (73.7 to 86.6)
Statistical analysis
  • SSD: Cohort 3: Group 5 vs C4591001 Study Cohort · Difference in percentages: 5.4 · 95% CI -3.0 to 13.8
PrimarySSE: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination

Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu=0.5 centimeter (cm) and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm),severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] or necrosis/exfoliative dermatitis \[redness\]).Pain at injection site was graded as mild (did not interfere with activity),moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit/hospitalization for severe pain). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions within 7 days after study vaccination and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.

Time frame:
Day 1 up to Day 7 after study vaccination
Reported as:
Number · Percentage of participants
SSE: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination
Percentage of participantsSSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcgSSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg
Redness: Any6.7 (0.8 to 22.1)0 (0.0 to 11.6)6.7 (0.8 to 22.1)8.1 (5.8 to 10.9)6.3 (3.1 to 11.3)10.9 (7.7 to 14.9)0 (0.0 to 16.8)15.0 (3.2 to 37.9)20.0 (5.7 to 43.7)10.0 (1.2 to 31.7)0 (0.0 to 16.8)10.0 (1.2 to 31.7)6.4 (3.9 to 9.8)10.4 (7.2 to 14.4)6.3 (3.8 to 9.7)10.6 (7.4 to 14.7)7.0 (4.4 to 10.5)7.4 (4.7 to 10.9)
Redness: Mild6.7 (0.8 to 22.1)0 (0.0 to 11.6)6.7 (0.8 to 22.1)3.8 (2.2 to 5.9)4.4 (1.8 to 8.9)6.3 (3.9 to 9.5)0 (0.0 to 16.8)5.0 (0.1 to 24.9)5.0 (0.1 to 24.9)5.0 (0.1 to 24.9)0 (0.0 to 16.8)10.0 (1.2 to 31.7)4.0 (2.1 to 6.9)6.0 (3.6 to 9.4)3.3 (1.6 to 6.0)4.0 (2.1 to 6.9)4.3 (2.3 to 7.3)3.5 (1.8 to 6.2)
Redness: Moderate0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)4.2 (2.6 to 6.4)1.9 (0.4 to 5.4)4.4 (2.4 to 7.2)0 (0.0 to 16.8)10.0 (1.2 to 31.7)15.0 (3.2 to 37.9)5.0 (0.1 to 24.9)0 (0.0 to 16.8)0 (0.0 to 16.8)2.0 (0.7 to 4.3)4.0 (2.1 to 6.9)2.7 (1.2 to 5.2)6.6 (4.1 to 10.1)2.7 (1.2 to 5.2)3.2 (1.5 to 5.8)
Redness: Severe0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)0.2 (0.0 to 1.2)0 (0.0 to 2.3)0.3 (0.0 to 1.7)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0.3 (0.0 to 1.9)0.3 (0.0 to 1.9)0.3 (0.0 to 1.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0.6 (0.1 to 2.3)
Redness: Grade 40 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 0.8)0 (0.0 to 2.3)0 (0.0 to 1.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)
Swelling: Any0 (0.0 to 11.6)6.7 (0.8 to 22.1)20.0 (7.7 to 38.6)9.6 (7.1 to 12.6)7.0 (3.5 to 12.1)11.9 (8.5 to 15.9)0 (0.0 to 16.8)10.0 (1.2 to 31.7)15.0 (3.2 to 37.9)5.0 (0.1 to 24.9)5.0 (0.1 to 24.9)10.0 (1.2 to 31.7)6.0 (3.6 to 9.4)13.1 (9.5 to 17.5)8.3 (5.4 to 12.0)10.0 (6.8 to 13.9)6.6 (4.1 to 10.1)5.4 (3.2 to 8.6)
Swelling: Mild0 (0.0 to 11.6)6.7 (0.8 to 22.1)13.3 (3.8 to 30.7)5.0 (3.2 to 7.3)4.4 (1.8 to 8.9)6.3 (3.9 to 9.5)0 (0.0 to 16.8)0 (0.0 to 16.8)5.0 (0.1 to 24.9)0 (0.0 to 16.8)0 (0.0 to 16.8)10.0 (1.2 to 31.7)3.4 (1.6 to 6.1)7.7 (5.0 to 11.4)5.0 (2.8 to 8.1)4.0 (2.1 to 6.9)4.7 (2.6 to 7.7)2.9 (1.3 to 5.4)
Swelling: Moderate0 (0.0 to 11.6)0 (0.0 to 11.6)6.7 (0.8 to 22.1)4.4 (2.7 to 6.6)2.5 (0.7 to 6.4)5.3 (3.1 to 8.4)0 (0.0 to 16.8)5.0 (0.1 to 24.9)10.0 (1.2 to 31.7)5.0 (0.1 to 24.9)5.0 (0.1 to 24.9)0 (0.0 to 16.8)2.7 (1.2 to 5.2)5.4 (3.1 to 8.6)3.3 (1.6 to 6.0)5.3 (3.1 to 8.5)2.0 (0.7 to 4.3)2.2 (0.9 to 4.6)
Swelling: Severe0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)0.2 (0.0 to 1.2)0 (0.0 to 2.3)0.3 (0.0 to 1.7)0 (0.0 to 16.8)5.0 (0.1 to 24.9)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0.7 (0.1 to 2.4)0 (0.0 to 1.2)0.3 (0.0 to 1.8)
Swelling: Grade 40 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 0.8)0 (0.0 to 2.3)0 (0.0 to 1.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)
Pain at the injection site: Any90.0 (73.5 to 97.9)83.3 (65.3 to 94.4)96.7 (82.8 to 99.9)82.9 (79.2 to 86.2)81.0 (74.0 to 86.8)86.3 (82.0 to 89.8)70.0 (45.7 to 88.1)70.0 (45.7 to 88.1)65.0 (40.8 to 84.6)100.0 (83.2 to 100.0)65.0 (40.8 to 84.6)85.0 (62.1 to 96.8)60.1 (54.3 to 65.7)71.1 (65.6 to 76.2)66.1 (60.5 to 71.4)70.8 (65.3 to 75.8)58.1 (52.3 to 63.8)67.9 (62.5 to 73.1)
Pain at the injection site: Mild60.0 (40.6 to 77.3)76.7 (57.7 to 90.1)33.3 (17.3 to 52.8)55.2 (50.6 to 59.7)67.7 (59.8 to 74.9)45.3 (39.8 to 50.9)55.0 (31.5 to 76.9)65.0 (40.8 to 84.6)55.0 (31.5 to 76.9)75.0 (50.9 to 91.3)60.0 (36.1 to 80.9)45.0 (23.1 to 68.5)51.7 (45.8 to 57.5)53.4 (47.5 to 59.1)52.8 (47.0 to 58.6)44.9 (39.1 to 50.7)52.8 (47.0 to 58.6)55.4 (49.7 to 61.0)
Pain at the injection site: Moderate30.0 (14.7 to 49.4)6.7 (0.8 to 22.1)60.0 (40.6 to 77.3)26.0 (22.2 to 30.2)13.3 (8.4 to 19.6)39.4 (34.0 to 45.0)10.0 (1.2 to 31.7)5.0 (0.1 to 24.9)10.0 (1.2 to 31.7)25.0 (8.7 to 49.1)5.0 (0.1 to 24.9)40.0 (19.1 to 63.9)8.1 (5.2 to 11.7)17.4 (13.3 to 22.2)13.3 (9.7 to 17.7)25.2 (20.4 to 30.6)5.0 (2.8 to 8.1)12.2 (8.8 to 16.3)
Pain at the injection site: Severe0 (0.0 to 11.6)0 (0.0 to 11.6)3.3 (0.1 to 17.2)1.7 (0.7 to 3.3)0 (0.0 to 2.3)1.6 (0.5 to 3.6)5.0 (0.1 to 24.9)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0.3 (0.0 to 1.9)0.3 (0.0 to 1.9)0 (0.0 to 1.2)0.7 (0.1 to 2.4)0.3 (0.0 to 1.8)0.3 (0.0 to 1.8)
Pain at the injection site: Grade 40 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 0.8)0 (0.0 to 2.3)0 (0.0 to 1.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)
PrimarySSE: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination

Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to 38.0 deg C and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C \& \>40.0 deg C. Fatigue, headache, chills, muscle pain and joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit or hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \> 2 times in 24h, severe: required intravenous hydration and Grade 4: ER or hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit or hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 up to Day 7 after study vaccination
Reported as:
Number · Percentage of participants
SSE: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination
Percentage of participantsSSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcgSSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg
Fever: >= 38.0 deg C13.3 (3.8 to 30.7)0 (0.0 to 11.6)10.0 (2.1 to 26.5)10.0 (7.5 to 13.0)10.8 (6.4 to 16.7)19.4 (15.2 to 24.1)5.0 (0.1 to 24.9)10.0 (1.2 to 31.7)10.0 (1.2 to 31.7)5.0 (0.1 to 24.9)20.0 (5.7 to 43.7)20.0 (5.7 to 43.7)3.7 (1.9 to 6.5)7.4 (4.7 to 11.0)8.3 (5.4 to 12.0)9.0 (6.0 to 12.8)5.0 (2.8 to 8.1)7.7 (5.0 to 11.2)
Fever: >= 38.0 deg C to 38.4 deg C3.3 (0.1 to 17.2)0 (0.0 to 11.6)10.0 (2.1 to 26.5)4.2 (2.6 to 6.4)6.3 (3.1 to 11.3)6.9 (4.4 to 10.2)5.0 (0.1 to 24.9)5.0 (0.1 to 24.9)0 (0.0 to 16.8)0 (0.0 to 16.8)15.0 (3.2 to 37.9)5.0 (0.1 to 24.9)2.0 (0.7 to 4.3)3.7 (1.9 to 6.5)3.7 (1.8 to 6.4)4.7 (2.6 to 7.7)3.7 (1.8 to 6.4)5.4 (3.2 to 8.6)
Fever: >38.4 deg C to 38.9 deg C10.0 (2.1 to 26.5)0 (0.0 to 11.6)0 (0.0 to 11.6)3.8 (2.2 to 5.9)3.8 (1.4 to 8.1)8.1 (5.4 to 11.7)0 (0.0 to 16.8)5.0 (0.1 to 24.9)5.0 (0.1 to 24.9)5.0 (0.1 to 24.9)5.0 (0.1 to 24.9)10.0 (1.2 to 31.7)1.7 (0.5 to 3.9)3.7 (1.9 to 6.5)3.7 (1.8 to 6.4)2.7 (1.2 to 5.2)0 (0.0 to 1.2)1.6 (0.5 to 3.7)
Fever: >38.9 deg C to 40.0 deg C0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)2.1 (1.0 to 3.8)0.6 (0.0 to 3.5)4.4 (2.4 to 7.2)0 (0.0 to 16.8)0 (0.0 to 16.8)5.0 (0.1 to 24.9)0 (0.0 to 16.8)0 (0.0 to 16.8)5.0 (0.1 to 24.9)0 (0.0 to 1.2)0 (0.0 to 1.2)1.0 (0.2 to 2.9)1.3 (0.4 to 3.4)1.3 (0.4 to 3.4)0.6 (0.1 to 2.3)
Fever: >40 deg C0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 0.8)0 (0.0 to 2.3)0 (0.0 to 1.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0.3 (0.0 to 1.8)0 (0.0 to 1.2)0 (0.0 to 1.2)
Fatigue: Any66.7 (47.2 to 82.7)63.3 (43.9 to 80.1)70.0 (50.6 to 85.3)73.8 (69.6 to 77.6)68.4 (60.5 to 75.5)77.5 (72.5 to 82.0)45.0 (23.1 to 68.5)55.0 (31.5 to 76.9)45.0 (23.1 to 68.5)65.0 (40.8 to 84.6)40.0 (19.1 to 63.9)70.0 (45.7 to 88.1)45.3 (39.6 to 51.1)52.3 (46.5 to 58.1)52.5 (46.7 to 58.3)58.8 (53.0 to 64.4)49.2 (43.4 to 55.0)57.4 (51.7 to 62.9)
Fatigue: Mild20.0 (7.7 to 38.6)26.7 (12.3 to 45.9)23.3 (9.9 to 42.3)25.2 (21.4 to 29.3)32.3 (25.1 to 40.2)25.9 (21.2 to 31.1)30.0 (11.9 to 54.3)15.0 (3.2 to 37.9)10.0 (1.2 to 31.7)35.0 (15.4 to 59.2)15.0 (3.2 to 37.9)45.0 (23.1 to 68.5)23.5 (18.8 to 28.7)22.5 (17.9 to 27.7)20.3 (15.9 to 25.3)24.6 (19.8 to 29.9)29.2 (24.2 to 34.7)27.2 (22.4 to 32.5)
Fatigue: Moderate43.3 (25.5 to 62.6)33.3 (17.3 to 52.8)40.0 (22.7 to 59.4)44.0 (39.5 to 48.5)34.8 (27.4 to 42.8)46.9 (41.3 to 52.5)10.0 (1.2 to 31.7)40.0 (19.1 to 63.9)35.0 (15.4 to 59.2)30.0 (11.9 to 54.3)25.0 (8.7 to 49.1)25.0 (8.7 to 49.1)21.5 (17.0 to 26.6)26.8 (21.9 to 32.3)29.6 (24.5 to 35.1)30.6 (25.4 to 36.1)18.3 (14.1 to 23.1)28.2 (23.3 to 33.5)
Fatigue: Severe3.3 (0.1 to 17.2)3.3 (0.1 to 17.2)6.7 (0.8 to 22.1)4.6 (2.9 to 6.9)1.3 (0.2 to 4.5)4.7 (2.6 to 7.6)5.0 (0.1 to 24.9)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0.3 (0.0 to 1.9)3.0 (1.4 to 5.7)2.7 (1.2 to 5.2)3.7 (1.8 to 6.4)1.7 (0.5 to 3.8)1.9 (0.7 to 4.1)
Fatigue: Grade 40 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 0.8)0 (0.0 to 2.3)0 (0.0 to 1.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)
Headache: Any46.7 (28.3 to 65.7)30.0 (14.7 to 49.4)60.0 (40.6 to 77.3)53.5 (49.0 to 58.1)50.0 (42.0 to 58.0)57.5 (51.9 to 63.0)20.0 (5.7 to 43.7)30.0 (11.9 to 54.3)35.0 (15.4 to 59.2)15.0 (3.2 to 37.9)30.0 (11.9 to 54.3)50.0 (27.2 to 72.8)26.5 (21.6 to 31.9)38.9 (33.4 to 44.7)36.5 (31.1 to 42.3)36.5 (31.1 to 42.3)33.6 (28.2 to 39.2)36.5 (31.2 to 42.1)
Headache: Mild40.0 (22.7 to 59.4)23.3 (9.9 to 42.3)26.7 (12.3 to 45.9)27.7 (23.7 to 31.9)29.1 (22.2 to 36.9)27.5 (22.7 to 32.7)10.0 (1.2 to 31.7)30.0 (11.9 to 54.3)30.0 (11.9 to 54.3)10.0 (1.2 to 31.7)20.0 (5.7 to 43.7)25.0 (8.7 to 49.1)15.8 (11.8 to 20.4)23.5 (18.8 to 28.7)22.3 (17.7 to 27.4)20.6 (16.2 to 25.6)23.6 (18.9 to 28.8)24.4 (19.7 to 29.5)
Headache: Moderate6.7 (0.8 to 22.1)6.7 (0.8 to 22.1)30.0 (14.7 to 49.4)24.2 (20.4 to 28.3)19.0 (13.2 to 26.0)27.2 (22.4 to 32.4)10.0 (1.2 to 31.7)0 (0.0 to 16.8)5.0 (0.1 to 24.9)5.0 (0.1 to 24.9)10.0 (1.2 to 31.7)25.0 (8.7 to 49.1)10.4 (7.2 to 14.4)14.4 (10.6 to 18.9)13.3 (9.7 to 17.7)14.6 (10.8 to 19.1)9.6 (6.5 to 13.5)10.9 (7.7 to 14.9)
Headache: Severe0 (0.0 to 11.6)0 (0.0 to 11.6)3.3 (0.1 to 17.2)1.7 (0.7 to 3.3)1.9 (0.4 to 5.4)2.8 (1.3 to 5.3)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0.3 (0.0 to 1.9)1.0 (0.2 to 2.9)1.0 (0.2 to 2.9)1.3 (0.4 to 3.4)0.3 (0.0 to 1.8)1.3 (0.4 to 3.2)
Headache: Grade 40 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 0.8)0 (0.0 to 2.3)0 (0.0 to 1.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)
Chills: Any23.3 (9.9 to 42.3)23.3 (9.9 to 42.3)40.0 (22.7 to 59.4)35.6 (31.3 to 40.1)27.8 (21.0 to 35.5)38.4 (33.1 to 44.0)5.0 (0.1 to 24.9)20.0 (5.7 to 43.7)15.0 (3.2 to 37.9)35.0 (15.4 to 59.2)25.0 (8.7 to 49.1)30.0 (11.9 to 54.3)16.4 (12.4 to 21.1)24.2 (19.4 to 29.4)25.6 (20.7 to 30.9)25.6 (20.7 to 30.9)13.0 (9.4 to 17.3)23.7 (19.1 to 28.8)
Chills: Mild13.3 (3.8 to 30.7)13.3 (3.8 to 30.7)13.3 (3.8 to 30.7)20.4 (16.9 to 24.3)15.8 (10.5 to 22.5)18.8 (14.6 to 23.5)0 (0.0 to 16.8)15.0 (3.2 to 37.9)5.0 (0.1 to 24.9)30.0 (11.9 to 54.3)5.0 (0.1 to 24.9)10.0 (1.2 to 31.7)10.7 (7.5 to 14.8)13.1 (9.5 to 17.5)13.0 (9.4 to 17.3)11.3 (8.0 to 15.4)8.3 (5.4 to 12.0)13.5 (9.9 to 17.8)
Chills: Moderate10.0 (2.1 to 26.5)10.0 (2.1 to 26.5)20.0 (7.7 to 38.6)14.6 (11.5 to 18.1)11.4 (6.9 to 17.4)17.8 (13.8 to 22.5)5.0 (0.1 to 24.9)5.0 (0.1 to 24.9)10.0 (1.2 to 31.7)5.0 (0.1 to 24.9)20.0 (5.7 to 43.7)15.0 (3.2 to 37.9)5.7 (3.4 to 9.0)10.4 (7.2 to 14.4)12.0 (8.5 to 16.2)12.0 (8.5 to 16.2)4.7 (2.6 to 7.7)10.3 (7.1 to 14.2)
Chills: Severe0 (0.0 to 11.6)0 (0.0 to 11.6)6.7 (0.8 to 22.1)0.6 (0.1 to 1.8)0.6 (0.0 to 3.5)1.9 (0.7 to 4.0)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)5.0 (0.1 to 24.9)0 (0.0 to 1.2)0.7 (0.1 to 2.4)0.7 (0.1 to 2.4)2.3 (0.9 to 4.7)0 (0.0 to 1.2)0 (0.0 to 1.2)
Chills: Grade 40 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 0.8)0 (0.0 to 2.3)0 (0.0 to 1.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)
Vomiting: Any0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)3.1 (1.8 to 5.1)0.6 (0.0 to 3.5)3.8 (2.0 to 6.5)5.0 (0.1 to 24.9)0 (0.0 to 16.8)0 (0.0 to 16.8)5.0 (0.1 to 24.9)0 (0.0 to 16.8)5.0 (0.1 to 24.9)1.3 (0.4 to 3.4)1.7 (0.5 to 3.9)3.0 (1.4 to 5.6)2.7 (1.2 to 5.2)1.7 (0.5 to 3.8)1.3 (0.4 to 3.2)
Vomiting: Mild0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)2.7 (1.4 to 4.6)0.6 (0.0 to 3.5)3.4 (1.7 to 6.1)5.0 (0.1 to 24.9)0 (0.0 to 16.8)0 (0.0 to 16.8)5.0 (0.1 to 24.9)0 (0.0 to 16.8)5.0 (0.1 to 24.9)0.7 (0.1 to 2.4)1.3 (0.4 to 3.4)2.3 (0.9 to 4.7)2.3 (0.9 to 4.7)1.7 (0.5 to 3.8)1.3 (0.4 to 3.2)
Vomiting: Moderate0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)0.4 (0.1 to 1.5)0 (0.0 to 2.3)0.3 (0.0 to 1.7)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0.7 (0.1 to 2.4)0.3 (0.0 to 1.9)0.7 (0.1 to 2.4)0.3 (0.0 to 1.8)0 (0.0 to 1.2)0 (0.0 to 1.2)
Vomiting: Severe0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 0.8)0 (0.0 to 2.3)0 (0.0 to 1.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)
Vomiting: Grade 40 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 0.8)0 (0.0 to 2.3)0 (0.0 to 1.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)
Diarrhea: Any20.0 (7.7 to 38.6)3.3 (0.1 to 17.2)13.3 (3.8 to 30.7)12.7 (9.9 to 16.0)10.8 (6.4 to 16.7)12.2 (8.8 to 16.3)15.0 (3.2 to 37.9)15.0 (3.2 to 37.9)15.0 (3.2 to 37.9)0 (0.0 to 16.8)5.0 (0.1 to 24.9)5.0 (0.1 to 24.9)4.4 (2.3 to 7.3)5.7 (3.4 to 9.0)8.0 (5.2 to 11.6)10.3 (7.1 to 14.3)9.0 (6.0 to 12.8)6.4 (4.0 to 9.7)
Diarrhea: Mild16.7 (5.6 to 34.7)3.3 (0.1 to 17.2)13.3 (3.8 to 30.7)9.6 (7.1 to 12.6)9.5 (5.4 to 15.2)10.0 (6.9 to 13.8)10.0 (1.2 to 31.7)10.0 (1.2 to 31.7)10.0 (1.2 to 31.7)0 (0.0 to 16.8)5.0 (0.1 to 24.9)5.0 (0.1 to 24.9)3.4 (1.6 to 6.1)3.7 (1.9 to 6.5)6.6 (4.1 to 10.1)9.0 (6.0 to 12.8)6.0 (3.6 to 9.3)5.8 (3.5 to 9.0)
Diarrhea: Moderate3.3 (0.1 to 17.2)0 (0.0 to 11.6)0 (0.0 to 11.6)3.1 (1.8 to 5.1)1.3 (0.2 to 4.5)2.2 (0.9 to 4.5)5.0 (0.1 to 24.9)5.0 (0.1 to 24.9)5.0 (0.1 to 24.9)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)1.0 (0.2 to 2.9)2.0 (0.7 to 4.3)0.7 (0.1 to 2.4)1.3 (0.4 to 3.4)1.7 (0.5 to 3.8)0.6 (0.1 to 2.3)
Diarrhea: Severe0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 0.8)0 (0.0 to 2.3)0 (0.0 to 1.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0.7 (0.1 to 2.4)0 (0.0 to 1.2)1.3 (0.4 to 3.4)0 (0.0 to 1.2)
Diarrhea: Grade 40 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 0.8)0 (0.0 to 2.3)0 (0.0 to 1.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)
New or worsened muscle pain: Any30.0 (14.7 to 49.4)30.0 (14.7 to 49.4)46.7 (28.3 to 65.7)39.8 (35.4 to 44.3)36.7 (29.2 to 44.7)42.2 (36.7 to 47.8)25.0 (8.7 to 49.1)20.0 (5.7 to 43.7)25.0 (8.7 to 49.1)35.0 (15.4 to 59.2)20.0 (5.7 to 43.7)35.0 (15.4 to 59.2)19.8 (15.4 to 24.8)25.5 (20.7 to 30.8)23.9 (19.2 to 29.1)30.6 (25.4 to 36.1)22.3 (17.7 to 27.4)27.2 (22.4 to 32.5)
New or worsened muscle pain: Mild6.7 (0.8 to 22.1)10.0 (2.1 to 26.5)23.3 (9.9 to 42.3)18.3 (15.0 to 22.1)20.3 (14.3 to 27.4)17.8 (13.8 to 22.5)10.0 (1.2 to 31.7)15.0 (3.2 to 37.9)10.0 (1.2 to 31.7)25.0 (8.7 to 49.1)5.0 (0.1 to 24.9)25.0 (8.7 to 49.1)11.7 (8.3 to 16.0)10.1 (6.9 to 14.1)11.6 (8.2 to 15.8)12.6 (9.1 to 16.9)13.3 (9.7 to 17.7)14.1 (10.4 to 18.5)
New or worsened muscle pain: Moderate23.3 (9.9 to 42.3)20.0 (7.7 to 38.6)23.3 (9.9 to 42.3)21.3 (17.7 to 25.2)15.8 (10.5 to 22.5)22.2 (17.8 to 27.1)15.0 (3.2 to 37.9)5.0 (0.1 to 24.9)15.0 (3.2 to 37.9)10.0 (1.2 to 31.7)15.0 (3.2 to 37.9)10.0 (1.2 to 31.7)8.1 (5.2 to 11.7)14.4 (10.6 to 18.9)12.0 (8.5 to 16.2)15.9 (12.0 to 20.6)9.0 (6.0 to 12.8)12.8 (9.3 to 17.0)
New or worsened muscle pain: Severe0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)0.2 (0.0 to 1.2)0.6 (0.0 to 3.5)2.2 (0.9 to 4.5)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 1.2)1.0 (0.2 to 2.9)0.3 (0.0 to 1.8)2.0 (0.7 to 4.3)0 (0.0 to 1.2)0.3 (0.0 to 1.8)
New or worsened muscle pain: Grade 40 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 0.8)0 (0.0 to 2.3)0 (0.0 to 1.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)
New or worsened joint pain: Any20.0 (7.7 to 38.6)16.7 (5.6 to 34.7)23.3 (9.9 to 42.3)25.4 (21.6 to 29.6)20.9 (14.8 to 28.1)24.1 (19.5 to 29.1)20.0 (5.7 to 43.7)25.0 (8.7 to 49.1)15.0 (3.2 to 37.9)20.0 (5.7 to 43.7)15.0 (3.2 to 37.9)35.0 (15.4 to 59.2)9.1 (6.1 to 12.9)16.1 (12.1 to 20.8)16.6 (12.6 to 21.3)19.6 (15.3 to 24.5)11.3 (8.0 to 15.4)18.6 (14.4 to 23.4)
New or worsened joint pain: Mild10.0 (2.1 to 26.5)13.3 (3.8 to 30.7)10.0 (2.1 to 26.5)12.5 (9.7 to 15.8)10.1 (5.9 to 15.9)9.1 (6.2 to 12.8)10.0 (1.2 to 31.7)15.0 (3.2 to 37.9)5.0 (0.1 to 24.9)20.0 (5.7 to 43.7)5.0 (0.1 to 24.9)15.0 (3.2 to 37.9)5.4 (3.1 to 8.6)9.7 (6.6 to 13.7)9.3 (6.3 to 13.2)8.3 (5.4 to 12.0)7.6 (4.9 to 11.2)10.3 (7.1 to 14.2)
New or worsened joint pain: Moderate10.0 (2.1 to 26.5)3.3 (0.1 to 17.2)13.3 (3.8 to 30.7)12.5 (9.7 to 15.8)10.8 (6.4 to 16.7)14.1 (10.4 to 18.4)10.0 (1.2 to 31.7)10.0 (1.2 to 31.7)10.0 (1.2 to 31.7)0 (0.0 to 16.8)10.0 (1.2 to 31.7)20.0 (5.7 to 43.7)3.7 (1.9 to 6.5)6.0 (3.6 to 9.4)7.3 (4.6 to 10.9)11.0 (7.7 to 15.1)3.7 (1.8 to 6.4)8.0 (5.3 to 11.6)
New or worsened joint pain: Severe0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)0.4 (0.1 to 1.5)0 (0.0 to 2.3)0.9 (0.2 to 2.7)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 1.2)0.3 (0.0 to 1.9)0 (0.0 to 1.2)0.3 (0.0 to 1.8)0 (0.0 to 1.2)0.3 (0.0 to 1.8)
New or worsened joint pain: Grade 40 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 0.8)0 (0.0 to 2.3)0 (0.0 to 1.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)0 (0.0 to 1.2)
PrimarySSE: Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Study Vaccination

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after study vaccination were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From study vaccination up to 1 Month after study vaccination
Reported as:
Number · Percentage of participants
SSE: Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Study Vaccination
Percentage of participantsSSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcgSSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg
SSE: Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Study Vaccination13.3 (3.8 to 30.7)6.7 (0.8 to 22.1)13.3 (3.8 to 30.7)7.7 (5.5 to 10.4)6.3 (3.1 to 11.3)9.3 (6.4 to 13.1)10.0 (1.2 to 31.7)0 (0.0 to 16.8)15.0 (3.2 to 37.9)5.0 (0.1 to 24.9)5.0 (0.1 to 24.9)5.0 (0.1 to 24.9)5.9 (3.5 to 9.2)6.6 (4.1 to 10.0)8.5 (5.6 to 12.2)3.6 (1.8 to 6.3)6.2 (3.8 to 9.6)10.4 (7.3 to 14.4)
PrimarySSE: Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 6 Month After Study Vaccination

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
From study vaccination up to 6 Months after study vaccination
Reported as:
Number · Percentage of participants
SSE: Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 6 Month After Study Vaccination
Percentage of participantsSSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcgSSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg
SSE: Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 6 Month After Study Vaccination0 (0.0 to 0.0)0 (0.0 to 0.0)0 (0.0 to 0.0)0.6 (0.1 to 1.8)1.3 (0.2 to 4.5)0.9 (0.2 to 2.7)5.0 (0.1 to 24.9)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.8)5.0 (0.1 to 24.9)2.0 (0.7 to 4.2)0.7 (0.1 to 2.4)3.9 (2.0 to 6.7)1.3 (0.4 to 3.3)1.3 (0.4 to 3.3)1.9 (0.7 to 4.1)
PrimarySSE: Percentage of Participants With Elevated Troponin I Levels Before the Study Vaccination- 18 to 55 Years of Age

Percentage of participants with elevated troponin I levels before study vaccination were reported in this outcome measure.

Time frame:
Before study vaccination (pre-dose)
Reported as:
Number · Percentage of participants
SSE: Percentage of Participants With Elevated Troponin I Levels Before the Study Vaccination- 18 to 55 Years of Age
Percentage of participantsSSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcgSSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg
SSE: Percentage of Participants With Elevated Troponin I Levels Before the Study Vaccination- 18 to 55 Years of Age0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)
PrimarySSE: Percentage of Participants With Elevated Troponin I Levels 3 Days After Study Vaccination- 18 to 55 Years of Age

Percentage of participants with elevated troponin I levels before study vaccination were reported in this outcome measure.

Time frame:
3 days after study vaccination
Reported as:
Number · Percentage of participants
SSE: Percentage of Participants With Elevated Troponin I Levels 3 Days After Study Vaccination- 18 to 55 Years of Age
Percentage of participantsSSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcgSSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg
SSE: Percentage of Participants With Elevated Troponin I Levels 3 Days After Study Vaccination- 18 to 55 Years of Age0 (0.0 to 11.6)0 (0.0 to 11.6)0 (0.0 to 11.6)
PrimarySSE: Geometric Mean Ratio (GMR) Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After Study Vaccination

GMR calculated based on GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers at 1 month after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).

Time frame:
1 month after study vaccination
Reported as:
Geometric mean · Titer
SSE: Geometric Mean Ratio (GMR) Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After Study Vaccination
TiterSSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg
SSE: Geometric Mean Ratio (GMR) Based on Geometric Mean Titers of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers 1 Month After Study Vaccination455.8 (365.9 to 567.6)1014.5 (825.6 to 1246.7)1435.2 (1208.1 to 1704.8)711.0 (588.3 to 859.2)900.1 (726.3 to 1115.6)
Statistical analysis
  • SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg vs SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 2.23 · 95% CI 1.65 to 3.00
  • SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg vs SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg · Geometric mean ratio (gmr): 3.15 · 95% CI 2.38 to 4.16
  • SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg vs SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg · Geometric mean ratio (gmr): 1.56 · 95% CI 1.17 to 2.08
  • SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg vs SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg · Geometric mean ratio (gmr): 1.97 · 95% CI 1.45 to 2.68
PrimarySSE: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Study Vaccination

Seroresponse was defined as achieving \>= 4-fold rise from baseline (before study vaccination). If baseline measurement is below lower limit of quantification (LLOQ), postvaccination measure of \>= 4 × LLOQ is considered seroresponse. Exact 2-sided CI, based on Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.

Time frame:
1 month after study vaccination
Reported as:
Number · Percentage of participants
SSE: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Study Vaccination
Percentage of participantsSSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg
SSE: Percentage of Participants With Seroresponse to the SARS-CoV-2 Omicron BA.1 Strain at 1 Month After Study Vaccination57.0 (48.7 to 65.1)76.7 (69.4 to 82.9)86.1 (79.9 to 91.0)71.6 (64.2 to 78.3)67.9 (60.1 to 75.0)
Statistical analysis
  • SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg vs SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg · Difference in percentages: 19.6 · 95% CI 9.3 to 29.7
  • SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg vs SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg · Difference in percentages: 29.1 · 95% CI 19.4 to 38.5
  • SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg vs SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg · Difference in percentages: 14.6 · 95% CI 4.0 to 24.9
  • SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg vs SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg · Difference in percentages: 10.9 · 95% CI 0.1 to 21.4
PrimarySSF: Geometric Mean Titer (GMTs) of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers Before Vaccination

GMT of SARS-CoV-2 Omicron BA.1 strain neutralizing titers before vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).

Time frame:
Before vaccination (pre-dose)
Reported as:
Geometric mean · Titer
SSF: Geometric Mean Titer (GMTs) of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers Before Vaccination
TiterSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: Geometric Mean Titer (GMTs) of SARS-CoV-2 Omicron BA.1 Strain Neutralizing Titers Before Vaccination41.7 (22.4 to 77.4)33.2 (17.6 to 62.6)32.0 (17.0 to 60.1)36.8 (17.5 to 77.1)78.8 (29.3 to 211.6)21.5 (14.2 to 32.7)
PrimarySSF: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination

Local reactions were recorded by participants in e-diary. Redness and swelling were measured and recorded in measuring device units (mdu) where, 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (necrosis \[swelling\] or necrosis/exfoliative dermatitis \[redness\]). Grade 4 were classified by investigator or medically qualified person. Percentage of participants reporting local reactions after study vaccination and associated 2-sided 95% confidence interval (CI) based on Clopper and Pearson method was presented.

Time frame:
Day 1 up to Day 7 after the study vaccination
Reported as:
Number · Percentage of participants
SSF: Percentage of Participants With Local Reactions Within 7 Days After Study Vaccination
Percentage of participantsSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
Redness: Any19.0 (5.4 to 41.9)21.1 (6.1 to 45.6)23.8 (8.2 to 47.2)20.0 (5.7 to 43.7)10.0 (1.2 to 31.7)28.6 (11.3 to 52.2)
Redness: Mild4.8 (0.1 to 23.8)10.5 (1.3 to 33.1)14.3 (3.0 to 36.3)5.0 (0.1 to 24.9)5.0 (0.1 to 24.9)23.8 (8.2 to 47.2)
Redness: Moderate14.3 (3.0 to 36.3)10.5 (1.3 to 33.1)9.5 (1.2 to 30.4)10.0 (1.2 to 31.7)5.0 (0.1 to 24.9)4.8 (0.1 to 23.8)
Redness: Severe0 (0.0 to 16.1)0 (0.0 to 17.6)0 (0.0 to 16.1)5.0 (0.1 to 24.9)0 (0.0 to 16.8)0 (0.0 to 16.1)
Redness: Grade 40 (0.0 to 16.1)0 (0.0 to 17.6)0 (0.0 to 16.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
Swelling: Any14.3 (3.0 to 36.3)15.8 (3.4 to 39.6)14.3 (3.0 to 36.3)15.0 (3.2 to 37.9)15.0 (3.2 to 37.9)28.6 (11.3 to 52.2)
Swelling: Mild4.8 (0.1 to 23.8)5.3 (0.1 to 26.0)4.8 (0.1 to 23.8)5.0 (0.1 to 24.9)5.0 (0.1 to 24.9)23.8 (8.2 to 47.2)
Swelling: Moderate9.5 (1.2 to 30.4)10.5 (1.3 to 33.1)9.5 (1.2 to 30.4)10.0 (1.2 to 31.7)10.0 (1.2 to 31.7)4.8 (0.1 to 23.8)
Swelling: Severe0 (0.0 to 16.1)0 (0.0 to 17.6)0 (0.0 to 16.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
Swelling: Grade 40 (0.0 to 16.1)0 (0.0 to 17.6)0 (0.0 to 16.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
Pain at the injection site: Any71.4 (47.8 to 88.7)94.7 (74.0 to 99.9)90.5 (69.6 to 98.8)80.0 (56.3 to 94.3)75.0 (50.9 to 91.3)90.5 (69.6 to 98.8)
Pain at the injection site: Mild52.4 (29.8 to 74.3)52.6 (28.9 to 75.6)66.7 (43.0 to 85.4)45.0 (23.1 to 68.5)55.0 (31.5 to 76.9)57.1 (34.0 to 78.2)
Pain at the injection site: Moderate19.0 (5.4 to 41.9)36.8 (16.3 to 61.6)19.0 (5.4 to 41.9)35.0 (15.4 to 59.2)20.0 (5.7 to 43.7)33.3 (14.6 to 57.0)
Pain at the injection site: Severe0 (0.0 to 16.1)5.3 (0.1 to 26.0)4.8 (0.1 to 23.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
Pain at the injection site: Grade 40 (0.0 to 16.1)0 (0.0 to 17.6)0 (0.0 to 16.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
PrimarySSF: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination

Systemic events were recorded in e-diary. Fever: oral temperature greater than or equal to 38.0 deg C and categorized as \>=38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C \& \>40.0 deg C. Fatigue, headache, chills, muscle pain and joint pain: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity) and Grade 4 (ER visit or hospitalization). Vomiting: mild: 1-2 times in 24 h, moderate: \> 2 times in 24h, severe: required intravenous hydration and Grade 4: ER or hospitalization for hypotensive shock. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h and Grade 4: ER visit or hospitalization for severe diarrhea. Grade 4 were classified by investigator or medically qualified person. Exact 95% CI was based on Clopper and Pearson method.

Time frame:
Day 1 up to Day 7 after the study vaccination
Reported as:
Number · Percentage of participants
SSF: Percentage of Participants With Systemic Events Within 7 Days After Study Vaccination
Percentage of participantsSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
Fever: >= 38.0 deg C9.5 (1.2 to 30.4)10.5 (1.3 to 33.1)9.5 (1.2 to 30.4)10.0 (1.2 to 31.7)5.0 (0.1 to 24.9)4.8 (0.1 to 23.8)
Fever: >= 38.0 deg C to 38.4 deg C9.5 (1.2 to 30.4)5.3 (0.1 to 26.0)4.8 (0.1 to 23.8)5.0 (0.1 to 24.9)0 (0.0 to 16.8)4.8 (0.1 to 23.8)
Fever: >38.4 deg C to 38.9 deg C0 (0.0 to 16.1)5.3 (0.1 to 26.0)0 (0.0 to 16.1)5.0 (0.1 to 24.9)5.0 (0.1 to 24.9)0 (0.0 to 16.1)
Fever: >38.9 deg C to 40.0 deg C0 (0.0 to 16.1)0 (0.0 to 17.6)4.8 (0.1 to 23.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
Fever: >40.0 deg C0 (0.0 to 16.1)0 (0.0 to 17.6)0 (0.0 to 16.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
Fatigue: Any47.6 (25.7 to 70.2)36.8 (16.3 to 61.6)42.9 (21.8 to 66.0)55.0 (31.5 to 76.9)50.0 (27.2 to 72.8)57.1 (34.0 to 78.2)
Fatigue: Mild9.5 (1.2 to 30.4)10.5 (1.3 to 33.1)9.5 (1.2 to 30.4)10.0 (1.2 to 31.7)5.0 (0.1 to 24.9)23.8 (8.5 to 47.2)
Fatigue: Moderate23.8 (8.2 to 47.2)21.1 (6.1 to 45.6)28.6 (11.3 to 52.2)35.0 (15.4 to 59.2)40.0 (19.1 to 63.9)33.3 (14.6 to 57.0)
Fatigue: Severe14.3 (3.0 to 36.3)5.3 (0.1 to 26.0)4.8 (0.1 to 23.8)10.0 (1.2 to 31.7)5.0 (0.1 to 24.9)0 (0.0 to 16.1)
Fatigue: Grade 40 (0.0 to 16.1)0 (0.0 to 17.6)0 (0.0 to 16.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
Headache: Any28.6 (11.3 to 52.2)26.3 (9.1 to 51.2)23.8 (8.2 to 47.2)55.0 (31.5 to 76.9)35.0 (15.4 to 59.2)38.1 (18.1 to 61.6)
Headache: Mild19.0 (5.4 to 41.9)15.8 (3.4 to 39.6)4.8 (0.1 to 23.8)15.0 (3.2 to 37.9)20.0 (5.7 to 43.7)19.0 (5.4 to 41.9)
Headache: Moderate9.5 (1.2 to 30.4)10.5 (1.3 to 33.1)14.3 (3.0 to 36.3)40.0 (19.1 to 63.9)15.0 (3.2 to 37.9)19.0 (5.4 to 41.9)
Headache: Severe0 (0.0 to 16.1)0 (0.0 to 17.6)4.8 (0.1 to 23.8)0 (0.0 to 16.8)0 (0.0 to 16.7)0 (0.0 to 16.1)
Headache: Grade 40 (0.0 to 16.1)0 (0.0 to 17.6)0 (0.0 to 16.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
Chills: Any14.3 (3.0 to 36.3)15.8 (3.4 to 39.6)23.8 (8.2 to 47.2)25.0 (8.7 to 49.1)5.0 (0.1 to 24.9)14.3 (3.0 to 36.3)
Chills: Mild4.8 (0.1 to 23.8)10.5 (1.3 to 33.1)14.3 (3.0 to 36.3)10.0 (1.2 to 31.7)0 (0.0 to 16.8)9.5 (1.2 to 30.4)
Chills: Moderate9.5 (1.2 to 30.4)5.3 (0.1 to 26.0)4.8 (0.1 to 23.8)5.0 (0.1 to 24.9)5.0 (0.1 to 24.9)4.8 (0.1 to 23.8)
Chills: Severe0 (0.0 to 16.1)0 (0.0 to 17.6)4.8 (0.1 to 23.8)10.0 (1.2 to 31.7)0 (0.0 to 16.8)0 (0.0 to 16.1)
Chills: Grade 40 (0.0 to 16.1)0 (0.0 to 17.6)0 (0.0 to 16.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
Vomiting: Any0 (0.0 to 16.1)0 (0.0 to 17.6)0 (0.0 to 16.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
Vomiting: Mild0 (0.0 to 16.1)0 (0.0 to 17.6)0 (0.0 to 16.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
Vomiting: Moderate0 (0.0 to 16.1)0 (0.0 to 17.6)0 (0.0 to 16.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
Vomiting: Severe0 (0.0 to 16.1)0 (0.0 to 17.6)0 (0.0 to 16.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
Vomiting: Grade 40 (0.0 to 16.1)0 (0.0 to 17.6)0 (0.0 to 16.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
Diarrhea: Any14.3 (3.0 to 36.3)5.3 (0.1 to 26.0)9.5 (1.2 to 30.4)5.0 (0.1 to 24.9)0 (0.0 to 16.8)0 (0.0 to 16.1)
Diarrhea: Mild9.5 (1.2 to 30.4)5.3 (0.1 to 26.0)4.8 (0.1 to 23.8)5.0 (0.1 to 24.9)0 (0.0 to 16.8)0 (0.0 to 16.1)
Diarrhea: Moderate0 (0.0 to 16.1)0 (0.0 to 17.6)4.8 (0.1 to 23.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
Diarrhea: Severe4.8 (0.1 to 23.8)0 (0.0 to 17.6)0 (0.0 to 16.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
Diarrhea: Grade 40 (0.0 to 16.1)0 (0.0 to 17.6)0 (0.0 to 16.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
New or worsened muscle pain: Any19.0 (5.4 to 41.9)42.1 (20.3 to 66.5)23.8 (8.2 to 47.2)30.0 (11.9 to 54.3)25.0 (8.7 to 49.1)28.6 (11.3 to 52.2)
New or worsened muscle pain: Mild4.8 (0.1 to 23.8)10.5 (1.3 to 33.1)14.3 (3.0 to 36.3)10.0 (1.2 to 31.9)15.0 (3.2 to 37.9)23.8 (8.2 to 47.2)
New or worsened muscle pain: Moderate14.3 (3.0 to 36.3)31.6 (12.6 to 56.6)4.8 (0.1 to 23.8)20.0 (5.7 to 43.7)10.0 (1.2 to 31.7)4.8 (0.1 to 23.8)
New or worsened muscle pain: Severe0 (0.0 to 16.1)0 (0.0 to 17.6)4.8 (0.1 to 23.8)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
New or worsened muscle pain: Grade 40 (0.0 to 16.1)0 (0.0 to 17.6)0 (0.0 to 16.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
New or worsened joint pain: Any14.3 (3.0 to 36.3)15.8 (3.4 to 39.6)14.3 (3.0 to 36.3)20.0 (5.7 to 43.7)10.0 (1.2 to 31.7)9.5 (1.2 to 30.4)
New or worsened joint pain: Mild4.8 (0.1 to 23.8)10.5 (1.3 to 33.1)9.5 (1.2 to 30.4)10.0 (1.2 to 31.7)10.0 (1.2 to 31.7)4.8 (0.1 to 23.8)
New or worsened joint pain: Moderate9.5 (1.2 to 30.4)5.3 (0.1 to 26.0)4.8 (0.1 to 23.8)10.0 (1.2 to 31.7)0 (0.0 to 16.8)4.8 (0.1 to 23.8)
New or worsened joint pain: Severe0 (0.0 to 16.1)0 (0.0 to 17.6)0 (0.0 to 16.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
New or worsened joint pain: Grade 40 (0.0 to 16.1)0 (0.0 to 17.6)0 (0.0 to 16.1)0 (0.0 to 16.8)0 (0.0 to 16.8)0 (0.0 to 16.1)
PrimarySSF: Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Study Vaccination

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants reporting AEs within 1 month after study vaccination were reported in this outcome measure. Exact 2-sided CI was calculated using the Clopper and Pearson method. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From study vaccination up to 1 Month after study vaccination
Reported as:
Number · Percentage of participants
SSF: Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Study Vaccination
Percentage of participantsSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: Percentage of Participants Reporting Adverse Events (AEs) Within 1 Month After Study Vaccination0 (0.0 to 16.1)10.5 (1.3 to 33.1)9.5 (1.2 to 30.4)5.0 (0.1 to 24.9)10.0 (1.2 to 31.7)0 (0.0 to 16.1)
PrimarySSF: Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 6 Months After Study Vaccination

An SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening; resulted in persistent disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required inpatient hospitalization or prolongation of existing hospitalization. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
From study vaccination up to 6 Months after study vaccination
Reported as:
Number · Percentage of participants
SSF: Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 6 Months After Study Vaccination
Percentage of participantsSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: Percentage of Participants Reporting Serious Adverse Events (SAEs) Within 6 Months After Study Vaccination0 (0.0 to 16.1)5.3 (0.1 to 26.0)4.8 (0.1 to 23.8)0 (0.0 to 16.8)5.0 (0.1 to 24.9)0 (0.0 to 16.1)
PrimarySSF: GMTs of SARS-CoV-2 Reference-Strain-Neutralizing Titers Before Vaccination

GMT of SARS-CoV-2 reference-strain-neutralizing titers before vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).

Time frame:
Before vaccination (pre-dose)
Reported as:
Geometric mean · Titer
SSF: GMTs of SARS-CoV-2 Reference-Strain-Neutralizing Titers Before Vaccination
TiterSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMTs of SARS-CoV-2 Reference-Strain-Neutralizing Titers Before Vaccination541.1 (345.1 to 848.3)382.4 (176.3 to 829.3)437.5 (244.0 to 784.2)315.2 (188.0 to 528.4)803.4 (347.8 to 1855.8)256.0 (135.1 to 485.0)
PrimarySSF: GMTs of SARS-CoV-2 Omicron BA.4/BA.5 Strain Neutralizing Titers Before Vaccination

GMT of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers before vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).

Time frame:
Before vaccination (pre-dose)
Reported as:
Geometric mean · Titer
SSF: GMTs of SARS-CoV-2 Omicron BA.4/BA.5 Strain Neutralizing Titers Before Vaccination
TiterSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMTs of SARS-CoV-2 Omicron BA.4/BA.5 Strain Neutralizing Titers Before Vaccination27.1 (16.8 to 43.7)18.0 (12.1 to 26.7)20.2 (12.6 to 32.3)23.4 (13.9 to 39.4)42.2 (19.6 to 91.1)15.0 (11.8 to 19.1)
PrimarySSF: Geometric Mean Ratio (GMR) Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Day 7

GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at Day 7 were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Day 7 (7 days after vaccination)
Reported as:
Geometric mean · Titer
SSF: Geometric Mean Ratio (GMR) Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Day 7
TiterSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: Geometric Mean Ratio (GMR) Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Day 7146.1 (102.5 to 208.2)101.6 (48.6 to 212.6)217.1 (97.8 to 481.9)315.2 (164.6 to 603.5)337.8 (133.8 to 852.7)222.9 (125.7 to 395.1)
Statistical analysis
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 60 mcg · Geometric mean ratio (gmr): 0.79 · 95% CI 0.40 to 1.56
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 1.78 · 95% CI 0.93 to 3.43
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 60 mcg · Geometric mean ratio (gmr): 2.35 · 95% CI 1.22 to 4.55
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg · Geometric mean ratio (gmr): 1.49 · 95% CI 0.76 to 2.89
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 2.33 · 95% CI 1.20 to 4.53
PrimarySSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Day 7

GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at Day 7 were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Day 7 (7 days after vaccination)
Reported as:
Geometric mean · Titer
SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Day 7
TiterSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Day 71917.2 (1153.8 to 3185.7)1241.4 (624.3 to 2468.6)1472.3 (855.4 to 2534.0)1499.2 (838.6 to 2680.4)2702.4 (1419.7 to 5143.8)1845.8 (1087.4 to 3133.1)
Statistical analysis
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 60 mcg · Geometric mean ratio (gmr): 0.76 · 95% CI 0.40 to 1.42
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 0.86 · 95% CI 0.47 to 1.58
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 60 mcg · Geometric mean ratio (gmr): 1.06 · 95% CI 0.57 to 1.95
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg · Geometric mean ratio (gmr): 1.13 · 95% CI 0.61 to 2.09
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 1.35 · 95% CI 0.73 to 2.50
PrimarySSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain Neutralizing Titers at Day 7

GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at Day 7 were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Day 7 (7 days after vaccination)
Reported as:
Geometric mean · Titer
SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain Neutralizing Titers at Day 7
TiterSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain Neutralizing Titers at Day 775.5 (52.7 to 108.0)56.6 (32.1 to 99.8)73.0 (38.7 to 137.9)76.1 (46.0 to 125.9)123.6 (63.8 to 239.5)70.7 (48.5 to 103.0)
Statistical analysis
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 60 mcg · Geometric mean ratio (gmr): 0.95 · 95% CI 0.58 to 1.56
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 1.22 · 95% CI 0.77 to 1.93
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 60 mcg · Geometric mean ratio (gmr): 1.13 · 95% CI 0.71 to 1.80
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg · Geometric mean ratio (gmr): 1.16 · 95% CI 0.73 to 1.84
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 1.49 · 95% CI 0.94 to 2.37
PrimarySSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 1

GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at 1 month were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Month 1 (1 month after vaccination)
Reported as:
Geometric mean · Titer
SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 1
TiterSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 1420.0 (252.2 to 699.5)188.1 (88.9 to 398.2)699.4 (398.9 to 1226.4)675.6 (343.2 to 1329.8)1024.0 (509.4 to 2058.3)477.7 (236.0 to 967.1)
Statistical analysis
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 60 mcg · Geometric mean ratio (gmr): 0.49 · 95% CI 0.24 to 1.03
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 1.84 · 95% CI 0.90 to 3.76
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 60 mcg · Geometric mean ratio (gmr): 1.72 · 95% CI 0.84 to 3.50
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg · Geometric mean ratio (gmr): 1.75 · 95% CI 0.85 to 3.59
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 1.56 · 95% CI 0.76 to 3.20
PrimarySSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 1

GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at 1 month were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Month 1 (1 month after vaccination)
Reported as:
Geometric mean · Titer
SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 1
TiterSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 14674.1 (3112.1 to 7020.2)2048.4 (1007.8 to 4163.7)3327.0 (1867.6 to 5926.9)3565.8 (1992.1 to 6382.7)5404.7 (3359.8 to 8694.1)2521.4 (1388.9 to 4577.4)
Statistical analysis
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 60 mcg · Geometric mean ratio (gmr): 0.50 · 95% CI 0.26 to 0.95
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 0.76 · 95% CI 0.41 to 1.43
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 60 mcg · Geometric mean ratio (gmr): 0.98 · 95% CI 0.52 to 1.84
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg · Geometric mean ratio (gmr): 0.96 · 95% CI 0.51 to 1.80
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 0.71 · 95% CI 0.38 to 1.34
PrimarySSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 1

GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at 1 month were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Month 1 (1 month after vaccination)
Reported as:
Geometric mean · Titer
SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 1
TiterSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 1157.6 (94.0 to 264.2)85.7 (52.5 to 139.8)151.0 (72.6 to 314.1)230.7 (140.0 to 379.2)284.0 (134.7 to 599.1)147.0 (86.3 to 250.4)
Statistical analysis
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 60 mcg · Geometric mean ratio (gmr): 0.72 · 95% CI 0.38 to 1.37
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 1.19 · 95% CI 0.65 to 2.21
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 60 mcg · Geometric mean ratio (gmr): 1.63 · 95% CI 0.88 to 3.02
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg · Geometric mean ratio (gmr): 1.28 · 95% CI 0.68 to 2.39
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 1.42 · 95% CI 0.76 to 2.67
PrimarySSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 3

GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at 3 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Month 3 (3 month after vaccination)
Reported as:
Geometric mean · Titer
SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 3
TiterSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 3247.3 (119.7 to 510.7)118.5 (54.6 to 257.1)461.4 (203.8 to 1044.7)711.0 (388.8 to 1300.1)512.0 (246.9 to 1061.6)285.6 (132.8 to 614.1)
Statistical analysis
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 60 mcg · Geometric mean ratio (gmr): 0.52 · 95% CI 0.21 to 1.25
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 2.07 · 95% CI 0.88 to 4.88
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 60 mcg · Geometric mean ratio (gmr): 2.96 · 95% CI 1.24 to 7.06
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg · Geometric mean ratio (gmr): 1.52 · 95% CI 0.64 to 3.62
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg · Geometric mean ratio: 1.53 · 95% CI 0.64 to 3.67
PrimarySSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 3

GMR was calculated based on the GMT of SARS-CoV-2 Omicron reference strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at 3 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Month 3 (3 month after vaccination)
Reported as:
Geometric mean · Titer
SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 3
TiterSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 32896.3 (1738.8 to 4824.3)1290.2 (675.2 to 2465.3)2610.3 (1265.9 to 5382.4)2949.6 (1550.2 to 5612.3)2610.3 (1506.5 to 4522.8)1474.8 (815.0 to 2668.9)
Statistical analysis
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 60 mcg · Geometric mean ratio (gmr): 0.52 · 95% CI 0.25 to 1.09
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 1.00 · 95% CI 0.49 to 2.04
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 60 mcg · Geometric mean ratio (gmr): 1.29 · 95% CI 0.63 to 2.68
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg · Geometric mean ratio (gmr): 0.78 · 95% CI 0.38 to 1.59
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 0.66 · 95% CI 0.32 to 1.36
PrimarySSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 3

GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at 3 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Month 3 (3 month after vaccination)
Reported as:
Geometric mean · Titer
SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 3
TiterSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 3222.9 (123.3 to 402.7)132.8 (63.7 to 276.7)322.5 (147.6 to 704.6)458.9 (206.8 to 1018.6)296.2 (143.2 to 612.6)141.3 (86.4 to 231.1)
Statistical analysis
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 60 mcg · Geometric mean ratio (gmr): 0.75 · 95% CI 0.32 to 1.76
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 1.69 · 95% CI 0.74 to 3.85
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 60 mcg · Geometric mean ratio (gmr): 2.12 · 95% CI 0.92 to 4.91
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg · Geometric mean ratio (gmr): 1.00 · 95% CI 0.43 to 2.33
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 0.89 · 95% CI 0.39 to 2.04
PrimarySSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 6

GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.1 strain neutralizing titers at 6 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Month 6 (6 month after vaccination)
Reported as:
Geometric mean · Titer
SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 6
TiterSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers at Month 6239.6 (98.8 to 581.4)229.5 (68.7 to 766.4)1058.4 (490.3 to 2284.6)1722.2 (844.3 to 3512.9)588.1 (280.3 to 1234.2)284.0 (131.8 to 612.4)
Statistical analysis
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 60 mcg · Geometric mean ratio (gmr): 0.99 · 95% CI 0.31 to 3.12
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 4.57 · 95% CI 1.49 to 14.07
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 60 mcg · Geometric mean ratio (gmr): 7.30 · 95% CI 2.34 to 22.76
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg · Geometric mean ratio (gmr): 2.26 · 95% CI 0.72 to 7.10
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 1.28 · 95% CI 0.41 to 4.03
PrimarySSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 6

GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 reference strain neutralizing titers at 6 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Month 6 (6 months after vaccination)
Reported as:
Geometric mean · Titer
SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 6
TiterSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMR Based on GMT of SARS-CoV-2 Reference-Strain-Neutralizing Titers at Month 61424.5 (667.9 to 3037.9)1371.0 (508.5 to 3696.4)2756.4 (1328.0 to 5721.4)3956.5 (2256.3 to 6937.8)2702.4 (1457.6 to 5010.0)1097.5 (555.3 to 2169.1)
Statistical analysis
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 60 mcg · Geometric mean ratio (gmr): 1.01 · 95% CI 0.38 to 2.70
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 1.99 · 95% CI 0.76 to 5.20
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 60 mcg · Geometric mean ratio (gmr): 2.99 · 95% CI 1.13 to 7.94
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg · Geometric mean ratio (gmr): 1.80 · 95% CI 0.68 to 4.75
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 0.84 · 95% CI 0.32 to 2.24
PrimarySSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 6

GMR was calculated based on the GMT of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers and reported in statistical analysis. GMTs of SARS-CoV-2 Omicron BA.4/BA.5 strain neutralizing titers at 6 months were reported in this outcome measure in descriptive data section. GMTs and the 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
Month 6 (6 months after vaccination)
Reported as:
Geometric mean · Titer
SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 6
TiterSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMR Based on GMT of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 6203.2 (85.5 to 483.1)265.5 (75.9 to 928.9)645.1 (281.1 to 1480.5)1305.2 (601.1 to 2834.1)430.5 (204.7 to 905.4)187.4 (80.5 to 436.3)
Statistical analysis
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 60 mcg · Geometric mean ratio (gmr): 1.50 · 95% CI 0.44 to 5.12
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 3.22 · 95% CI 0.99 to 10.46
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 OMI 60 mcg · Geometric mean ratio (gmr): 6.46 · 95% CI 1.96 to 21.27
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg · Geometric mean ratio (gmr): 2.08 · 95% CI 0.63 to 6.89
  • SSF: BNT162b2 30 mcg vs SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg · Geometric mean ratio (gmr): 0.95 · 95% CI 0.28 to 3.17
PrimarySSF: Geometric Mean Fold-Rise (GMFR) of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination

GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to Day 7 was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

Time frame:
From before the study vaccination to Day 7 (7 days after vaccination)
Reported as:
Geometric mean · Fold rise
SSF: Geometric Mean Fold-Rise (GMFR) of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination
Fold riseSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: Geometric Mean Fold-Rise (GMFR) of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination3.5 (2.1 to 5.8)2.9 (1.6 to 5.4)6.8 (4.3 to 10.7)8.6 (5.1 to 14.3)4.3 (2.0 to 9.1)9.8 (6.9 to 14.0)
PrimarySSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination

GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to Day 7 was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

Time frame:
From before the study vaccination to Day 7 (7 days after vaccination)
Reported as:
Geometric mean · Fold rise
SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination
Fold riseSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination3.5 (2.5 to 5.0)3.1 (1.8 to 5.2)3.4 (2.2 to 5.1)4.8 (3.0 to 7.5)3.4 (1.4 to 8.1)6.3 (3.9 to 10.2)
PrimarySSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination

GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to Day 7 was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

Time frame:
From before the study vaccination to Day 7 (7 days after vaccination)
Reported as:
Geometric mean · Fold rise
SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination
Fold riseSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 7 Days After Vaccination2.8 (2.1 to 3.7)2.8 (1.8 to 4.4)3.6 (2.5 to 5.2)3.2 (2.2 to 4.8)2.9 (1.9 to 4.4)4.7 (3.4 to 6.5)
PrimarySSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination

GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to 1 month was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

Time frame:
From before the study vaccination to 1 month after vaccination
Reported as:
Geometric mean · Fold rise
SSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination
Fold riseSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination10.1 (5.5 to 18.4)5.4 (2.6 to 11.4)20.4 (11.8 to 35.3)18.4 (9.5 to 35.6)13.0 (6.7 to 25.1)21.1 (11.5 to 38.8)
PrimarySSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination

GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 1 month was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

Time frame:
From before the study vaccination to 1 month after vaccination
Reported as:
Geometric mean · Fold rise
SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination
Fold riseSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination8.6 (5.5 to 13.6)5.0 (2.5 to 10.0)7.2 (4.7 to 10.9)11.3 (6.2 to 20.8)6.7 (3.7 to 12.1)8.6 (4.1 to 17.8)
PrimarySSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination

GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to 1 month was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

Time frame:
From before the study vaccination to 1 month after vaccination
Reported as:
Geometric mean · Fold rise
SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination
Fold riseSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 1 Month After Vaccination5.9 (3.8 to 9.1)4.7 (3.1 to 7.1)7.5 (4.6 to 12.3)9.8 (7.3 to 13.3)6.7 (3.5 to 13.0)9.5 (6.0 to 15.2)
PrimarySSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination

GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to 3 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

Time frame:
From before the study vaccination to 3 months after vaccination
Reported as:
Geometric mean · Fold rise
SSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination
Fold riseSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination5.9 (2.7 to 12.8)3.3 (1.4 to 7.5)13.5 (6.0 to 30.0)17.9 (8.7 to 36.5)6.5 (3.2 to 13.1)12.0 (6.4 to 22.3)
PrimarySSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination

GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 3 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

Time frame:
From before the study vaccination to 3 months after vaccination
Reported as:
Geometric mean · Fold rise
SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination
Fold riseSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination5.0 (2.9 to 8.5)3.2 (1.6 to 6.3)5.6 (2.6 to 11.9)8.6 (4.3 to 17.2)3.2 (1.8 to 5.8)4.5 (2.4 to 8.2)
PrimarySSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination

GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to 3 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

Time frame:
From before the study vaccination to 3 months after vaccination
Reported as:
Geometric mean · Fold rise
SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination
Fold riseSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 3 Months After Vaccination8.6 (4.3 to 16.9)7.4 (3.7 to 14.9)16.0 (7.5 to 34.0)18.5 (9.2 to 37.3)7.2 (4.1 to 12.7)9.4 (5.9 to 15.2)
PrimarySSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination

GMFR of SARS-CoV-2 Omicron BA.1 strain-neutralizing titers before vaccination to 6 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

Time frame:
From before the study vaccination to 6 months after vaccination
Reported as:
Geometric mean · Fold rise
SSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination
Fold riseSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMFR of SARS-CoV-2 Omicron BA.1 Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination5.8 (2.2 to 15.0)6.9 (1.6 to 30.4)33.1 (13.7 to 79.6)46.9 (17.6 to 124.7)7.5 (2.4 to 22.8)12.6 (5.8 to 27.3)
PrimarySSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination

GMFR of SARS-CoV-2 reference-strain-neutralizing titers before vaccination to 6 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

Time frame:
From before the study vaccination to 6 months after vaccination
Reported as:
Geometric mean · Fold rise
SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination
Fold riseSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMFR of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination2.6 (1.1 to 6.1)3.6 (1.0 to 12.7)6.3 (2.6 to 15.2)12.6 (6.0 to 26.1)3.4 (1.3 to 8.9)3.9 (1.8 to 8.2)
PrimarySSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination

GMFR of SARS-CoV-2 Omicron BA.4/BA.5 strain-neutralizing titers before vaccination to 6 months was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

Time frame:
From before the study vaccination to 6 months after vaccination
Reported as:
Geometric mean · Fold rise
SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination
Fold riseSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: GMFR of SARS-CoV-2 Omicron BA.4/BA.5 Strain-Neutralizing Titers From Before the Study Vaccination to 6 Months After Vaccination7.5 (2.8 to 20.2)16.6 (4.1 to 66.8)32.0 (12.7 to 80.7)55.7 (22.2 to 140.0)10.2 (3.7 to 28.0)13.0 (5.4 to 31.4)
PrimarySSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Day 7

Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse on Day 7 was reported in this outcome measure.

Time frame:
Day 7 (7 days after vaccination)
Reported as:
Number · Percentage of participants
SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Day 7
Percentage of participantsSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Day 752.4 (29.8 to 74.3)44.4 (21.5 to 69.2)71.4 (47.8 to 88.7)85.0 (62.1 to 96.8)55.0 (31.5 to 76.9)90.0 (68.3 to 98.8)
PrimarySSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Day 7

Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse on Day 7 was reported in this outcome measure.

Time frame:
Day 7 (7 days after vaccination)
Reported as:
Number · Percentage of participants
SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Day 7
Percentage of participantsSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Day 752.4 (29.8 to 74.3)55.6 (30.8 to 78.5)61.9 (38.4 to 81.9)80.0 (56.3 to 94.3)55.0 (31.5 to 76.9)80.0 (56.3 to 94.3)
PrimarySSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Day 7

Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse on Day 7 was reported in this outcome measure.

Time frame:
Day 7 (7 days after vaccination)
Reported as:
Number · Percentage of participants
SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Day 7
Percentage of participantsSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Day 733.3 (14.6 to 57.0)43.8 (19.8 to 70.1)42.9 (21.8 to 66.0)40.0 (19.1 to 63.9)40.0 (19.1 to 63.9)61.9 (38.4 to 81.9)
PrimarySSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 1

Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.

Time frame:
Month 1 (1 month after vaccination)
Reported as:
Number · Percentage of participants
SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 1
Percentage of participantsSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 185.7 (63.7 to 97.0)61.1 (35.7 to 82.7)90.0 (68.3 to 98.8)85.0 (62.1 to 96.8)90.0 (68.3 to 98.8)85.0 (62.1 to 96.8)
PrimarySSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 1

Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.

Time frame:
Month 1 (1 month after vaccination)
Reported as:
Number · Percentage of participants
SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 1
Percentage of participantsSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 181.0 (58.1 to 94.6)61.1 (35.7 to 82.7)85.0 (62.1 to 96.8)85.0 (62.1 to 96.8)70.0 (45.7 to 88.1)75.0 (50.9 to 91.3)
PrimarySSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 1

Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 1 month was reported in this outcome measure.

Time frame:
Month 1 (1 month after vaccination)
Reported as:
Number · Percentage of participants
SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 1
Percentage of participantsSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 175.0 (50.9 to 91.3)61.1 (35.7 to 82.7)66.7 (43.0 to 85.4)95.0 (75.1 to 99.9)80.0 (56.3 to 94.3)85.0 (62.1 to 96.8)
PrimarySSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 3

Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 3 months was reported in this outcome measure.

Time frame:
Month 3 (3 months after vaccination)
Reported as:
Number · Percentage of participants
SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 3
Percentage of participantsSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 365.0 (40.8 to 84.6)50.0 (26.0 to 74.0)75.0 (50.9 to 91.3)84.2 (60.4 to 96.6)70.0 (45.7 to 88.1)89.5 (66.9 to 98.7)
PrimarySSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 3

Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 3 months was reported in this outcome measure.

Time frame:
Month 3 (3 months after vaccination)
Reported as:
Number · Percentage of participants
SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 3
Percentage of participantsSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 365.0 (40.8 to 84.6)55.6 (30.8 to 78.5)65.0 (40.8 to 84.6)78.9 (54.4 to 93.9)55.0 (31.5 to 76.9)63.2 (38.4 to 83.7)
PrimarySSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 3

Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 3 months was reported in this outcome measure.

Time frame:
Month 3 (3 months after vaccination)
Reported as:
Number · Percentage of participants
SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 3
Percentage of participantsSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 375.0 (50.9 to 91.3)61.1 (35.7 to 82.7)85.7 (63.7 to 97.0)84.2 (60.4 to 96.6)63.2 (38.4 to 83.7)85.7 (63.7 to 97.0)
PrimarySSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 6

Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 6 months was reported in this outcome measure.

Time frame:
Month 6 (6 months after vaccination)
Reported as:
Number · Percentage of participants
SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 6
Percentage of participantsSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: Percentage of Participants With Seroresponse to Omicron BA.1 Strain-Neutralizing Titers at Month 642.9 (21.8 to 66.0)47.4 (24.4 to 71.1)85.7 (63.7 to 97.0)90.0 (68.3 to 98.8)65.0 (40.8 to 84.6)85.0 (62.1 to 96.8)
PrimarySSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 6

Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 6 months was reported in this outcome measure.

Time frame:
Month 6 (6 months after vaccination)
Reported as:
Number · Percentage of participants
SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 6
Percentage of participantsSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: Percentage of Participants With Seroresponse to the Reference-Strain-Neutralizing Titers at Month 642.9 (21.8 to 66.0)42.1 (20.3 to 66.5)61.9 (38.4 to 81.9)85.0 (62.1 to 96.8)55.0 (31.5 to 76.9)50.0 (27.2 to 72.8)
PrimarySSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 6

Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse at 6 months was reported in this outcome measure.

Time frame:
Month 6 (6 months after vaccination)
Reported as:
Number · Percentage of participants
SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 6
Percentage of participantsSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg
SSF: Percentage of Participants With Seroresponse to Omicron BA.4/BA.5 Strain-Neutralizing Titers at Month 652.4 (29.8 to 74.3)50.0 (26.0 to 74.0)85.7 (63.7 to 97.0)90.0 (68.3 to 98.8)70.0 (45.7 to 88.1)75.0 (50.9 to 91.3)
SecondarySSA: Occurrence of First Severe COVID-19 Infection (FDA Definition) Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection: Evaluable Efficacy Population

Occurrence (number of cases) of first severe COVID-19 infection based on FDA definition after booster dose without past SARS-CoV-2 infection is reported. FDA definition: confirmed COVID-19 and presence of at least 1 of the following: 1) clinical signs at rest indicative of severe systemic illness (respiratory rate greater than or equal to \[\>=\]30 breaths per minute, heart rate \>= 125 beats per minute, oxygen saturation less than or equal to \[\<=\]93% on room air at sea level, or Horovitz quotient \<300 mmHg); 2) respiratory failure (needing high-flow oxygen, noninvasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation); 3) evidence of shock (systolic blood pressure \[BP\] \<90 mmHg, diastolic BP \<60 mmHg, or requiring vasopressors); 4) significant acute renal, hepatic, or neurologic dysfunction; 5) admission to an intensive care unit; 6) death.

Time frame:
From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 1.105 and for Placebo was 0.951
Reported as:
Number · Number of 1st severe Covid19cases/1000PY
SSA: Occurrence of First Severe COVID-19 Infection (FDA Definition) Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection: Evaluable Efficacy Population
Number of 1st severe Covid19cases/1000PYSSA: BNT162b2 30 mcg: Blinded and Open Label PeriodSSA: Placebo: Blinded Period
SSA: Occurrence of First Severe COVID-19 Infection (FDA Definition) Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection: Evaluable Efficacy Population02.103
Statistical analysis
  • SSA: BNT162b2 30 mcg: Blinded and Open Label Period vs SSA: Placebo: Blinded Period · Adjusted surveillance time: 100.0 · 95% CI -358.6 to 100.0
SecondarySSA: Occurrence of First Severe COVID-19 Infection (FDA Definition) Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection: Evaluable Efficacy Population

Occurrence (number of cases) of first severe COVID-19 infection based on FDA definition after booster dose with and without past SARS-CoV-2 infection is reported. FDA definition: confirmed COVID-19 and presence of at least 1 of the following: 1) clinical signs at rest indicative of severe systemic illness (respiratory rate \>= 30 breaths per minute, heart rate \>= 125 beats per minute, oxygen saturation \<= 93% on room air at sea level, or Horovitz quotient \<300 mm Hg); 2) respiratory failure (defined as needing high-flow oxygen, noninvasive ventilation, mechanical ventilation, or extracorporeal membrane oxygenation); 3) evidence of shock (systolic BP \<90 mm Hg, diastolic BP \<60 mm Hg, or requiring vasopressors); 4) significant acute renal, hepatic, or neurologic dysfunction; 5) admission to an intensive care unit; 6) death.

Time frame:
From 7 Days after booster vaccination to end of surveillance period, total surveillance time (in 1000 person-year) for BNT162b2 was 1.182 and for Placebo was 1.011
Reported as:
Number · Number of 1st severe Covid19cases/1000PY
SSA: Occurrence of First Severe COVID-19 Infection (FDA Definition) Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection: Evaluable Efficacy Population
Number of 1st severe Covid19cases/1000PYSSA: BNT162b2 30 mcg: Blinded and Open Label PeriodSSA: Placebo: Blinded Period
SSA: Occurrence of First Severe COVID-19 Infection (FDA Definition) Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection: Evaluable Efficacy Population01.978
Statistical analysis
  • SSA: BNT162b2 30 mcg: Blinded and Open Label Period vs SSA: Placebo: Blinded Period · Adjusted surveillance time: 100.0 · 95% CI -355.5 to 100.0
SecondarySSA: Occurrence of First Severe COVID-19 Infection (CDC Definition) Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection

Occurrence (number of cases) of first severe COVID-19 infection based on CDC definition after booster dose without past SARS-CoV-2 infection is reported. CDC definition: confirmed COVID-19 and presence of at least 1 of the following: 1) hospitalization; 2) admission to an intensive care unit; 3) intubation or mechanical ventilation; 4) death.

Time frame:
From 7 Days after booster vaccination
Reported as:
Number · Number of 1st severe Covid19cases/1000PY
SSA: Occurrence of First Severe COVID-19 Infection (CDC Definition) Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection
Number of 1st severe Covid19cases/1000PYSSA: BNT162b2 30 mcg: Blinded and Open Label PeriodSSA: Placebo: Blinded Period
SSA: Occurrence of First Severe COVID-19 Infection (CDC Definition) Per 1000 Person-Years of Blinded Follow-up Without Evidence of Past SARS-CoV-2 Infection00
SecondarySSA: Occurrence of First Severe COVID-19 Infection (CDC Definition) Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection

Occurrence (number of cases) of first severe COVID-19 infection based on CDC definition after booster dose with and without past SARS-CoV-2 infection is reported. CDC definition: confirmed COVID-19 AND presence of at least 1 of the following: 1) hospitalization; 2) admission to an intensive care unit; 3) intubation or mechanical ventilation; 4) death.

Time frame:
From 7 Days after booster vaccination
Reported as:
Number · Number of 1st severe Covid19cases/1000PY
SSA: Occurrence of First Severe COVID-19 Infection (CDC Definition) Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection
Number of 1st severe Covid19cases/1000PYSSA: BNT162b2 30 mcg: Blinded and Open Label PeriodSSA: Placebo: Blinded Period
SSA: Occurrence of First Severe COVID-19 Infection (CDC Definition) Per 1000 Person-Years of Blinded Follow-up With and Without Evidence of Past SARS-CoV-2 Infection00
SecondarySSC: GMTs of SARS-CoV-2 Reference-Strain Neutralizing Titers at Baseline and 7 Days After the Booster Dose

GMT of SARS-CoV-2 reference-strain neutralizing titers at baseline and 7 days after the booster dose was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).

Time frame:
At baseline and 7 days after the booster dose
Reported as:
Geometric mean · Titer
SSC: GMTs of SARS-CoV-2 Reference-Strain Neutralizing Titers at Baseline and 7 Days After the Booster Dose
TiterSSC: BNT162b2 10 mcgSSC: BNT162b2 30 mcg
Baseline1846.7 (1232.1 to 2767.9)2230.4 (1451.8 to 3426.7)
Day 715193.4 (12335.9 to 18712.8)22689.7 (18949.8 to 27167.7)
SecondarySSC: GMTs of SARS-CoV-2 Omicron BA.1- Neutralizing Titers at Baseline and 7 Days After the Booster Dose

GMT of SARS-CoV-2 Omicron BA.1- neutralizing titers at baseline and 7 days after the booster dose was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).

Time frame:
At baseline and 7 days after booster dose
Reported as:
Geometric mean · Titer
SSC: GMTs of SARS-CoV-2 Omicron BA.1- Neutralizing Titers at Baseline and 7 Days After the Booster Dose
TiterSSC: BNT162b2 10 mcgSSC: BNT162b2 30 mcg
Baseline68.2 (39.1 to 119.1)131.1 (68.7 to 250.7)
Day 71356.4 (970.1 to 1896.4)2655.7 (2046.7 to 3445.9)
SecondarySSC: GMFRs of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Baseline to 7 Days After the Booster Dose

GMFR of SARS-CoV-2 reference-strain-neutralizing titers from baseline (before the booster dose) to 7 days after the booster dose was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

Time frame:
From baseline (before booster dose) to 7 days after the booster dose
Reported as:
Geometric mean · Fold rise
SSC: GMFRs of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Baseline to 7 Days After the Booster Dose
Fold riseSSC: BNT162b2 10 mcgSSC: BNT162b2 30 mcg
SSC: GMFRs of SARS-CoV-2 Reference-Strain-Neutralizing Titers From Baseline to 7 Days After the Booster Dose8.2 (5.9 to 11.5)10.2 (6.8 to 15.2)
SecondarySSC: GMFRs of SARS-CoV-2 Omicron BA.1-Neutralizing Titers From Baseline to 7 Days After the Booster Dose

GMFR of SARS-CoV-2 Omicron BA.1-strain-neutralizing titers from baseline (before the booster dose) to 7 days after the booster dose was reported in this outcome measure. GMFR and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises from before vaccination and the corresponding CIs (based on the student's t distribution).

Time frame:
From baseline (before booster dose) to 7 days after the booster dose
Reported as:
Geometric mean · Fold rise
SSC: GMFRs of SARS-CoV-2 Omicron BA.1-Neutralizing Titers From Baseline to 7 Days After the Booster Dose
Fold riseSSC: BNT162b2 10 mcgSSC: BNT162b2 30 mcg
SSC: GMFRs of SARS-CoV-2 Omicron BA.1-Neutralizing Titers From Baseline to 7 Days After the Booster Dose19.7 (12.3 to 31.6)20.2 (11.7 to 35.0)
SecondarySSC: Percentages of Participants With Seroresponse to Reference Strain at 7 Days After the Booster Dose

Seroresponse was defined as achieving \>= 4-fold rise from before booster dose. If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse to reference strain at 7 days after the booster dose was reported in this outcome measure.

Time frame:
7 days after the booster dose
Reported as:
Number · Percentage of participants
SSC: Percentages of Participants With Seroresponse to Reference Strain at 7 Days After the Booster Dose
Percentage of participantsSSC: BNT162b2 10 mcgSSC: BNT162b2 30 mcg
SSC: Percentages of Participants With Seroresponse to Reference Strain at 7 Days After the Booster Dose71.2 (56.9 to 82.9)68.1 (52.9 to 80.9)
SecondarySSC: Percentages of Participants With Seroresponse to Omicron BA.1 at 7 Days After the Booster Dose

Seroresponse was defined as achieving \>= 4-fold rise from before booster dose. If the baseline measurement is below the lower limit of quantification (LLOQ), the postvaccination measure of \>= 4 × LLOQ is considered a seroresponse. Exact 2-sided CI, based on the Clopper and Pearson method was used. Percentage of participants achieving seroresponse to Omicron BA.1 strain at 7 days after the booster dose was reported in this outcome measure.

Time frame:
7 days after the booster dose
Reported as:
Number · Percentage of participants
SSC: Percentages of Participants With Seroresponse to Omicron BA.1 at 7 Days After the Booster Dose
Percentage of participantsSSC: BNT162b2 10 mcgSSC: BNT162b2 30 mcg
SSC: Percentages of Participants With Seroresponse to Omicron BA.1 at 7 Days After the Booster Dose77.6 (63.4 to 88.2)74.5 (59.7 to 86.1)
SecondarySSE: GMR Based on Geometric Mean Titers of SARS-CoV-2 Reference Strain Neutralizing Titers at 1 Month After the Study Vaccination- >55 Years of Age

GMR based on GMT of SARS-CoV-2 reference strain neutralizing titers was calculated and reported in statistical analysis section. GMT of SARS-CoV-2 Reference strain-neutralizing titers at 1 month after the study vaccination was reported in this outcome measure. GMTs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on Student's t distribution).

Time frame:
1 month after study vaccination
Reported as:
Geometric mean · Titer
SSE: GMR Based on Geometric Mean Titers of SARS-CoV-2 Reference Strain Neutralizing Titers at 1 Month After the Study Vaccination- >55 Years of Age
TiterSSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcgSSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg
SSE: GMR Based on Geometric Mean Titers of SARS-CoV-2 Reference Strain Neutralizing Titers at 1 Month After the Study Vaccination- >55 Years of Age5998.1 (5223.6 to 6887.4)5933.2 (5188.2 to 6785.2)7816.9 (6820.7 to 8958.6)
Statistical analysis
  • SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg vs SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg · Geometric mean ratio (gmr): 0.99 · 95% CI 0.82 to 1.20
  • SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg vs SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg · Geometric mean ratio (gmr): 1.30 · 95% CI 1.07 to 1.58

Adverse events

Collected over Death/SAEs: 6 months after last dose (or 1 month after each dose for SSB, or 6 months after BNT162b2 for SSA original placebo). Non-SAEs: 1 month after each booster dose (or after Dose 2 for SSD naïve group, or after BNT162b2 for SSA original placebo). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SSA: BNT162b2 30 mcg- Blinded and Open Label Period5/5,080 (0.1%)73/5,080 (1.4%)1,201/5,080 (23.6%)
SSA: Placebo: Blinded Period2/5,041 (0%)42/5,041 (0.8%)202/5,041 (4%)
SSA: Original Placebo/BNT162b2 (30 mcg)- Open Label Period5/4,429 (0.1%)45/4,429 (1%)771/4,429 (17.4%)
SSB: BNT162b20/1,453 (0%)2/1,453 (0.1%)1,180/1,453 (81.2%)
SSB: Placebo0/1,463 (0%)2/1,463 (0.1%)615/1,463 (42%)
SSF: BNT162b2 30 mcg0/21 (0%)0/21 (0%)17/21 (81%)
SSF: BNT162b2 60 mcg0/19 (0%)1/19 (5.3%)19/19 (100%)
SSF: BNT162b2 OMI 30 mcg0/21 (0%)1/21 (4.8%)20/21 (95.2%)
SSF: BNT162b2 OMI 60 mcg0/20 (0%)0/20 (0%)18/20 (90%)
SSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcg0/20 (0%)1/20 (5%)18/20 (90%)
SSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcg0/21 (0%)0/21 (0%)20/21 (95.2%)
SSC: BNT162b2 10 mcg0/75 (0%)0/75 (0%)49/75 (65.3%)
SSC: BNT162b2 30 mcg0/65 (0%)1/65 (1.5%)57/65 (87.7%)
SSD: Cohort 1: Group 10/216 (0%)2/216 (0.9%)124/216 (57.4%)
SSD: Cohort 1: Group 2a2/197 (1%)3/197 (1.5%)131/197 (66.5%)
SSD: Cohort 1: Group 2b1/204 (0.5%)2/204 (1%)109/204 (53.4%)
SSD: Cohort 2: Group 3a1/315 (0.3%)5/315 (1.6%)260/315 (82.5%)
SSD: Cohort 2: Group 3 b0/213 (0%)1/213 (0.5%)167/213 (78.4%)
SSD: Cohort 2: Group 4a0/323 (0%)2/323 (0.6%)270/323 (83.6%)
SSD: Cohort 2: Group 4b0/238 (0%)3/238 (1.3%)175/238 (73.5%)
SSD: Cohort 3: Group 5a1/210 (0.5%)7/210 (3.3%)135/210 (64.3%)
SSD: Cohort 3: Group 5b1/172 (0.6%)1/172 (0.6%)69/172 (40.1%)
SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcg0/30 (0%)0/30 (0%)29/30 (96.7%)
SSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg0/30 (0%)0/30 (0%)27/30 (90%)
SSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg0/30 (0%)0/30 (0%)29/30 (96.7%)
SSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcg0/482 (0%)3/482 (0.6%)431/482 (89.4%)
SSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcg0/159 (0%)2/159 (1.3%)143/159 (89.9%)
SSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcg0/321 (0%)3/321 (0.9%)297/321 (92.5%)
SSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcg0/20 (0%)1/20 (5%)15/20 (75%)
SSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcg0/20 (0%)0/20 (0%)15/20 (75%)
SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcg0/20 (0%)0/20 (0%)15/20 (75%)
SSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcg0/20 (0%)0/20 (0%)20/20 (100%)
SSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg0/20 (0%)0/20 (0%)16/20 (80%)
SSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg1/20 (5%)1/20 (5%)17/20 (85%)
SSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcg0/305 (0%)6/305 (2%)220/305 (72.1%)
SSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcg0/302 (0%)2/302 (0.7%)243/302 (80.5%)
SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcg1/307 (0.3%)12/307 (3.9%)241/307 (78.5%)
SSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcg1/307 (0.3%)4/307 (1.3%)248/307 (80.8%)
SSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcg0/308 (0%)4/308 (1.3%)226/308 (73.4%)
SSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg1/313 (0.3%)6/313 (1.9%)247/313 (78.9%)
Most frequent serious events
Showing 10 of 193
Most frequent serious events
EventSSA: BNT162b2 30 mcg- Blinded and Open Label PeriodSSA: Placebo: Blinded PeriodSSA: Original Placebo/BNT162b2 (30 mcg)- Open Label PeriodSSB: BNT162b2SSB: PlaceboSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcgSSC: BNT162b2 10 mcgSSC: BNT162b2 30 mcgSSD: Cohort 1: Group 1SSD: Cohort 1: Group 2aSSD: Cohort 1: Group 2bSSD: Cohort 2: Group 3aSSD: Cohort 2: Group 3 bSSD: Cohort 2: Group 4aSSD: Cohort 2: Group 4bSSD: Cohort 3: Group 5aSSD: Cohort 3: Group 5bSSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcgSSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg
DyspnoeaRespiratory, thoracic and mediastinal disorders0/50801/50410/44290/14530/14630/211/190/210/200/200/210/750/650/2160/1970/2040/3150/2130/3230/2380/2100/1720/300/300/300/4820/1590/3210/200/200/200/200/200/200/3050/3020/3070/3070/3080/313
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/50801/50411/44290/14530/14630/210/190/210/201/200/210/750/650/2160/1970/2040/3150/2130/3230/2380/2100/1720/300/300/300/4820/1590/3210/200/200/200/200/200/200/3050/3020/3070/3070/3080/313
Brain neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/50800/50410/44290/14530/14630/210/190/210/200/200/210/750/650/2160/1970/2040/3150/2130/3230/2380/2100/1720/300/300/300/4820/1590/3211/200/200/200/200/200/200/3050/3020/3070/3070/3080/313
Cardiopulmonary failureCardiac disorders0/50800/50410/44290/14530/14630/210/190/210/200/200/210/750/650/2160/1970/2040/3150/2130/3230/2380/2100/1720/300/300/300/4820/1590/3210/200/200/200/200/201/200/3050/3020/3070/3070/3080/313
VertigoEar and labyrinth disorders0/50800/50410/44290/14530/14630/210/191/210/200/200/210/750/650/2160/1970/2040/3150/2130/3230/2380/2100/1720/300/300/300/4820/1590/3210/200/200/200/200/200/200/3050/3020/3070/3070/3080/313
ConstipationGastrointestinal disorders0/50800/50410/44290/14530/14630/210/190/210/200/200/210/751/650/2160/1970/2040/3150/2130/3230/2380/2100/1720/300/300/300/4820/1590/3210/200/200/200/200/200/200/3050/3020/3070/3070/3080/313
Dilated cardiomyopathyCardiac disorders0/50800/50410/44290/14530/14630/210/190/210/200/200/210/750/650/2162/1970/2040/3150/2130/3230/2380/2100/1720/300/300/300/4820/1590/3210/200/200/200/200/200/200/3050/3020/3070/3070/3080/313
Atrial fibrillationCardiac disorders3/50800/50412/44290/14530/14630/210/190/210/200/200/210/750/650/2160/1970/2040/3150/2130/3230/2380/2100/1720/300/300/300/4820/1590/3210/200/200/200/200/200/200/3050/3020/3070/3070/3083/313
PneumoniaInfections and infestations0/50801/50411/44290/14530/14630/210/190/210/200/200/210/750/650/2160/1970/2040/3150/2130/3230/2380/2100/1720/300/300/300/4820/1590/3210/200/200/200/200/200/202/3050/3020/3070/3070/3080/313
CellulitisInfections and infestations1/50800/50411/44291/14530/14630/210/190/210/200/200/210/750/650/2160/1970/2040/3150/2130/3230/2380/2100/1720/300/300/300/4821/1590/3210/200/200/200/200/200/200/3050/3020/3070/3070/3080/313
Most frequent other events
Showing 10 of 58
Most frequent other events
EventSSA: BNT162b2 30 mcg- Blinded and Open Label PeriodSSA: Placebo: Blinded PeriodSSA: Original Placebo/BNT162b2 (30 mcg)- Open Label PeriodSSB: BNT162b2SSB: PlaceboSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcgSSC: BNT162b2 10 mcgSSC: BNT162b2 30 mcgSSD: Cohort 1: Group 1SSD: Cohort 1: Group 2aSSD: Cohort 1: Group 2bSSD: Cohort 2: Group 3aSSD: Cohort 2: Group 3 bSSD: Cohort 2: Group 4aSSD: Cohort 2: Group 4bSSD: Cohort 3: Group 5aSSD: Cohort 3: Group 5bSSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcgSSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcg
Injection site pain (PAIN)General disorders0/50800/50410/44291038/1453163/146315/2118/1919/2116/2015/2019/2142/7550/6596/216110/19785/204229/315145/213239/323153/238109/21060/17227/3025/3029/30398/482128/159276/32114/2014/2013/2020/2013/2017/20179/305212/302199/307214/307177/308208/313
Fatigue (FATIGUE)General disorders0/50800/50410/4429723/1453356/146310/217/199/2111/2010/2012/2137/7535/6567/21661/19757/204189/315119/213184/323117/23887/21035/17220/3019/3021/30354/482108/159248/3219/2011/209/2013/208/2014/20135/305156/302158/307177/307147/308177/313
Headache (HEADACHE)Nervous system disorders0/50800/50410/4429585/1453332/14636/215/195/2111/207/208/2131/7534/6564/21670/19755/204140/31578/213137/32381/23867/21039/17214/309/3018/30257/48279/159184/3214/206/207/203/206/2010/2079/305116/302110/307110/30799/308114/313
Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders0/50800/50410/4429402/145388/14634/218/195/216/205/206/210/750/6532/21641/19728/20499/31551/21386/32358/23845/21023/1729/309/3014/30191/48258/159135/3215/204/205/207/204/207/2059/30576/30272/30792/30770/30882/313
Chills (CHILLS)General disorders0/50800/50410/4429278/145369/14633/213/195/215/201/203/2110/7515/6531/21635/19721/20493/31539/21380/32341/23832/21014/1727/307/3012/30171/48244/159123/3211/204/203/207/205/206/2049/30572/30277/30778/30738/30874/313
Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders0/50800/50410/4429178/145355/14633/213/193/214/202/202/210/750/6523/21633/19720/20469/31528/21346/32326/23829/21014/1726/305/307/30122/48233/15977/3214/205/203/204/203/207/2027/30548/30250/30759/30734/30857/313
Injection site erythema (REDNESS)General disorders0/50800/50410/442974/14539/14634/214/195/214/202/206/211/754/657/21618/1975/20421/31510/21313/3239/23814/2107/1722/300/302/3039/48210/15935/3210/203/204/202/200/202/2019/30531/30219/30733/30722/30822/313
Injection site swelling (SWELLING)General disorders0/50800/50410/442986/14537/14633/213/193/213/203/206/212/756/6517/21623/19711/20425/3158/21327/32314/23827/21016/1720/302/306/3046/48211/15938/3210/202/203/201/201/202/2018/30539/30225/30731/30720/30817/313
Diarrhoea (DIARRHEA)Gastrointestinal disorders0/50800/50410/4429109/145377/14633/211/192/211/200/200/213/756/6519/21620/19713/20425/31518/21335/32313/23820/2103/1726/301/304/3061/48217/15939/3213/203/203/200/201/201/2013/30517/30224/30731/30726/30821/313
Pyrexia (FEVER)General disorders0/50800/50410/442974/145317/14632/212/192/212/201/201/213/754/6512/2167/19710/20425/3159/21322/32313/23811/2104/1724/300/303/3048/48217/15962/3211/202/202/201/204/204/2011/30522/30225/30727/30715/30824/313

Baseline characteristics

Safety population included all randomized participants who received at least 1 dose of the study intervention.

Age, Customized
Age, Customized(Participants)SSA: BNT162b2 30 mcg: Blinded and Open Label PeriodSSA: Placebo: Blinded PeriodSSB: BNT162b2 30 mcg Then PlaceboSSB: Placebo Then BNT162b2 30 mcgSSC: BNT162b2 10 mcgSSC: BNT162b2 30 mcgSSD: Cohort 1: Group 1SSD: Cohort 1: Group 2SSD: Cohort 1: Group 2bSSD: Cohort 2: Group 3SSD: Cohort 2: Group 4SSD: Cohort 3: Group 5SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcgSSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcgSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcgTotal
Adolescents (12-17 years)46442332287565000000000000000000000000000000691
Adults (18-64 years)385938115205040021619720431532321030303048215932165575912610512112311210967689911989
From 65-84 years1166117400000000000000001415151315101761961861831941991512151211123633
85 years and over912000000000000000000000131012500000034
Sex: Female, Male
Sex: Female, Male(Participants)SSA: BNT162b2 30 mcg: Blinded and Open Label PeriodSSA: Placebo: Blinded PeriodSSB: BNT162b2 30 mcg Then PlaceboSSB: Placebo Then BNT162b2 30 mcgSSC: BNT162b2 10 mcgSSC: BNT162b2 30 mcgSSD: Cohort 1: Group 1SSD: Cohort 1: Group 2SSD: Cohort 1: Group 2bSSD: Cohort 2: Group 3SSD: Cohort 2: Group 4SSD: Cohort 3: Group 5SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcgSSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcgSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcgTotal
Female262425264344473733137119121152156106141715269891808914127111601571531541441629913108128528
Male2456251531928538327978831631671041613152137014112116813914514515415316415112108101297819
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SSA: BNT162b2 30 mcg: Blinded and Open Label PeriodSSA: Placebo: Blinded PeriodSSB: BNT162b2 30 mcg Then PlaceboSSB: Placebo Then BNT162b2 30 mcgSSC: BNT162b2 10 mcgSSC: BNT162b2 30 mcgSSD: Cohort 1: Group 1SSD: Cohort 1: Group 2SSD: Cohort 1: Group 2bSSD: Cohort 2: Group 3SSD: Cohort 2: Group 4SSD: Cohort 3: Group 5SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcgSSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcgSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcgTotal
White39984002491493555016892372243125242638912425016191517141626825426126227727221192120202112265
Black or African American47045715915511917617217821341552313410321022211922232013190000002203
American Indian or Alaska Native86924600102141000213000000000201000000206
Asian28826961587542142451233422025312143132016201617000000994
Native Hawaiian or other Pacific Islander711110100023000022100000021000000000034
Multiracial209197241210101161012221001228001000356313000000559
Not reported22131371094821000010200000000101100000086
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SSA: BNT162b2 30 mcg: Blinded and Open Label PeriodSSA: Placebo: Blinded PeriodSSB: BNT162b2 30 mcg Then PlaceboSSB: Placebo Then BNT162b2 30 mcgSSC: BNT162b2 10 mcgSSC: BNT162b2 30 mcgSSD: Cohort 1: Group 1SSD: Cohort 1: Group 2SSD: Cohort 1: Group 2bSSD: Cohort 2: Group 3SSD: Cohort 2: Group 4SSD: Cohort 3: Group 5SSE: Sentinel Cohort (18-55 Years): BNT 30mcg + BNT OMI 30 mcgSSE: Sentinel Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Sentinel Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (18-55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (18-55 Years): BNT 15 mcg +BNT OMI 15 mcgSSE: Expanded Cohort (18 to 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Sentinel Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Sentinel Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Sentinel Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 60 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 30 mcgSSE: Expanded Cohort (> 55 Years): BNT162b2 OMI 60 mcgSSE: Expanded Cohort (> 55 Years): BNT 15 mcg + BNT OMI 15 mcgSSE: Expanded Cohort (> 55 Years): BNT 30 mcg +BNT OMI 30 mcgSSF: BNT162b2 30 mcgSSF: BNT162b2 60 mcgSSF: BNT162b2 OMI 30 mcgSSF: BNT162b2 OMI 60 mcgSSF: BNT162b2 15 mcg + BNT162b2 OMI 15 mcgSSF: BNT162b2 30 mcg + BNT162b2 OMI 30 mcgTotal
Hispanic/Latino7597501521501511604484673436617391143245738444645440000002369
Non-Hispanic/non-Latino43094283595577595320919620026627720227262741314228219191617181624826426326126326921192120192113937
Not reported128651111010100030000000000000000001041
08

Study locations

154 sites
  • North Alabama Research Center
    Athens, Alabama 35611, United States
  • Accel Research Sites - Birmingham Clinical Research Unit
    Birmingham, Alabama 35216, United States
  • Medical Affiliated Research Center
    Huntsville, Alabama 35801, United States
  • AMR Clinical
    Mobile, Alabama 36608, United States
  • Johns Hopkins Center for American Indian Health
    Chinle, Arizona 86503, United States
  • Hope Research Institute
    Phoenix, Arizona 85018, United States
  • The Pain Center of Arizona
    Phoenix, Arizona 85018, United States
  • HOPE Research Institute
    Phoenix, Arizona 85023, United States
  • Alliance for Multispecialty Research, LLC
    Tempe, Arizona 85281, United States
  • Johns Hopkins Center for American Indian Health
    Whiteriver, Arizona 85941, United States
  • Whiteriver Indian Hospital- Garrett Building
    Whiteriver, Arizona 85941, United States
  • Whiteriver Indian Hospital
    Whiteriver, Arizona 85941, United States
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Collaborative Neuroscience Research, LLC
    Long Beach, California 90806, United States
  • Collaborative Neuroscience Research, LLC
    Los Alamitos, California 90720, United States
  • Kaiser Permanente Los Angeles Medical Center
    Los Angeles, California 90027, United States
  • Kaiser Permenente Medical Center Infectious Disease
    Los Angeles, California 90027, United States
  • Velocity Clinical Research, Los Angeles
    Los Angeles, California 90057, United States
  • Velocity Clinical Research, North Hollywood
    North Hollywood, California 91606, United States
  • Kaiser Permanente Oakland
    Oakland, California 94611, United States
  • Paradigm Clinical Research Centers, Inc
    Redding, California 96001, United States
  • UC Davis Medical Center
    Sacramento, California 95817, United States
  • California Research Foundation
    San Diego, California 92123, United States
  • Kaiser Permanente Santa Clara
    Santa Clara, California 95051, United States
  • Bayview Research Group, LLC
    Valley Village, California 91607, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Lynn Institute of Denver
    Aurora, Colorado 80012, United States
  • Clinical Research Consulting
    Milford, Connecticut 06460, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06510, United States
  • Yale-New Haven Hospital
    New Haven, Connecticut 06511, United States
  • Yale Center for Clinical Investigation
    New Haven, Connecticut 06519, United States
  • Alliance for Multispecialty Research, LLC
    Coral Gables, Florida 33134, United States
  • Indago Research & Health Center, Inc
    Hialeah, Florida 33012, United States
  • Research Centers of America ( Hollywood )
    Hollywood, Florida 33024, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Clinical Neuroscience Solutions, Inc. dba CNS Healthcare
    Jacksonville, Florida 32256, United States
  • Acevedo Clinical Research Associates
    Miami, Florida 33142, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • IACT Health
    Columbus, Georgia 31904, United States
  • Meridian Clinical Research
    Savannah, Georgia 31406, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Velocity Clinical Research, Sioux City
    Sioux City, Iowa 51106, United States
  • AMR Clinical
    Newton, Kansas 67114, United States
  • AMR Clinical
    Wichita, Kansas 67207, United States
  • Kentucky Pediatric/ Adult Research
    Bardstown, Kentucky 40004, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • Louisiana State University Health Sciences Shreveport
    Shreveport, Louisiana 71101, United States
  • Johns Hopkins Bayview Medical Center
    Baltimore, Maryland 21224, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • University of Massachusetts Chan Medical School
    Worcester, Massachusetts 01655, United States
  • Michigan Center of Medical Research (MICHMER)
    Farmington Hills, Michigan 48334, United States
  • Velocity Clinical Research, Covington
    Gulfport, Mississippi 39503, United States
  • Clinical Research Professionals
    Chesterfield, Missouri 63005, United States
  • Sundance Clinical Research
    St Louis, Missouri 63141, United States
  • Bozeman Health Deaconess Hospital d/b/a Bozeman Health Clinical Research
    Bozeman, Montana 59715, United States
  • Bozeman Health Deaconess Hospital
    Bozeman, Montana 59715, United States
  • Methodist Physicians Clinic/CCT Research
    Fremont, Nebraska 68025, United States
  • Velocity Clinical Research, Norfolk
    Norfolk, Nebraska 68701, United States
  • Quality Clinical Research
    Omaha, Nebraska 68114, United States
  • Velocity Clinical Research, Omaha
    Omaha, Nebraska 68134, United States
  • Wake Research - Clinical Research Center of Nevada, LLC
    Las Vegas, Nevada 89106, United States
  • South Jersey Infectious Disease
    Somers Point, New Jersey 08244, United States
  • IMA Clinical Research Warren
    Warren Township, New Jersey 07059, United States
  • Gallup Indian Medical Center
    Gallup, New Mexico 87301, United States
  • Johns Hopkins Center for American Indian Health
    Gallup, New Mexico 87301, United States
  • Johns Hopkins Center for American Indian Health
    Shiprock, New Mexico 87420, United States
  • Northern Navajo Medical Center
    Shiprock, New Mexico 87420, United States
  • Meridian Clinical Research LLC
    Binghamton, New York 13901, United States
  • NYU Langone Health
    New York, New York 10016, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
  • University of Rochester Medical Center- Kari Steinmetz
    Rochester, New York 14642, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13215, United States
  • Velocity Clinical Research, Vestal
    Vestal, New York 13850, United States
  • Accellacare
    Cary, North Carolina 27518, United States
  • Accellacare
    Charlotte, North Carolina 28211, United States
  • Duke University - Main Hospital and Clinics
    Durham, North Carolina 27703, United States
  • PharmQuest Life Sciences, LLC
    Greensboro, North Carolina 27408, United States
  • Accellacare
    Hickory, North Carolina 28601, United States
  • Accellacare
    Raleigh, North Carolina 27609, United States
  • M3 Wake Research, Inc.
    Raleigh, North Carolina 27612, United States
  • Accellacare - Salisbury
    Salisbury, North Carolina 28144, United States
  • Accellacare (formerly PMG Research of Wilmington, LLC)
    Wilmington, North Carolina 28401, United States
  • Accellacare
    Wilmington, North Carolina 28401, United States
  • Accellacare
    Winston-Salem, North Carolina 27103, United States
  • Lillestol Research
    Fargo, North Dakota 58104, United States
  • Meridian Clinical Research, LLC
    Cincinnati, Ohio 45219, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Cincinnati Children's Hospital
    Cincinnati, Ohio 45229, United States
  • Meridian Clinical Research
    Cincinnati, Ohio 45246, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • VA Northeast Ohio Healthcare System
    Cleveland, Ohio 44106, United States
  • Velocity Clinical Research, Cleveland
    Cleveland, Ohio 44122, United States
  • Centricity Research Columbus Ohio Multispecialty
    Columbus, Ohio 43213, United States
  • Dayton Clinical Research
    Dayton, Ohio 45406, United States
  • Dayton Clinical Research
    Dayton, Ohio 45409, United States

Showing the first 100 of 154 sites across 5 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Fitz-Patrick D, Sahgal O, Fouche LF, Mitha E, Malahleha M, Gayed J, Keep G, Zhang Y, Modjarrad K, Belanger T, Xu X, Cooper D, Mensa FJ, Sahin U, Tureci Ӧ, Swanson KA, Anderson AS, Gurtman A, Kitchin N. Immunogenicity, Tolerability, and Safety of BA.1-Adapted BNT162b2 Vaccine in 18- to 55-Year-Olds Previously Vaccinated with BNT162b2 or Who Were COVID-19 Vaccine-Naive. Infect Dis Ther. 2026 Jul 25. doi: 10.1007/s40121-026-01409-1. Online ahead of print. PubMed 42501282 ↗
  • Winokur P, Diya O, Fitz-Patrick D, Dever M, Gayed J, Lockhart S, Xu X, Zhang Y, Bangad V, Wadsworth LT, Cannon K, Cardona JF, Usdan L, Ginis J, Mensa FJ, Zou J, Xie X, Lu C, Buitrago S, Scully IL, Cooper D, Koury K, Jansen KU, Tureci O, Sahin U, Swanson KA, Gruber WC, Kitchin N. Safety and Immunogenicity of a Fourth Dose of Omicron BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18-55 Years Old. Clin Infect Dis. 2026 May 20;82(5):e1083-e1092. doi: 10.1093/cid/ciag026. PubMed 41560517 ↗
  • Muik A, Lui BG, Quandt J, Diao H, Fu Y, Bacher M, Gordon J, Toker A, Grosser J, Ozhelvaci O, Grikscheit K, Hoehl S, Kohmer N, Lustig Y, Regev-Yochay G, Ciesek S, Beguir K, Poran A, Vogler I, Tureci O, Sahin U. Progressive loss of conserved spike protein neutralizing antibody sites in Omicron sublineages is balanced by preserved T cell immunity. Cell Rep. 2023 Aug 29;42(8):112888. doi: 10.1016/j.celrep.2023.112888. Epub 2023 Jul 31. PubMed 37527039 ↗
  • Winokur P, Gayed J, Fitz-Patrick D, Thomas SJ, Diya O, Lockhart S, Xu X, Zhang Y, Bangad V, Schwartz HI, Denham D, Cardona JF, Usdan L, Ginis J, Mensa FJ, Zou J, Xie X, Shi PY, Lu C, Buitrago S, Scully IL, Cooper D, Koury K, Jansen KU, Tureci O, Sahin U, Swanson KA, Gruber WC, Kitchin N; C4591031 Clinical Trial Group. Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years. N Engl J Med. 2023 Jan 19;388(3):214-227. doi: 10.1056/NEJMoa2213082. PubMed 36652353 ↗
  • Moreira ED Jr, Kitchin N, Xu X, Dychter SS, Lockhart S, Gurtman A, Perez JL, Zerbini C, Dever ME, Jennings TW, Brandon DM, Cannon KD, Koren MJ, Denham DS, Berhe M, Fitz-Patrick D, Hammitt LL, Klein NP, Nell H, Keep G, Wang X, Koury K, Swanson KA, Cooper D, Lu C, Tureci O, Lagkadinou E, Tresnan DB, Dormitzer PR, Sahin U, Gruber WC, Jansen KU; C4591031 Clinical Trial Group. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. N Engl J Med. 2022 May 19;386(20):1910-1921. doi: 10.1056/NEJMoa2200674. Epub 2022 Mar 23. PubMed 35320659 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in May 2023, 22 months.

Results were first posted in Nov 2025, 2 years 5 months after primary completion.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 22 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2021
First posted
Jul 9, 2021
StartActual
Jul 1, 2021
Primary completionActual
May 25, 2023
CompletionActual
May 25, 2023
Results first posted
Nov 10, 2025
Last update
Nov 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04955626
Lead sponsor
BioNTech SE
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Jul 9, 2021
Start date
Jul 1, 2021
Primary completion
May 25, 2023
Completion
May 25, 2023
Results posted
Nov 10, 2025
Last update
Nov 10, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BNT162 Vaccine

Start the discussion